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Call To Order & Welcome  
 
Nancy Bennett, MD, MS 
ACIP Chair 
 
Dr. Bennett called the June 2016 Advisory Committee on Immunization Practices (ACIP) 
meeting to order and welcomed those present.  She said that they were very honored to have 
Dr. Frieden in attendance to deliver the keynote address, and invited him to give the opening 
remarks. 
 
Opening Remarks 
 
Thomas Frieden, MD, MPH 
Director, Centers for Disease Control and Prevention 
 
Dr. Frieden welcomed the ACIP and thanked them for their attendance, attention, focus, and 
commitment to continuing to openly debate, discuss, and move forward immunization policy for 
the United States (US).  He said that he often points to the ACIP as one of the truly great 
examples of the way this country sets health policy in a manner that combines science with an 
understanding of its impact on people.  ACIP is, indeed, a model for the world and he expressed 
his appreciation for the members’ contributions and commitment. 
 
Recognizing that the ACIP had a full agenda and would be discussing a series of very important 
issues over the next two days, he pointed out that they also would have to address a particularly 
unusual and challenging situation with regard to influenza.  Though he did not plan to discuss 
the details of what the ACIP would deliberate later in the day, he said he did want to take a step 
back to think more about actionable data.  In public health, action often must be taken based on 
what is currently known.  He emphasized the importance of keeping in mind that a non-decision 
is also a decision.  While he was aware that ACIP had carefully assessed this for many years 
and that there are varying perspectives on it across the world, he said he wanted to challenge 
them with some of his perspectives on the issue. 
 
He first reiterated the principles of Centers for Disease Control and Prevention’s (CDC’s) pledge 
to the American people.  Dr. Walter Dowdle outlined this years ago.  Dr. Frieden first saw it 20 
years ago when he was required to take ethics training with CDC.  He was sitting in his home 
office in India working for CDC and the World Health Organization (WHO).  He was so struck 
with the following five points that he has kept them on his desk ever since:  
 
 
 
 
 
 
Be a diligent steward of the funds entrusted to our agency 
Provide an environment for intellectual and personal growth and integrity 
Base all public health decisions on the highest quality scientific data that is derived openly 
and objectively 
Place the benefits to society above the benefits to our institution 
Treat all persons with dignity, honesty, and respect 
Call To Order & Welcome, Dr. Frieden’s Opening  
Remarks, Meeting Overview, Announcements, & Introductions 
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Focusing on the principle to “base all public health decisions on the highest quality scientific 
data that is derived openly and objectively,” Dr. Frieden stressed that there was a lot packed 
into that single bullet point.  He pointed out that the words “randomized controlled trial (RCT)” is 
not included in that bullet.  Randomized, double-blind, placebo-controlled trials are, in fact, one 
of the great accomplishments of the 20th Century. 
  
Given that his background is as a Tuberculosis (TB) Control Specialist, Dr. Frieden said that he 
must wave the flag for tuberculosis control work.  In 1946, the British Medical Research Council 
(MRC) conducted the first RCT that showed unequivocally that streptomycin was effective for 
TB.  In fact, streptomycin is not that good because as a single drug, one rapidly develops 
resistance.  What followed from the British MRC was a remarkable, several decades long, multi-
country collaboration of RCTs that optimized treatment of TB.  These were truly matters of 
decades long commitment and brilliance, because the trials had recruited over a couple of years 
and followed everyone for five years.  They systematically figured out how to reduce treatment 
from 12 months, to 9 months, to 6 months; how long each medication must be given; the 
different doses; and which medications were equivalent.  With those treatment regimens 
developed over decades, 50 million patients have been treated over recent years as this has 
been expanded around the world. 
 
That notwithstanding, Dr. Frieden emphasized that RCTs are a fantastic tool.  However, there 
are some challenges.  With regard to influenza, there is a striking disconnect between what the 
RCTs found and what other trials with other information sources found about efficacy.  The 
influenza program is unique.  No other vaccine is given every year.  No other vaccine is 
evaluated for efficacy every year.  This helps to measure the impact of public health 
interventions and determine what difference is being made in order to report, based on reliable 
model information, how many cases, hospitalizations, and deaths are prevented each year. 
Influenza is a serious and formidable challenge.  Even in a “good” year, it causes millions of 
illnesses, hundreds of thousands of hospitalizations, and thousands to tens of thousands of 
deaths.  The only thing that can be predicted definitely about influenza is that is unpredictable. 
 
Dr. Frieden said that he wanted to leave the issue of influenza, which ACIP would be discussing 
in the afternoon, to speak further about RCTs.  He quoted Angus Deaton, Nobel Laureate in 
Economics who said that “Randomized controlled trials cannot automatically trump other 
evidence, they do not occupy any special place in some hierarchy of evidence, nor does it make 
sense to refer to them as ‘hard’ while other methods are ‘soft.’  These rhetorical devices are just 
that; metaphor is not argument, nor does endless repetition make it so” [Deaton A. J Econ 
Literature 2010;48:424-455].  While this quote refers to the use of RCTs in development 
policies, it is equally relevant to use in medicine and science.  There are definitely limitations of 
RCTs.  That is not to say that RCTs are not important, not wonderful, not potentially pivotal.  
However, it is important to put them within the landscape of evidence and data used for 
decision-making. 
  
Dr. Frieden said he thought it was worth outlining some of the limitations of RCTs.  Some of 
these are in the implementation phase, so an RCT might be done incorrectly.  However, some 
of them are inherent to the practice of RCTs.  One limitation is external validity, so it may be that 
what is correct today is not correct tomorrow.  It may be that there is a temporal component, or 
that what is relevant in one place is not in another.  It may be that the changing epidemiology of 
disease changes the outcome, or that the program impact changes.  Even if the RCT is 
meticulously done, it may lack external validity and not be generalizable to other settings.  Dr. 
Frieden said he would never forget an offhand comment in an article that George Comstock 
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wrote on TB that someone really should study the prognosis of a positive tuberculin test.  Dr. 
Frieden was really confused by that remark, but was too shy to ask him for years.  He finally 
asked him 20 years later, “Dr. Comstock, you did that in Alaska.  In fact, it is always your studies 
that we point to when we say that there is a 5% to 10% lifetime risk of progressing from TB 
infection to TB disease.  Why do you say that someone should study the prognosis of a positive 
tuberculin test?”  Dr. Comstock said, “Well, because that’s what it was then.  But, we don’t know 
what it is now.  Maybe the force of infection was greater.  Maybe there were differences in the 
genetic make-up or environmental components of the individual.”  It was a remarkably 
perceptive statement from someone who had done the definitive studies and knew that they 
were not definitive. 
 
There also are temporal changes.  Treatments, exposures, and populations change.  This is 
commonly observed in modern medicine where someone conducts an RCT of Intervention X 
and finds that it is no better than Intervention Y that costs a tenth as much and is much older.  
By the time it comes out they say, “Ah yes, but now we have Intervention X2 so we’re going to 
use that.”  There is often a situation of not having information that is relevant to the decisions 
people are making, or at least that do not appear to be relevant.  In addition, there are many 
rare diseases that added up affect many people.  However, there will never be enough 
participants to accrue an RCT of sufficient size. 
  
Efficiency is another issue.  RCTs take time and money and there are often quicker, more 
efficient ways to get an answer.  There also are design and implementation limitations.  These 
may be inherent or not.  For example, treatment may not be standardized in the case of surgery 
or psychotherapy.  Placebo effects are an interesting topic.  With certain mental health 
conditions, people have such confidence in the treatment that the placebo has quite a good 
impact.  That has changed dramatically over the last few decades.  Randomization may be 
challenging, and controls / confounding may be issues. 
 
RCTs generally cannot evaluate population-level interventions and impacts.  In the field of TB, 
one might conduct a trial of one modality of treatment, but that may not indicate whether multi-
drug resistance is being risked in society as a whole.  Or in the case of vaccine, there may be a 
major impact on health population or herd immunity that would not be captured in an RCT.  
Finally, there is what Dr. Frieden refers to as the “dark matter of clinical medicine.”  The fact is, 
when this is considered objectively, an enormous proportion of what is done in modern medicine 
today is not based on data, and there is no realistic possibility or probability that there will be an 
RCT to evaluate it soon. 
 
It can be said that either RCTs are the “only game in town” or that RCTs and other sources can 
be used as well when possible.  A few other data sources include observational, program 
implementation and evaluation, epidemiological analyses, aggregated clinical information 
(potentially as a prelude to an RCT), and others.  Program implementation and evaluation is like 
a treatment trial.  A public health program can be implemented and it can be determined 
whether there is an impact.  There are situations in which the aggregate information may be 
more accurate than the individual information.  Aggregate information has been used to deal 
with nutritional issues, public programming issues, et cetera.  In terms of aggregated clinical 
information, some of the older case series provided granular information on individual patients 
and are much more informative than some of the more recent journal articles that give 
aggregated information.  With a rare condition, a case series can help to understand what 
happened and see how that might reflect on individual treatment / prognosis.  Interestingly in 
terms of electronic health records (IHRs), patient registries, patient willingness to participate and 
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share their information, there is a possibility of developing granular information across 
programs. 
 
An example that is always raised in relation to observational or non-randomized information is 
the fiasco with the recommendation of hormone replacement therapy (HRT).  There is a pretty 
strong argument that the data itself, had it been analyzed correctly, would not have led to the 
recommendation for HRT.  The people who conducted that study are excellent epidemiologists.  
Everyone makes mistakes and hindsight is always 20/20.  With any form of data, whether it be 
RCTs (for which limitations must be recognized) or other data sources, it is important to have 
humility because action is always being taken on imperfect data. 
 
On Dr. Frieden’s first day of medical school, the Dean told them, “Half of what we teach you is 
wrong, but we don’t know what half it is so you will be tested on all of it.”  It is important to take a 
holistic approach to health data.  That begins with having clarity about the health outcome being 
sought.  Knowledge is not being sought for the purposes of seeking knowledge.  Instead, 
knowledge is being sought for the purpose of improving health and addressing a specific health 
outcome.  Therefore, data sources are needed that are fit to the purpose of achieving that 
health outcome.  Also needed is rigor in evaluating all data sources for their strengths and 
limitations.  There must be humility about conclusions regardless of the data sources, with an 
understanding that conclusions may change over time as Professor Comstock knew they might, 
or that there may be problems with the analyses, changes in modalities, and/or that viruses and 
bacteria may be evolving.  The focus must be on when the data are sufficient for action.  There 
always will be an argument for more research.  There always will be an argument for more 
perfect data.  Nevertheless, it is always important to understand that even a non-decision is a 
decision.  Failure to act is a decision.  The goal is to seek actionable data—data that are 
sufficient in an open, objectively derived, transparent fashion to make a recommendation and 
substantiate why. 
 
Dr. Bennett thanked Dr. Frieden for the very inspiring and motivating presentation, which 
certainly would be taken up by ACIP’s Evidence-Based Recommendations Work Group (WG).  
She then introduced Dr. Cohn for the meeting overview, roll call, and introductions. 
 
Overview  
 
Amanda Cohn, MD 
Executive Secretary, ACIP / CDC 
 
Dr. Cohn welcomed everyone to the June 2016 ACIP meeting.  She indicated that the 
proceedings of this meeting would be accessible to people not in attendance via the World Wide 
Web, and welcomed those who could not attend the meeting in person.  She then recognized 
several others in the room who were to be present throughout the duration of the meeting to 
assist with various meeting functions:  Stephanie Thomas, Natalie Greene, and Chris Caraway. 
She noted that handouts of the presentations were distributed to the ACIP members and were 
made available for others on the tables outside of the auditorium.  Slides presented during this 
meeting will be posted on the ACIP website approximately two weeks after the meeting 
concludes after being made visually accessible to all viewers, including the visually disabled.  
The live webcast will be posted within four weeks following the meeting, and the meeting 
minutes will be available on the website within approximately 90 days following this meeting.  
Members of the press interested in conducting interviews with ACIP members were instructed to 
contact Ian Branam, located at the press table, for assistance in arranging interviews. 
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The next ACIP meeting will be convened at CDC on Wednesday and Thursday, October 19-20, 
2016.  Registration for all meeting attendees is required.  The registration deadline for Non-US 
citizens is September 28, 2016 and for US citizens registration closes October 10, 2016.  
Registration is not required for webcast viewing.  As a reminder for non-US citizens attending 
ACIP meetings, completion of several forms is required for each meeting at the time of 
registration.  It is important that these forms are submitted within the required time frame.  
Stephanie Thomas, the ACIP Committee Management Specialist, will be able to help with any 
questions about the process. 
 
Dr. Cohn then made the following announcements pertaining to Ex Officio and Liaison 
Representatives: 
 
Ex Officio Members 
 
 
 
 
Dr. Jennifer Gordon is representing the National Vaccine Program Office (NVPO) 
 
Liaison Representatives 
 
Dr. Corey Robertson is representing Pharmaceutical Research and Manufacturers of 
America (PhRMA) 
Dr. Kimberly Thompson, Professor of Preventive Medicine and Global Health, University of 
Central Florida (UCF) College of Medicine is representing National Vaccine Advisory 
Committee (NVAC) as the Chair, replacing Dr. Walt Orenstein  
Regarding public comments, Dr. Cohn indicated that topics presented during ACIP meetings 
include open discussion with time reserved for public comment.  She explained that time for 
public comment pertaining to topics on the agenda was scheduled following the end of the day’s 
sessions, and that time for public comments also would be prior to each vote by ACIP to enable 
these comments to be considered before a vote.  Registration for public comments is solicited in 
advance of meetings.  People who planned to make public comments were instructed to visit 
the registration table at the rear of the auditorium where Ms. Stephanie Thomas would record 
their name and provide information on the process.  People making public comments were 
instructed to provide 3 pieces of information:  name, organization if applicable, and any conflicts 
of interest (COI).  Registration for public comment also was solicited in advance of this meeting 
through the Federal Register.  Given time constraints, each comment was limited to 3 minutes.  
Participants unable to present comments during this meeting were invited to submit their 
comments in writing for inclusion in the meeting minutes. 
 
Recommendations and immunization schedules can be downloaded from the ACIP website. 
ACIP has a policy that every three to five years each recommendation is reviewed, and then 
renewed, revised, or retired.  During every meeting, an update is provided on the status of ACIP 
recommendations.  There was one ACIP publication since February 2016 meeting, which is 
reflected in the following table: 
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Applications for ACIP membership are due no later than June 30, 2016 for the 4-year term 
beginning July 1, 2018.  Detailed instructions for submission of names of potential candidates to 
serve as ACIP members may be found on the ACIP web site: 
E-mail:  acip@cdc.gov Web homepage:  www.cdc.gov/vaccines/acip/index.html 
Nominations:  www.cdc.gov/vaccines/acip/committee/req-nominate.html 
A current CV, at least one recommendation letter from a non-federal government employee, and 
complete contact information are required.  These may be submitted as e-mail attachments to 
Dr. Jean Clare Smith at jsmith2@cdc.gov 
To summarize COI provisions applicable to the ACIP, as noted in the ACIP Policies and 
Procedures manual, members of the ACIP agree to forgo participation in certain activities 
related to vaccines during their tenure on the committee.  For certain other interests that 
potentially enhance a member’s expertise while serving on the committee, CDC has issued 
limited COI waivers.  Members who conduct vaccine clinical trials or serve on data safety 
monitoring boards (DSMBs) may present to the committee on matters related to those vaccines, 
but these members are prohibited from participating in committee votes on issues related to 
those vaccines.  Regarding other vaccines of the concerned company, a member may 
participate in discussions, with the proviso that he/she abstains on all votes related to the 
vaccines of that company.  It is important to note that at the beginning of each meeting, ACIP 
members state any COIs. 
Announcements:  Welcomes & Goodbyes 
Nancy Bennett, MD, MS 
ACIP Chair 
Dr. Bennett shared the following announcements, welcoming individuals new to ACIP and 
wishing farewell to those who were moving on, emphasizing how sad it was to be losing several 
members.  She presented Certificates of Appreciation to each departing member. 
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  Dr. Nancy Messonnier 
 
Dr. Messonnier was named Director of the National Center for Immunization and Respiratory 
Diseases (NCIRD) in March 2016.  Dr. Messonnier received her BA from the University of 
Pennsylvania and MD from the University of Chicago School of Medicine, and completed 
internal medicine residency training at the University of Pennsylvania.  She joined CDC in 1995 
as an Epidemic Intelligence Service (EIS) officer in the Childhood and Respiratory Diseases 
Branch, and she served as Branch Chief of the Meningitis and Vaccine-Preventable Disease 
Branch in NCIRD from the Center’s formation in 2006 through 2012.  Since 2012, Dr. 
Messonnier has held several additional leadership positions across CDC, and most recently 
served as Deputy Director of NCIRD. 
 
  Dr. Kathy Harriman 
 
Dr. Harriman is Chief of the Vaccine Preventable Disease Epidemiology  
Section, Immunization Branch of the California Department of Public Health (CDPH) in 
Richmond, California.  Dr. Harriman has done an outstanding job of representing public health 
on ACIP, for which ACIP is extremely grateful.  Dr. Harriman believed that going to Africa to 
work on Ebola was not a good enough excuse to miss a meeting, so she decided to break her 
leg as well.  She has served on the following ACIP WGs:  Adult Immunization (Chair), General 
Recommendations (Chair), Meningococcal Vaccines (Member), Pertussis-Containing Vaccines 
(Member), and Hepatitis Vaccines (Member).  She has helped to keep ACIP on track with her 
great public health expertise and vision. 
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  Dr. Lee Harrison 
 
Dr. Harrison is Professor of Medicine and Epidemiology in the Infectious Diseases Epidemiology 
Research Unit at the University of Pittsburgh in Pittsburgh, Pennsylvania (PA).  Dr. Harrison 
was so deeply engaged in the Zoster WG that he actually got Zoster.  He has always been an 
incredible voice for everyone with inquisitive questions, calm reason, and delightful nature.  He 
has served on the following ACIP Work Groups:  Smallpox Vaccine (Chair), Meningococcal 
Vaccines (Member), Herpes Zoster (Member), Influenza (Member), and Meningococcal Disease 
Outbreaks (Member). 
  
  Dr. Ruth Karron 
 
Dr. Karron is a Professor and Director of the Center for Immunization Research in the 
Department of International Health at Johns Hopkins Bloomberg School of Public Health  
Baltimore, Maryland.  Clearly, Dr. Karron has magical powers.  She has managed to Chair the 
Influenza WG and to convince Dr. Walter to take it over from her.  Given the breadth and depth 
of the issues through which Dr. Karron has led the ACIP, this is truly striking.  She has had the 
shortest tenure of any WG member on the respiratory syncytial virus (RSV) WG.  Since new 
ACIP members have not yet been named, it is possible that Dr. Karron will continue to Chair 
that WG.  She always asks critical questions and exhibits incredible persistence in seeking to 
acquire the most important information to help ACIP make decisions. 
 
  Dr. Lorry Rubin 
 
Dr. Rubin is the Director of Pediatric Infectious Diseases at the Steven and Alexandra Cohen 
Children’s Medical Center of New York of the North Shore-Long Island Jewish Health System in 
New Hyde Park, New York.  He is also Professor of Pediatrics at Hofstra-North Shore LIJ 
School of Medicine in Hempstead, New York.  When Dr. Rubin took over as the Chair of the 
Meningococcal WG, he was promised that it was soon to go on hiatus.  It is still almost going on 
hiatus.  Dr. Rubin has made incredible contributions across the board for ACIP.  Though Dr. 
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Bennett was his mentor when he joined ACIP, she said she learned everything she knows from 
him.  Dr. Rubin has always been completely on point, is entirely unflappable, and his wisdom 
has helped ACIP in many ways.  He has served on the following ACIP WGs:  Meningococcal 
Vaccines (Chair), Yellow Fever/Japanese Encephalitis Vaccines (Chair), and Pneumococcal 
Vaccines (Member). 
 
Dr. Bennett thanked departing members for their service, emphasizing what a pleasure and 
honor it had been to work with them, and what sadness there was in seeing them go. 
 
Before officially beginning the meeting, Dr. Bennett called the roll to determine whether any 
ACIP members had COIs.  The following COIs were declared: 
 
 
 
 
Dr. Belongia has a conflict for influenza and RSV due to receiving research support from 
Medimmune and Novovax. 
Dr. Romero has a conflict for RSV for funding non-related to vaccine trials and therapeutics. 
The remainder of the ACIP members declared no conflicts. 
 
Dr. Bennett then requested that the liaison and ex officio members introduce themselves.  A list 
of Members, Ex Officio Members, and Liaisons are included in the appendixes at this end of this 
document. 
 
   
Centers for Disease Control and Prevention (CDC) 
 
Dr. Messonnier thanked everyone for the warm welcome and said that she was looking forward 
to this new role.  She reported that in the June 6, 2016 Morbidity and Mortality Weekly Report 
(MMWR), CDC released a Vitalsigns™ on Legionnaires’ disease titled, Legionnaires’ Disease: 
Use water management programs in  buildings to help prevent outbreaks.  This is a new look for 
CDC at Legionnaires’ disease and the launch of a new initiative to try to be more proactive 
about the role of Legionnaires’ disease.  The 2016 National Immunization Conference (NIC) will 
be convened on September 13-15, 2016 at the Hilton Hotel in downtown Atlanta.  The NIC is 
one of the largest public health events sponsored by CDC, with approximately 1500 participants 
(physicians, nurses, scientists, program managers) representing all 50 states and US territories.  
It is a 3-day conference with 3 plenary sessions, 12 breakout sessions, multiple workshops, 
immunization question and answer (Q & A) sessions, exhibits, posters, and the Hilleman 
Lecture.  The agenda for the event is still under development.  Registration is open through 
August 22, 2016.  Space is limited, so Dr. Messonnier encouraged everyone to sign up early. 
 
Centers for Medicare and Medicaid Services (CMS) 
 
Dr. Cohn delivered the report for CMS on behalf of Dr. Hence, who was unable to attend but 
was watching the webcast:  CMS recently released the 2015 Annual Report on the Quality of 
Care for Children in Medicaid and CHIP (Children’s Health Insurance Program), and the same 
report for adults.  This year for the first time, CMS developed a number of domain-specific 
reports.  One of the domain-specific reports is Primary Care Access and Preventive Care in 
Medicaid and CHIP that includes information on a number of immunization quality measures.  
These reports can be found in the “Quality of Care” section of www.medicaid.gov  
 
Agency Updates 
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Department of Defense (DoD) 
 
Dr. Sergienko reported that the Walter Reid Army Institute of Research (WRAIR) is working in 
conjunction with the Beth Israel Deaconess Medical Center at Harvard on two Zika vaccine 
candidates.  They have been tested as single doses in mice and have been shown to be 
protective.  WRAIR is moving forward with the purified inactivated virus vaccine called Zika 
purified inactivated virus (PIV) and expects to move that into human trials before the end of 
2016.  Other immunization-related news is that the Accession Screening and Immunization 
Screening Program within the Defense Health Agency (DHA) Immunization Healthcare Branch 
is continuing forward.  This is a program to ensure that military recruits receive the appropriate 
immunizations in adherence to accepted medical standards, and to gain clinical and economic 
advantages by delivering only the vaccines that are needed.  This has been done through a 
combination of screening and serological testing, and shows that the requirements for 
immunization have been reduced for incoming recruits.  There is a continuous quality 
immunization improvement process ongoing within the DHA that dispatches immunization 
healthcare specialists out to DoD facilities and immunization clinics throughout the world, 
ensuring that those installations adhere to the standards for military immunizations.  The DoD 
educational training activity for the next fiscal year is ongoing, ensuring that the members of all 
of those facilities providing immunizations complete 8 hours of immunization training annually.  
For further information on all of these programs, the DHA Immunization Healthcare Branch has 
migrated from a prior website to a new website, which is www.health.mil/vaccines.  This has an 
expanded portfolio on all immunization-related programs. 
  
Department of Veterans Affairs (DVA) 
 
Dr. Kim reported that DVA continues to collaborate with 5 states on the Veterans Information 
Systems and Technology Architecture (VistA) to have privately provided immunizations 
autonomously written to VA records.  The plan is to add a minimum of 10 more states each 
fiscal year for the next two years.  This project is also developing the capacity for inbound 
communications from the DoD for read / write to a veteran’s electronic medical record (EMR) of 
their immunizations received during military service.  DVA completed a successful partnership 
with Walgreen’s for the 2015-2016 influenza season.  Through this program, no cost influenza 
vaccinations for veterans were provided if they were enrolled in VA healthcare.  This was a 
national program available at approximately 8000 Walgreen’s locations.  Automated data 
population into the VA health record was provided through this program, as well as an update of 
the VA clinician prompts for influenza.  Through this program, approximately 50,000 vaccines 
were administered to veterans at Walgreen’s, with almost all being influenza vaccines.  VA 
clinical reminders, which are electronic decision support tools, were released for tetanus and 
herpes zoster immunizations for use in the VA healthcare system in May 2016. 
 
Food and Drug Administration (FDA) 
 
Dr. Sun reported that since the February 2016 ACIP meeting, FDA approved Flucelvax® 
trivalent influenza vaccine for those 4 through 18 years of age that was previously approved for 
18 years of age and above.  Flucelvax Quadrivalent® was approved for all individuals 4 years of 
age and older.  Trumemba® 2-dose was approved for an alternative regimen consisting of a 0- 
and 6-month schedule.  Previously, Trumenba® was approved only for a 0-, 2-, and 6-month 
schedule.  On March 21, 2016, the first Fluzone® Southern Hemisphere formulation was 
approved for the US.  For this year, this is based on WHO recommendations.  In future years, it 
will be based on the Vaccines and Related Biological Products Advisory Committee (VRBPAC) 
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that will probably be held twice a year now.  A cholera vaccine was recently approved for 
travelers for individuals 18 through 64 years of age.  In addition to these approvals, it has been 
almost a year since the Pregnancy and Lactation Labeling Rule has been in place.  This is 
applicable to all drug prescribing information, and will start appearing in all vaccine labels.  This 
is a way in which the FDA has tried to improve communication of safety data related to use of 
drugs and vaccines in pregnant women and women who are breastfeeding.  The old pregnancy 
classification had been set aside. 
 
Health Resources and Services Administration (HRSA) 
 
Dr. Nair reported that the national Vaccine Immunization Compensation Program (VICP) has 
had a busy year processing claims.  As of early May 2016, 637 claims have been filed for the 
current fiscal year.  Thus far, 303 of these claims have been adjudicated.  To date in 2016, $125 
million in awards have been paid to petitioners, and $11 million have been paid to attorneys for 
fees and costs for compensated and dismissed claims.  More data about the program can be 
obtained on the HRSA website.  HRSA completed development of proposed regulations to 
update the Vaccine Injury Table.  The Notice for Proposed Rulemaking was issued in July 2015 
and was available for comment for 180 days, which concluded in January 2016.  A hearing to 
obtain comments from the public on the proposed changes took place on January 14, 2016.  
Comments received from the public are still being reviewed in order to finalize that rule.  To date 
in this fiscal year, the Countermeasures Injury Compensation Program (CICP) has 
compensated 27 claims totaling $4.5 million. 
  
Indian Health Services (IHS) 
 
No report. 
 
National Institutes of Health (NIH) 
 
Dr. Gorman reported that NIH is working with four vaccine manufacturers and producers to 
enable them to develop Zika virus vaccine through Investigational New Drugs (INDs) and 
clinical trials.  There is a deoxyribonucleic acid (DNA)-based vaccine, a live-attenuated vaccine, 
a genetically engineered Zika virus vaccine, and the vaccine being developed by WRAIR.  On 
June 21, 2016, NIH announced that the Zika in Infants and Pregnancy (ZIP) trial would be 
ongoing.  ZIP is a collaborative effort between the National Institute of Allergy and Infectious 
Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), and 
National Institute of Environmental Health Sciences (NIEHS).  The plan is to enroll 10,000 
pregnancies and follow the infants for infections and environmental status.  An experimental 
malaria vaccine, developed by Sanaria, has been shown to provide protection for one year 
against malaria.  Those who are vaccinated are followed for one year and then re-challenged in 
a challenge model.  All vaccinees were protected for one year in duration.  The NIAID awarded 
a large contract for the study of adjuvants, matching adjuvants with antigens and providing 
multiple adjuvants to a single adjuvant to determine whether better immune responses can be 
evoked.  NIH and NIAID have a longstanding policy of not releasing promissory notes.  
However, for this particularly report, they were allowed to release a promissory note.  A large-
scale HIV vaccine trial is being planned in South Africa.  Based on the results of a previous trial 
in Southeast Asia where there seemed to be some evidence of protection, those vaccines have 
been improved or ways to increase their immune response have been changed.  The trial is 
anticipated to start in November 2016 in South Africa pending the multiple regulatory approvals 
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required between now and then.  A paper was published recently pertaining to the promises and 
challenges of vaccines for hospital-associated infections (HAIs). 
 
National Vaccine Program Office (NVPO) / NVAC 
 
Dr. Gordon indicated that she was reporting on behalf of Dr. Gellin, who also is the Designated 
Federal Official (DFO) for the President’s Advisory Council on Combating Antibiotic-Resistant 
Bacteria (PACCARB) that was meeting at the same time as ACIP.  Dr. Gelling asked Dr. 
Gordon to convey to ACIP that the Secretary asked PACCARB to provide guidance on best 
ways to incentivize the development of therapeutics, rapid diagnostics, and vaccines.  In order 
to address this charge, PACCARB is in the process of establishing three WGs, including one 
that will be dedicated to understanding these issues for vaccines. 
  
In terms of activities within the NVPO office, NVPO is in the process of finalizing a mid-course 
review of its 2010 National Vaccine Plan (NVP).  This analysis represents a comprehensive 
stakeholder engagement to help identify and build consensus on priority areas thought to have 
the greatest potential impact for the remaining five years of the NVP.  NVPO hopes to have the 
results available for distribution by the summer of 2016.  The results will be used to guide the 
development of the 2016-2020 implementation plan. 
 
As part of its effort to support adult immunization, NVPO in partnership with American Academy 
of Pediatrics (AAP), the Gerontological Society of America (GSA), and the National Foundation 
for Infectious Diseases (NFID) co-hosted the 3rd Immunization Congress:  Financing Across the 
Lifespan on April 27-28, 2016 in Washington, DC.  The purpose of this Congress was to identify 
the financial challenges facing different physician types in providing vaccines in their offices to 
their patient populations.  The Immunization Congress is in the process of publishing the 
proceedings, which will be available soon. 
  
After a highly competitive independent review, NVPO has awarded a cooperative agreement to 
Emory University in support of their research project titled, “Transforming Vaccine Hesitancy 
into Confidence—Research to Address Parents' Vaccine Decision-Making and Inform 
Development of Novel Immunization Communication Education Strategies.”  This award stems 
from NVAC’s recommendations pertaining to vaccine confidence and Goal 3 in the NVP, which 
addresses vaccine communication. 
  
Dr. Kimberly Thompson was recently appointed to serve as the incoming Chair of NVAC.  
NVAC convened its last meeting June 7-8, 2016 in Washington, DC.  The agenda included a 
number of discussions on mechanisms to overcome economic and scientific challenges to 
vaccine research and development.  There was an update on efforts to improve human 
papillomavirus (HPV) vaccinations among adolescents.  Updates were presented by the NVAC 
Maternal Immunization WG and the Mid-Course Review WG.  Both of these WGs plan to 
finalize their analyses for discussion during the September 2016 NVAC meeting.  
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Introduction 
 
Arthur Reingold, MD 
University of California, Berkeley 
Chair, ACIP Cholera Vaccine Work Group 
 
Dr. Reingold reminded everyone that the Cholera Vaccine WG was formed in August 2015 with 
the relatively specific mandate of preparing for the licensure of a new cholera vaccine for use in 
the US among travelers.  During the October 2015 ACIP meeting, the WG presented an 
overview of cholera background and epidemiology.  During the February 2016 ACIP meeting, 
PaxVax presented Vaxchora™ clinical data and the Cholera Vaccine WG presented a Grading 
of Recommendation Assessment, Development, and Evaluation (GRADE) evaluation. 
 
FDA approved Vaxchora™ (CVD-103 HgR) vaccine on June 10, 2016 for prevention of cholera 
caused by serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected 
areas.  Vaxchora is the only FDA-approved vaccine for the prevention of cholera. 
 
The Cholera Vaccine WG activities since February 2016 have included summarization of 
additional data on special populations (pregnant women, breastfeeding women, 
immunocompromised people, and children), shedding and transmission of vaccine strain, 
duration of protection; and development of proposed recommendations. 
 
Dr. Reingold indicated that during this session, Dr. Karen Wong from CDC would provide a 
cholera vaccine update and proposed recommendations, followed by a vote on use of this 
vaccine. 
 
Cholera Vaccine Update / Proposed Recommendations 
 
Karen K. Wong, MD, MPH 
Medical Officer 
Division of Foodborne, Waterborne, and Environmental Diseases 
National Center for Emerging and Zoonotic Infectious Diseases 
Centers for Disease Control and Prevention 
 
Dr. Wong reminded everyone that cholera is caused by toxigenic Vibrio cholerae O1.  It causes 
watery diarrhea that may be severe and rapidly fatal without proper treatment.  Cholera is 
endemic in more than 50 countries, and may also cause epidemics.  Rehydration can reduce 
fatality rate to less than 1%.  In the US, most cases occur among travelers to cholera-affected 
areas.  Cholera is rare; however, an increase in cases in travelers from Haiti was observed after 
the epidemic began in October 2010.  Safe food and water and personal hygiene measures are 
key to prevention.  Populations who may be at higher risk of poor outcomes from cholera 
include travelers without ready access to rehydration therapy and medical care and travelers 
with a condition that carries increased risk of poor clinical outcomes from cholera, such as blood 
type O, pregnancy, immunocompromising conditions, cardiovascular disease, and renal 
disease. 
 
Cholera Vaccine 
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CVD 103-HgR is a live attenuated single-dose oral cholera vaccine that protects against 
toxigenic V. cholera infection.  More than 500,000 doses of the previous formulation were 
distributed before manufacture ceased for business reasons.  The vaccine was redeveloped as 
Vaxchora™, hereafter referred to as the “new formulation” of the vaccine.  Vaccine efficacy (VE) 
has been assessed by immunogenicity and protection against oral cholera challenge. 
 
During the February 2016 ACIP meeting, the WG presented its GRADE review and concluded 
that CVD 103-HgR vaccine is safe and effective for prevention of infection with toxigenic V. 
cholerae O1.  The overall evidence type was 2.  For Safety outcomes, the evidence type was 3. 
For Efficacy, the evidence type was 1. 
  
No data exist on the use of CVD 103-HgR vaccine in pregnant or breastfeeding women.  
Pregnant women are at risk of poor outcomes from cholera infection.  The vaccine is not 
absorbed systemically; therefore, maternal exposure to CVD 103-HgR is not expected to result 
in exposure of the fetus or breastfed infant to the vaccine.  No data exist on the use of the new 
vaccine formulation in immunocompromised populations.  However, one study of the vaccine 
formulation in HIV+ adults in Mali found that vibriocidal seroconversion was slightly lower 
among HIV-positive than HIV-negative participants (58% versus 71%).  No differences were 
found between vaccinated and comparison populations for any systemic adverse events (AEs). 
 
No data exist on the use of the new vaccine formulation in children.  However, limited data exist 
on use of the older formulation.  There were 10 studies that included participants 3 months to 17 
years of age.  Studies were conducted in Ecuador, Chile, and Indonesia.  None were in the US.  
There were no pediatric challenge studies.  The vibriocidal antibody responses corresponded to 
VEs between 29% to 98%, and no association was detected between CVD 103-HgR and any 
systemic or serious adverse events (SAEs). 
 
Some data exist on the shedding of the new vaccine formulation strain.  In two randomly 
allocated study groups combined, 11.1% of subjects shed the vaccine strain in stool at any point 
up to 7 days post-vaccination [Chen WH, Greenberg RN et al. Clin Vaccine Immunol. 
2014;21(1):66–73]. 
 
In a study of the new vaccine formulation, the vaccine strain was not isolated from stools of 28 
household contacts cultured 7 days post-vaccination.  With the older formulation, the vaccine 
strain was isolated from stool in less than 1% of household contacts cultured up to 5 days post-
vaccine.  It is important to note that both studies may miss transmission events that would be 
detected after 5 or 7 days.  Seroconversion was detected in 3.7% of family contacts when 
tested at 9 or 28 days [Chen WH, Greenberg RN et al. Clin Vaccine Immunol. 2014;21(1):66–
73; and Simanjuntak CH et al. Journal Inf Dis. 1993;168:1169-76]. 
 
Duration of protection has been assessed from cholera challenge studies.  For the new 
formulation, VE for protection against severe diarrhea was evaluated up to 3 months post-
vaccination at 79.5%.  For the older formulation, VE for protection against diarrhea of any 
severity was evaluated up to 4 to 6 months post-vaccination and approached 100% [Tacket CO 
et al. J Infect Dis. 1992 Oct;166(4):837-41].  The duration of the immune response has been 
evaluated for the new formulation.  Vibriocidal antibody seroconversion was detected in 90.4% 
of vaccinees up to 180 days, or 6 months, post-vaccination.  No data exist on re-immunization 
with the new vaccine formulation [Chen WH, Greenberg RN et al. Clin Vaccine Immunol. 
2014;21(1):66–73; and Chen WH, Cohen MB et al. Clin Infect Dis. 2016 Jun 1;62(11):1329-35]. 
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FDA announced Vaxchora™ approval on June 10, 2016 for use in adults 18 through 64 years 
old traveling to cholera-affected areas.  The package insert states certain limitations of use.  
The first two concern people who may already be immune:  1) effectiveness is not established in 
persons living in cholera-affected areas; and 2) effectiveness is not established in persons with 
pre-existing immunity due to previous exposure to V. cholerae or receipt of a cholera vaccine.  
The package insert also states that the vaccine is not shown to protect against disease caused 
by non-O1 serogroups. 
 
The package insert states that safety and effectiveness are not established in 
immunocompromised persons.  The vaccine strain may be shed in the stool of recipients for at 
least 7 days.  It says to use caution when considering whether to administer Vaxchora™ to 
individuals with immunocompromised close contacts.  It also mentions the establishment of a 
pregnancy exposure registry, and states that safety and effectiveness are not established in 
persons younger than 18 years of age or those 65 years of age and older. 
 
The WG had certain considerations for formulating the recommendation option.  From the 
GRADE review, the evidence supports the safety and efficacy of the vaccine.  In terms of the 
risk, cholera among travelers is rare but can be severe.  Most travelers to cholera-affected 
areas are at low risk of severe infection.  The WG felt that a Category A recommendation for a 
clearly defined population would be easier for clinicians to interpret and implement.  The WG’s 
approach to the recommendation option was to propose a Category A recommendation for a 
defined subpopulation of travelers.  This proposed recommendation would require assessment 
of the individual traveler’s risk factors and travel plans.  The WG felt that the recommendation 
should be clear that vaccine is not routinely recommended for most travelers due to the low risk 
of cholera.  Given that the duration of protection beyond 3 to 6 months is not known at this time, 
the WG included no formal recommendations for re-immunization in the proposed option.  It is 
important to assess data on re-immunization as it becomes available and to update the 
recommendation at that time. 
 
Dr. Wong indicated that the proposed recommendation for prevention of severe cholera among 
travelers consisted of personal protective measures and use of CVD 103-HgR vaccine.  The 
vaccine portion would be a Category A recommendation.  The vaccine recommendation would 
require travel to an area of active toxigenic V. cholerae O1 transmission AND increased risk of 
exposure to toxigenic V. cholerae O1 OR increased risk of poor outcome if infected.  She 
presented the following text of the proposed recommendation: 
 
Personal Protective Measures 
 
 
 
All travelers to cholera-affected areas should follow safe food and water precautions 
and proper sanitation and personal hygiene measures as primary prevention 
strategies against cholera infection. 
Travelers who develop severe diarrhea should seek medical attention, particularly 
rehydration therapy, promptly. 
 
Use of CVD 103-HgR Vaccine 
 
1. Vaccination against cholera is not routinely recommended for most travelers who are 
at low risk of exposure to toxigenic V. cholerae O1. Prevention of cholera and other 
diarrheal diseases primarily depends on following safe food and water precautions 
and personal hygiene measures.  
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2. The decision to vaccinate should be made after detailed assessment of the individual 
traveler’s risk of exposure to toxigenic V. cholerae O1 and the traveler’s risk of 
severe outcomes if infected.  
3. CVD 103-HgR vaccine is recommended for travelers to an area of active cholera 
transmission 
a. who are at increased risk of toxigenic V. cholerae O1 exposure, or 
b. whose individual risk factors or travel situations carry increased risk of poor 
clinical outcome if infected. 
c. These populations include: 
 
 
 
 
 
 
 
People with increased risk of exposure to toxigenic V. cholerae O1, which 
can include:  
Travelers, including those visiting friends and relatives, who are 
unable to consistently follow safe food and water precautions and 
personal hygiene measures in an area of active toxigenic V. 
cholerae O1 transmission 
Healthcare personnel and others who have direct contact with 
body fluids (vomitus or stool) from cholera patients 
People with increased risk of poor clinical outcome if infected, which can 
include: 
Travelers who may be without rapid access to adequate 
rehydration and medical care 
Travelers with a condition known to carry increased risk of poor 
clinical outcomes from cholera, such as low gastric acidity or 
blood type O 
Travelers with chronic medical conditions, including but not limited 
to travelers with conditions such as cardiovascular or kidney 
disease who would tolerate dehydration poorly 
 
There would be 2 footnotes: 
 
1An area of active cholera transmission is defined as a province, state, or other 
administrative subdivision within a country with endemic or epidemic cholera caused by 
toxigenic V. cholerae O1 and includes areas with cholera activity within the last 1 year 
that are prone to recurrence of cholera epidemics; it does not include areas where rare 
sporadic cases have been reported. Most travelers from the United States do not visit 
areas with active cholera transmission. The vaccine is not routinely recommended for 
most travelers from the United States.  
 
2Long-term travelers and frequent travelers to areas of active cholera transmission may 
also be at increased risk of exposure, because the cumulative risk of exposure to unsafe 
food or water is presumed to be higher with longer duration of travel.  However, data are 
limited on the duration of protection beyond 3–6 months afforded by vaccination with 
CVD 103-HgR.  
 
To review, the first section about personal protective measures talked about following safe food 
and water and personal hygiene precautions, and seeking medical attention promptly for severe 
diarrhea.  The section about use of vaccine stated that the vaccine is not routinely 
recommended for most travelers.  It recommended detailed assessment of the traveler’s risk of 
exposure and risk of severe outcomes.  It stated that the vaccine is recommended for travelers 
to an area of active cholera transmission who are at increased risk of exposure, or whose risk 
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factors or travel situations carry increased risk of a poor clinical outcome if infected.  Examples 
were given of populations who meet these criteria. 
 
 
 
Discussion Points 
 
Dr. Messonnier said her understanding was that the definition of “travelers” means adults, 
children were excluded, and pregnant women were not excluded. 
 
Dr. Wong responded that it means adults for the indicated age range of 18 through 64 years of 
age.  The data on pregnant women are limited or non-existent, and the WG would expect to 
elaborate on that in the recommendation.  However, the recommendation does not exclude 
recommending pregnant women. 
  
Dr. Belongia wondered  if it was true in every country where cholera transmission is endemic 
that 99% of cases are due to O1 and a small proportion are due to O139, or if there are areas 
where O139 is more of an issue. 
 
Dr. Wong indicated that O139 is more common in areas of Asia and Southeast Asia, but most 
cholera throughout the world is O1.  
 
Dr. Walter questioned whether there is any information and guidance on appropriate timing of 
vaccination prior to travel, and if there is an upper limit. 
 
Dr. Wong replied that the recommendation is 10 days prior to travel, and that she did not believe 
that there is an upper limit. 
 
Dr. Moore said she appreciated the concrete definition of who should receive the vaccine, and 
wondered whether CDC would help them in implementing this by consistently updating its travel 
site with the specific areas that meet the criterion for active transmission.  She could understand 
clinicians being challenged to figure out which areas meet the criterion for active transmission.  
This would be simple for the website to keep current. 
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Dr. Wong responded that the various mechanisms to report cholera epidemiology can be 
incomplete, and cholera epidemiology can change quickly.  Therefore, discussion is underway 
with CDC’s Travelers’ Health Branch (THB) regarding how that website can be used to help 
clinicians assess where areas of active cholera transmission are. 
 
Dr. Kempe suggested in the guidelines to include a linkage that will make if very easy to 
connect to this information.  Another implementation-related issue is low gastric acidity.  She 
asked whether that included people on chronic acid blockers, and thought some definition of 
that would be helpful. 
 
Dr. Wong confirmed that low gastric acidity could have many causes, including medications.  
Individuals with low gastric acidity are known to be at risk for more severe outcomes.  That is 
going to be a potentially large segment of the population.  However, restricting the 
recommendation to areas of low transmission will confine this to a narrow population to begin 
with. 
 
Dr. Kempe thought that if this would include people on chronic Prilosec®, this should be 
specified in the recommendation. 
 
Dr. Belongia asked whether there was any recommendation regarding co-administration with 
oral typhoid vaccine. 
 
Dr. Wong responded that there are no data regarding co-administration with the new vaccine 
formulation, which is stated in the package insert.  There are studies with the older formulation 
that were presented during the last ACIP meeting that found no interaction when co-
administered with typhoid vaccine. 
 
Dr. Messonnier noted that the defining criteria come from defining this as only people traveling 
places where cholera is raging.  Regarding the second criterion, she wondered whether any 
thought had been given to the fact that combining the proportion of those travelers who were 
either blood type O or for some reason were on acid suppressing therapy would mean that most 
people traveling to a cholera-endemic area would meet the second criterion.  If so, perhaps the 
recommendation would be simpler by merely focusing on the cholera-endemic area. 
 
Dr. Wong replied that this point was discussed extensively within the WG.  Blood type O is very 
common, as are medications that cause low gastric acidity.  The rationale was that defining the 
area of active cholera transmission would be the initial narrowing filter.  There was discussion 
regarding the possibility of including only that point and the increased risk of exposure. 
 
Dr. Reingold added that the WG spent a lot of timing talking about the fact that half the 
population is blood group O.  In the recommendation, the attempt was to point to the fact that 
the number of people traveling to areas with substantial transmission is limited.  Most travelers 
are not going to be in a situation where they are at risk of cholera or severe dehydration. 
 
Dr. Romero asked whether there were any data on co-administration of this vaccine with 
trivalent or bivalent oral polio vaccine. 
 
Dr. Wong responded that there were no data pertaining to the new formulation, but there are 
with regard to the older formulation that were presented during the last ACIP meeting.  There 
were no interactions. 
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Recognizing that children are not included in the current language under consideration, Dr. 
Kimberlin (AAP) asked whether Dr. Wong was aware of any studies ongoing or planned in the 
pediatric population that might one day inform use of this product in people younger  than 17 
years of age. 
 
Dr. Wong requested that someone from PaxVax respond to this question. 
 
Dr. Danzig (PaxVax) indicated that PaxVax plans to start a pediatric study in 2017 in 2 through 
18 year olds.  The prior study on oral polio vaccine showed no interaction with CVD 103-HgR 
and the liquid formulation of the typhoid vaccine.  The oral typhoid vaccine would not be given 
co-administered with any buffer.  PaxVax would be worried more about the typhoid concomitant 
administration, but there was no interaction with the bacteria. 
 
Dr. Rubin asked whether there was any intent to offer guidance for administration of the vaccine 
to recipients who have a household or occupational exposure to immunocompromised persons.  
The FDA wording is “use with caution.”  He wondered whether they should amplify on that to 
say it should or should not be used in such cases. 
 
Dr. Wong indicated that the WG has not yet decided what should be said about people who may 
have immunocompromised household members.  The package insert does indicate to “use 
caution” and there are data from the older formulation to show that transmission can occur. 
 
Dr. Middleman (SAHM) noted that many of the young adults and adolescents she sees do not 
know their blood type.  She wondered whether there were any data about whether people 
typically know their blood type and if not, whether there should be a recommendation for people 
to get a type and cross before deciding whether to get the vaccine. 
 
Dr. Wong indicated that the WG discussed this extensively.  There is no recommendation 
currently in the wording that clinicians should test blood type as part of the decision-making 
process.  The WG has discussed that blood type O is very common, and people can assume 
that they are blood type O unless they know otherwise.  This is probably an area for clinician 
judgment and may depend upon the person and what their other risk factors may be. 
 
Dr. Baker expressed her appreciation for the details, data, and good questions / answers.  
However, she observed that the recommendation was very complicated.  While she did not 
have a solution and knew the WG tried to be as transparent with the data as possible, it 
reminded her of a Category B recommendation in which the burden is on the physician to have 
a discussion with the patient.  Even in a travel vaccine situation, there is a lot of finesse.  She 
thought the recommendation was pretty complicated to be a Category A if the goal was for the 
vaccine to be used for people at risk, because it will be a large number of people. 
 
Dr. Wong emphasized that the WG’s rationale was to make a clear and narrow 
recommendation. 
 
Dr. Zahn (NACCHO) asked how rare travel-associated cholera is in terms of numbers of 
reported or identified cases.  He also wondered whether there was an issue for persons in need 
of malaria prophylaxis in addition to potential cholera exposure. 
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Regarding how rare is rare, Dr. Wong noted that cholera is underreported.  Illness is often mild 
or moderate and self-limited, so it does not come to attention.  Because of the disease duration 
and incubation period, disease may occur when people are still outside of the US.  That being 
said, there may be about 100 cholera cases per year, though only a handful may be reported to 
CDC surveillance as laboratory confirmed infections.  But, increases have been seen after 
certain events such as the Haiti epidemic when there were more than 40 cases reported in one 
year.  There have also been some outbreaks such as the one that occurred on a plane with 
travelers returning to the US.  In terms of oral prophylaxis, with the older formulation there was a 
study in which various antimalarial prophylaxis regimens were assessed.  It was found that 
chloroquine may reduce the immunogenicity of the vaccine.  There are no studies with the new 
formulation, but the package insert recommends against co-administration with chloroquine or 
at least spacing it out. 
 
Dr. Mahon (SME) said she thought Dr. Baker’s point was really good.  There was strong feeling 
among the WG members that a Category A recommendation would be much easier to 
implement and that they should do as much of the work of defining that as possible rather than 
deferring too much to the clinician.  The sense of the WG would probably be that if there is a 
way to make the wording clearer and keep it a Category A recommendation, perhaps that would 
be more useful to the clinician. 
 
Dr. Baker commented that CDC is such a tremendous source of what countries / locations are 
at risk for severe cholera, that information will be readily available for people to look up. 
 
Dr. Reingold said that he recently had to advise his daughter when they were traveling through 
Southeast Asia whether to get Japanese Encephalitis Vaccine (JEV), the areas at risk, and how 
great the risk was in terms of their activities, the benefits, et cetera.  He thought in some ways, 
cholera was very similar.  It is very difficult to give a blanket recommendation to all travelers, 
and a lot of the burden is going to fall on physicians in travel clinics and based on good data 
from CDC and elsewhere about where active transmission is occurring.  The WG could not 
come up with a way to get around that problem, so he said they would be delighted to hear 
alternative suggestions. 
 
Regarding the surveillance issue and the fact that cholera is underreported, Dr. Thompson 
(NVAC) requested further discussion about the global surveillance quality with respect to 
identifying areas of active transmission and the challenge on the temporal side, which is that 
travelers get vaccinated before they go, but do not know what is going to occur while on travel.  
She wondered how to deal with the fact that there could be an active transmission in an area 
upon arrival that was not occurring prior to departing the US. 
 
Dr. Wong replied that global cholera surveillance is definitely patchy.  There is a WHO report, 
but reporting to that is certainly incomplete.  In terms of what could happen if an outbreak 
occurs after a traveler arrives in an area, one of the primary points in the recommendation is 
that the key to prevention is following safe food and water precautions and personal hygiene 
measures. 
 
Dr. Savoy (AAFP) pointed out that most family practice offices do not give this vaccine, but they 
may have patients who ask them whether they should go to a travel clinic to get it.  With a link to 
a graphic that is easy to follow, it would not be that complicated to determine whether someone 
needs to go to a travel clinic based on where they are traveling. 
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Dr. Wong said when providing examples, they would want to offer vignettes for physicians to 
help them understand what increased risk would look like. 
 
Dr. Kempe agreed.  She was concerned that a bullet about blood type and low gastric acid 
would result in a lot of question and confusion, and said she would like to debate the downside 
of removing it. 
 
Dr. Grogg (AOA) said that having been to Haiti during the epidemic, he was excited to have this 
vaccine available.  The AOA has always recommended, if planning to travel to an area for an 
extended period where there is cholera, obtaining the vaccine in that country because the US 
did not have the vaccine.  He thought more clarification was needed with regard to co-
administration of Yellow Fever (YF), typhoid, malaria, et cetera.  That could be in the form of a 
hyperlink.  He also inquired as to the cost of the vaccine. 
 
Dr. Wong replied that the WG would like to make the proper administration procedures as clear 
as possible for clinicians.  The thought was to elaborate on a number of the issues mentioned in 
the text of the full recommendation report.  Regarding the earlier comment about whether to 
remove the specific mention of blood type O and low gastric acidity, the way the 
recommendation is structured, the category of “Increase Risk of Poor Outcome” would have to 
be eliminated or change what it is called if blood type O and low gastric acidity were removed. 
She called upon PaxVax to respond to the question regarding cost. 
 
Dr. Mark Meltz (PaxVax) indicated that the price is anticipated to be between $200 to $300 per 
single dose, which is consistent with other travel vaccines on a per course basis. 
 
Dr. Riley added that the other aspect of increased risk for poor outcome that the WG discussed 
extensively was the ability to be treated.  If someone could be rehydrated safely, the risk of 
death would be reduced to less than 1%.  It would be incumbent on the physician to find out all 
of the risk factors and determine the risk / benefits, especially for pregnancy where there are no 
data about safety. 
 
Dr. O’Leary (PIDS) requested information regarding the magnitude of increased risk with blood 
type O and low gastric acidity. 
 
Dr. Wong indicated that while she did not have those numbers with her, gastric acidity is 
reduced immediately and basically stays very low for people on an inhibitor.  In terms of blood 
type O, the risk is for cholera gravis, which is severe cholera.  Often, cholera is a mild and self-
limited illness that does not even require treatment.  However, cholera gravis is the rapidly 
dehydrating form of the disease with the loss of liters of diarrhea very quickly.  People with 
blood type O are at increased risk for that severe, potentially life-threatening type of cholera. 
 
Dr. O’Leary (PIDS) clarified that he was asking for the magnitude of that risk.  Is it two-fold, five-
fold, 20% higher? 
 
Dr. Wong responded that she did not remember the exact numbers, but it is a substantially 
increased risk of several-fold. 
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Dr. Mahon (SME) inquired as to whether the recommendations for healthcare personnel (HCP) 
where there is discussion about having direct contact with body fluids it meant unprotected 
without personal protective equipment (PPE), or even if they have that on they should still be 
immunized. 
 
Dr. Wong replied that the WG had not discussed that level of detail. 
 
Dr. Romero was not sure that the physician attending to the traveler in the US would have a 
good idea of how rapid or good access they would have to medical care in the area to which 
they plan to travel.  If rapid / good access to medical care is going to be used as a determining 
factor to give the vaccine or not, this needs to be further considered.  He does not know what 
the access to medical care is for many of the pediatric patients he is asked to offer advice for 
when traveling to South America, Asia, or Africa. 
 
Dr. Michael Levine (Co-Inventor of CVD103-HgR) said that regarding the question about blood 
group O, it is important to take into account that blood group O does not increase the risk of 
infection or diarrhea.  It increases the chance of cholera gravis, a severe cholera that can kill 
someone if they do not get to rehydration promptly.  When he teaches, he likes to use the 
example of the lowest prevalence of blood group O in the world which is in the Gangetic Delta.  
In a lovely review paper that Roger Glass wrote a few decades ago, he pointed out that in this 
home of ancestral cholera with, he thinks, the Darwinian lowest prevalence of blood group O, 
two-thirds of the cases of cholera gravis are in blood group O.  In volunteers, if one gives 1 
million or 100 million organisms without buffer, one does not have positive cultures.  One does 
not have diarrhea.  If 1 million organisms are given with buffer, there is a 90% attack rate.  
Persons who are blood group O have a much greater propensity to develop severe cholera.  
Even an inoculum as low as 1000 organisms will give a 67% attack rate if the buffer is given.  In 
terms of risk, Dr. Levine emphasized that when there are large outbreaks, particularly in the 
Western Hemisphere (as in Peru, Ecuador, and Columbia in 1991 and Haiti in 2010), the 
consequence for US travelers increases greatly and bad things can occur.  It is when there is no 
access to healthcare that people are in danger.  Cholera is different.  Everyone knows about 
traveler’s diarrhea.  Cholera is really very special.  When someone is purging at a liter an hour, 
which could happen very quickly in the progression, in three hours they have lost the equivalent 
of the entire plasma volume.  In five hours, they have lost the equivalent of their entire blood 
volume and they are potentially near death.  This is not common, but it is like tornados.  They 
are rare.  Most people who live in tornado areas have not experienced it, but when it happens it 
can be very devastating.  There is a nice study that Dave Taylor did in the 1990s when he was 
assigned in Peru.  He cultured the American workers at the American Embassy, many of whom 
had bad traveler’s diarrhea.  When the attack rate is annualized, it is like endemic disease in the 
developing world.  Those folks all had easy access, but it shows how much more common 
cholera really is when one does very active surveillance, including bacteriologic culture. 
 
Regarding the relative increased risk of people with blood group O or with low gastric acidity, Dr. 
Belongia wondered what some approximation of the risk would be among people who do not 
have those risk factors.  Is the additional complexity really needed in the recommendation?  
Perhaps ACIP should state that they believe the vaccine should be acquired simply due to travel 
to an area where the risk is non-trivial, regardless of risk factors, because there is a still a risk of 
developing severe cholera.  Is the risk so low for someone who is not blood group O or does not 
have low gastric acidity that they do not need to worry about it?  Or if the risk is not that low, 
perhaps the complexity of these additional factors is not needed. 
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Dr. Karron thought it was important, if the recommendation was stratified, to include the 
increased risk of poor outcome in part as an educational measure for physicians.  It may be that 
individuals who are on protein pump inhibitors might not want to take those if going to a cholera-
endemic area.  It is helpful to educate the physicians about that.  It may be worth doing blood 
typing.  She wondered what the impact would be with removal of both narrowing categories, 
which would leave travel to an area of active transmission. 
 
Dr. Mahon (SME) emphasized that the WG spent a lot of time discussing this, and their attempt 
was to narrow and target the recommendation as much as possible.  However, as had been 
pointed out, it does not narrow it that much.  She personally thought it would be reasonable to 
strike the bottom two categories and to include educational material in the recommendation 
itself if it would be easier to implement.  The WG was driven very much by the travel medicine 
perspective of trying to understand exactly who would benefit most from this recommendation.  
She thought the sense of the clinicians was that this is implementable and people would not be 
vaccinated who would not benefit as much.  Most people who meet the first criterion are going 
to meet one or the other of the second criteria, so it is not going to be that big of a difference. 
 
Ms. Pellegrini said she was trying to think about this from the traveler’s perspective.  It seemed 
like the recommendation was most focused on preventing the most severe cases—the 
potentially fatal cases.  If she was a traveler, she would be interested in obtaining this vaccine to 
prevent herself from getting any cholera.  With the recommendation as stated, they seemed to 
be saying they were okay with the mild to moderate cases.  She would be happy to remove the 
qualifiers in order to prevent a greater percentage of cases, including the mild to moderate 
ones. 
 
Dr. Moore said that one counterpoint to that perhaps was, as people are assessing travel, it is 
$200 to $300 for this vaccine.  People also may be paying $200 or $300 for YF and other 
vaccines, and those are typically out-of-pocket costs.  There may be value to including the 
additional criteria so that people who really should get this vaccine understand that they really 
should get it, and those who do not have higher risk factors and will have access to other 
measures can make a decision not to get the vaccine. 
 
Dr. Bennett requested that Dr. Mahon respond to the difference between having these two 
criteria in the recommendation versus having them in the narrative about who is at highest risk. 
 
Dr. Mahon (SME) said she thought it was important to remember that everyone is at low risk, 
even in these categories.  Only several dozen cases of travel-associated cases are seen in the 
US every year.  Although it is possible that other people are getting sick while they are still 
abroad or are not being captured by the surveillance systems, the risk is still pretty low.  The 
pros and cons were well-articulated, and these are the groups who would benefit the most from 
the vaccine.  However, there is additional complexity in implementation that could lead to 
confusion, blood typing that could be a barrier, et cetera.  Personally, she thought either way 
was reasonable and it would be possible to begin with this or start without it and try to assess 
the situation over time. 
 
Dr. Reingold agreed that either way could work.  To him the parallels were somewhat similar to 
JE because it is highly specific within a region, when traveling to an area where there are pigs 
and mosquitos. 
 
Advisory Committee on Immunization Practices (ACIP)                                               Summary Report                                             June 22-23, 2016 
 
 
32 
 
 
Dr. Rubin suggested striking the lower right-hand part of the recommendation and having that 
as guidance, and keeping it simple in terms of being at increased risk based on itinerary.  It is a 
dialogue with the patient in the travel provider’s office that occurs each day.  The other risk 
factors would enter into the conversation.  As Dr. Romero said, it is difficult to know a patient’s 
access to rapid rehydration in the area to which they plan to travel.  This would include 
essentially everybody in the lower right-hand corner anyway. 
 
Regarding the issue of the blood group, Dr. Sun referred to the pivotal trial for the approval of 
this vaccine, in which an assessment was made of whether a patient had blood group O or not 
and vaccine efficacy was evaluated.  At the 10-day challenge versus the 3-month challenge, at 
10 days vaccine efficacy for blood group O was 84% and for non-group O was 100%.  At the 3-
month challenge time point, the efficacy for the O group was 78% and for non-group O was 
83%. 
 
Dr. Mahon (SME) said she thought if the committee wanted to strike the specifics, it would be 
best to strike both rather than just the right.  The thinking was that some people are at higher 
risk of exposure and, therefore, at higher risk of illness and severe illness and some people at 
lower risk of exposure, but if they did get exposed, would be at a high risk of severe illness.  
They thought of the two as going together. 
 
Vote:  Cholera Vaccine Recommendations 
 
Dr. Reingold motioned to approve the recommendation, striking the bottom two boxes and 
placing that information into the lengthy caveats, flow charts, and examples to inform clinicians.  
Dr. Walter seconded the motion.  The motion carried unanimously with 15 affirmative votes, 0 
negative vote, and 0 abstentions.  The disposition of the vote was as follows: 
 
15 Favored: Belongia, Bennett, Ezeanolue, Harriman, Harrison, Karron, Kempe, Moore, 
Pellegrini, Romero, Reingold, Riley, Rubin, Stephens, Walter 
  0 Opposed: N/A 
  0 Abstained:   N/A 
 
 
 
 
Introduction 
 
Lorry Rubin, MD 
Chair, Meningococcal Work Group 
Advisory Committee on Immunization Practices 
 
This being his final meeting, Dr. Rubin said that he wanted to thank everyone for allowing him to 
participate in ACIP for the last four years, which he certainly enjoyed and from which he learned 
a lot. 
 
He reminded everyone that as Dr. Sun mentioned earlier, a revised dosing schedule was 
approved for Trumenba®, Pfizer Vaccines’ MenB-FHbp vaccine.  The dosing schedule was 
approved by FDA on April 14, 2016 to change the 3-dose schedule of administration to a 0.5 mL 
Meningococcal Vaccines 
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dose at 0, 1-2, and 6 months versus the previous 0, 2, and 6 months schedule, as well as the 
approval of a 2-dose schedule with administration of a 0.5 mL dose at 0 and 6 months.  The 
revised schedule indicates that the choice and dosing schedule may depend upon the risk of 
exposure and the patient’s susceptibility to serogroup B meningococcal (MenB) disease. 
 
Dr. Rubin indicated that the presentation topics for this session would include the following: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Updates to the MenB-FHbp dosing schedule, including discussion on potential policy 
options for 2-dose and 3-dose schedules, with no vote planned 
Use of MenACWY vaccines in human immunodeficiency virus (HIV)-infected persons based 
on previous discussion during the February 2016 meeting, with anticipation of ACIP and 
VFC votes during this session 
Focusing on the quadrivalent vaccine and HIV, two policy options were to be raised for 
discussion with ACIP during this session: 
Human Immunodeficiency Virus (HIV)-infected persons aged ≥2 months should routinely 
receive MenACWY vaccine* (Category A) 
 
OR 
 
Human Immunodeficiency Virus (HIV)-infected persons aged ≥11 years should routinely 
receive MenACWY vaccine** (Category A) 
[*Includes MenACWY-D (Menactra®), MenACWY-CRM (Menveo®), and Hib-MenCY-TT 
(MenHibrix®); **Includes MenACWY-D (Menactra®) and MenACWY-CRM (Menveo®)] 
Dr. Rubin reported that the majority of the WG members support vaccinating HIV-infected 
persons beginning at 2 months of age.  The cost-effectiveness and GRADE analyses were 
based on vaccinating HIV-infected persons aged ≥2 months. 
Specific topics during this session included: 
Update: Trumenba® Label 
Summary of WG Discussion:  Trumenba® Label 
Cost-effectiveness of MenACWY in HIV-Infected Persons 
GRADE for MenACWY in HIV-Infected Persons 
Considerations for use of MenACWY in HIV-Infected Persons 
Proposed Recommendations / Vote 
VFC Vote 
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Update:  Trumenba® Label  
 
Dr. Laura York 
Medical Development 
Scientific and Clinical Affairs 
Pfizer 
 
Dr. York presented an update on Trumenba®, which was licensed in October 2014 and received 
FDA approval through the accelerated approval regulations to be used in a 3-dose series of 0, 
2, and 6 months for prevention of meningococcal B disease in individuals 10 through 25 years 
of age.  Recognizing that there are challenges with a 3-dose series, Pfizer continued to assess 
the data and have discussions with FDA to evaluate the potential for receiving a 2-dose 
schedule and the benefit that would be provided by that.  As Dr. Rubin noted, there has now 
been a US label change.  The vaccines were approved through an Accelerated Approval to 
provide access for outbreaks.  Now thought is being given to the use of this vaccine in the two 
recommendations that ACIP already has in place. 
 
As Dr. Rubin pointed out, the dosing schedule was approved by the FDA on April 14, 2016 to 
change the 3-dose schedule of administration to a 0.5 mL dose at 0, 1-2, and 6 months versus 
the previous 0, 2, and 6 months schedule, as well as the approval of a 2-dose schedule with 
administration of a 0.5 mL dose at 0 and 6 months.  The revised schedule indicates that the 
choice and dosing schedule may depend upon the risk of exposure and the patient’s 
susceptibility to meningococcal serogroup B disease.  Dr. York indicated that Pfizer had come to 
ACIP because providers do need guidance on how best to use these schedules. 
 
The data that supported the 2-dose label was from a pivotal study that was included in the 
licensure, B1971012, that evaluated the safety, tolerability, and immunogenicity of 2-dose and 
3-dose schedules.  These data were presented to ACIP previously prior to the initial approval.  
This study assessed two 3-dose schedules:  0, 1, 6 and 0, 2, 6 and then assessed schedules of 
0, 6 months; 0, 2 months; and 0, 4 months to evaluate how the interval may impact the immune 
response.  This was a Phase II study conducted in Europe in the Czech Republic, Finland, 
Germany, and Poland in male and female adolescents 11 through 18 years of age.  The primary 
endpoint was to determine the proportion of subjects achieving a human complement serum 
bactericidal antibody (hSBA) titer of at least 1:8 or over against each of the 4 primary strains 
used to measure the response that is solicited by Trumenba®. 
 
In terms of the immunogenicity results, this study shows the benefit of Trumenba® and the effect 
of the dosing schedule.  The 0, 1 schedule is assessing the data within the 0, 1, 6 three-dose 
series to provide more information in terms of interval.  With short intervals with a goal to raise 
immunity very rapidly, there is a good immune response to the four strains.  These strains are 
representative of the prevalent strains in the US.  They have antigens on them that differ from 
what is in the vaccine antigen, so they will display the ability of the antibody to recognize across 
a diversity of that antigen and across the diversity of meningococcal B. 
  
When two doses were given in a short interval, there were robust immune responses, but they 
were less than if the interval is extended.  This has been observed with other vaccines.  
Extending the interval between doses can show an improved immune response.  This depends 
upon whether the goal is to illicit immunity rapidly in the case of an outbreak, or whether there is 
low risk of exposure and being able to extend that to 6 months and use two doses to have a 
high proportion of individuals who will respond to the representative strains.  
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The 0, 2, 6 and 0, 1, 6 schedules were very comparable, which permitted moving to a schedule 
with more flexibility.  Looking at the responses to each of the strains, there is similarity between 
the 0, 6 and the 3-dose series as well.  Therefore, substantial benefit is provided with a 2-dose 
schedule on a 0, 6 interval in comparison to the 3-dose schedule. 
 
The composite response is an evaluation of the number of individuals who have a response to 
all 4 strains.  This offers predictive measures of what the response will be against virtually any 
meningococcal strain that will now be tested in the hSBA.  It is a very good predictive value.  In 
terms of 4-fold responses, there is a discernable difference between providing vaccine in a short 
interval versus the longer interval of 0, 6 and there is comparability in terms of the 0, 6 two-dose 
response and the three-dose schedules.  While there are differences in this, if two doses are 
given very close together and a third dose is administered, the responses will be maximized. 
  
The 0, 6 schedule does provide substantial benefit.  In terms of “before vaccination,” individuals 
may have background response to a particular strain, but the requirement is to respond to all 
four strains.  So vaccination provides a benefit in terms of antibody that is solicited, which will 
now recognize across that diversity.  There is comparability, or at least similarity, between the 2-
dose schedule and the two 3-dose schedules.  Very often, the confidence intervals overlap for 
some of the strains and may not for others, but they are very close. 
 
This is also true in terms of the geometric mean titers (GMTs).  There are differences in the 
titers achieved against the strains, but there are noticeable differences in the GMT that is 
actually achieved with 2 doses given very close together as opposed to the 0, 6 interval.  Again, 
these are similar in terms of the GMT of the 2-dose compared to the 3-dose schedule. 
 
Two isolates from one of the US outbreaks are almost virtually the same molecularly.  These 
data show that there are differences in terms of strains in this in vitro assay, but the predictive 
value seen in a composite is shown in this.  The predictive value of the 0, 6 schedule in terms of 
a composite is over 70% response, with a 70% to 80% response rate in terms of the 3-dose 
schedules.  On a 0, 6 schedule against Strain 1, over 90% of individuals achieve a titer of 1:4, 
which is a protective value.  In the 0, 2, 6 schedule the 2-dose and 3-dose schedules show 90% 
on this particular strain.  The second strain is very similar molecularly, but acts differently in the 
in vitro situation.  These are exploratory assays that are not very well-validated, but they do 
show the predictive value of 70% on a 0, 6 schedule and about 80% on a 3-dose schedule. 
 
In terms of duration of protection, differences can be discerned in these data.  Those data will 
be provided to the WG and ACIP before the October 2016 ACIP meeting, and certainly will be 
provided to the WG as soon as all of the cohorts within that study are collected and the testing 
done.  Pfizer has followed persistence in this study for four years and then followed with a 
booster.  Those data will be submitted to the WG and ACIP as well. 
 
Regarding safety, there are no changes in the US Prescribing Information (USPI) in terms of the 
reactogenicity, et cetera.  There are no changes within that document other than noting that a 
second or third dose of Trumenba® is virtually the same in terms of the safety profile.  Pfizer has 
continued the evaluation of post-dose 2 and post-dose 3.  Based on the cumulative safety 
summary of the 11 trials with over 15,000 subjects receiving MenB-FHbp, there is no distinction 
between the second and third dose.  MenB-FHbp has demonstrated an acceptable safety 
profile.  The most common local and systemic reactions were injection site pain, headache, 
fatigue, and muscle pain.  Reactogenicity events were mostly mild and moderate.  Median 
duration was 2 to 3 days for local reactions and 1 to 2 days for systemic reactions.  There was 
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no potentiation of reactions with subsequent doses.  MenB-FHbp has demonstrated an 
acceptable safety profile when co-administered with MCV4/Tdap, dTaP-IPV, or HPV4.  Similar 
proportions of newly diagnosed chronic medical conditions, autoimmune diseases, and 
neuroinflammatory conditions were reported in MenB-FHbp recipients and controls.  Rates of 
SAE were similar between MenB-FHbp recipients (1.6%) and controls (1.9%). 
 
In summary, Trumenba® (MenB-FHbp) was granted FDA approval under Accelerated Approval 
regulations in October 2014 for use in a 3-dose series (0,2,6 months) for the prevention of 
invasive meningococcal disease caused by serogroup B in individuals 10 years through 25 
years.  On April 14, 2016, FDA approved a label change under the same regulations with a 
flexible 3-dose schedule (0, 1-2 months and 6 months) and a 2-dose schedule (0, 6 months).  
Both schedules have been determined to be safe and effective.  ACIP guidance to providers is 
needed on the use of the FDA-approved dosing schedules for MenB-FHbp within the context of 
current vaccine recommendations for the prevention of MenB disease for use in individuals >10 
years at increased risk of disease and in adolescent and young adults. 
 
Summary of WG Discussions:  Trumenba® Label 
 
Jessica MacNeil, MPH 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
 
Ms. MacNeil provided a summary of the WG’s discussions pertaining to the revised dosing 
schedule for MenB-FHbp or Trumenba®.  On April 14, 2016, FDA approved updates to the 
Dosage and Administration section for MenB-FHbp.  The changes allow for administration of 
both a 3-dose schedule at 0, 1-2, and 6 months, and a 2-dose schedule at 0 and 6 months.  
Additionally, the package insert now includes the following statement, “The choice and dosing 
schedule may depend on the risk of exposure and the patient’s susceptibility to meningococcal 
serogroup B disease.” 
 
The current ACIP recommendations for the use of MenB are as follows: 
 
 
 
 
 
Certain persons aged ≥10 years who are at increased risk for meningococcal disease 
should receive MenB vaccine (Category A)1  
A MenB vaccine series may be administered to adolescents and young adults aged 16 
through 23 years to provide short-term protection against most strains of serogroup B 
meningococcal disease (Category B)2 
 
In the MenB Policy Notes, additional guidance is provided that states the following, which is 
consistent with the original licensing of these vaccines: 
 
MenB vaccine should either be administered as a 3-dose series of MenB-FHbp 
(Trumenba®) or a 2-dose series of MenB-4C (Bexsero®)1,2 
 
[1Folaranmi T., et al. Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup 
B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR; June 12, 
2015; Vol. 64, No. 22, p 608-612; 2MacNeil JR, et al. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young 
Adults: Recommendations of the Advisory Committee on Immunization Practices, 2014. MMWR; October 23, 2015, Vol. 64, 
No. 41, p 1171-1176]. 
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Ms. MacNeil then summarized the WG’s interpretation of data presented on the immunogenicity 
and safety data for the 2-dose schedule of MenB-FHbp at 0 and 6 months, as well as the 
proposed policy options language, and the WG’s discussion.  As a reminder, several dosing 
schedules were evaluated for MenB-FHbp including two 3-dose schedules and four 2-dose 
schedules. 
 
Based on the immunogenicity data presented by Dr. York, overall among the 2-dose schedules 
evaluated, the 0, 6 month schedule had the highest percentage of responders and GMTs and is 
most similar to a 3-dose schedule.  However, the proportion of subjects demonstrating at least a 
4-fold rise in hSBA titers is lower with a 2-dose schedule at (0, 6 months) compared to either 3-
dose schedule: 
 
 
 
 
2-dose schedule (0, 6 months): 73.5% (68.5-78.1)* 
3-dose schedule (0, 1, 6 months): 83.1% (78.6-86.9)* 
3-dose schedule (0, 2, 6 months): 81.7% (77.3-85.7)* 
 
[*Composite response (hSBA titer ≥1:8** for all 4 strains) 1 month post-last dose; **hSBA ≥1:16 for A22 
expressing strain]. 
 
Similarly, the GMTs are lower with a 2-dose schedule at 0 and 6 months compared to either 3-
dose schedule.  For some of the strains, the 95% confidence intervals do not overlap.  The WG 
felt that these lower GMTs suggest not as strong of an immune response to the 2-dose MenB-
FHbp compared to 3 doses. 
 
Although comparing hSBA responses following 2 doses of MenB-4C or MenB-FHbp is 
somewhat like comparing apples to oranges because of differences in the strains tested and the 
study population, the WG did feel that these were important data to consider as part of this 
discussion. 
 
The following graphic shows the composite hSBA response one month following two doses of 
MenB-4C on the left and MenB-FHbp on the right, with varying intervals between those two 
doses: 
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In general, the responses following 2 doses of MenB-FHbp are similar and are slightly lower 
than the response following 2 doses of MenB-4C. 
 
Preliminary antibody persistence data following the 2-dose schedule of MenB-FHbp was 
recently shared with the WG, and it is anticipated that more complete antibody persistence data 
may be available to be shared with the full ACIP in October 2016. 
 
As presented to ACIP previously, the MenB vaccines are generally more reactogenic than other 
vaccines given during adolescence.  The most common AE reported is pain at the injection site.  
Overall, the safety and tolerability profiles are similar for the 2-dose and 3-dose schedules of 
MenB-FHbp. 
 
After reviewing these data, the WG has discussed several different policy options.  For persons 
at increased risk and for use during outbreaks a preference for a 3-dose schedule of MenB-
FHbp would be stated.  For healthy adolescents, there are two options:  1) a 2-dose schedule of 
MenB-FHbp at 0 and 6 months or the 3-dose schedule could be given; or 2) a preference for a 
3-dose schedule of MenB-FHbp could be stated and guidance could be provided that if 
someone receives their second dose of MenB-FHbp 6 months after the first dose, no additional 
doses are needed. 
 
Based on the WG’s discussion, there was strong consensus among WG members to express a 
preference for a 3-dose schedule for persons at increased risk, including outbreaks, in order to 
provide early protection and maximize the immune response.  There also was a strong 
preference for a 3-dose schedule for healthy adolescents.  For people who want to maximize 
protection, 3 doses are preferred.  Both the 2- and 3-dose schedules take 6 months to 
complete.  Guidance could be provided that if someone receives their second dose of MenB-
FHbp 6 months after the first dose, no additional doses are needed. 
Additional data are anticipated to be available for ACIP to consider in October 2016, which 
include the following: 
 
 
 
 
 
 
Results of antibody persistence following a 2-dose (0, 6 month) schedule 
Results from an independent evaluation of hSBA data for MenB-FHbp and MenB-4C against 
several US outbreak strains, which clearly show the benefits of a third dose of MenB-FHbp  
Results of a study on the impact of MenB-FHbp on carriage among US college students 
 
In addition to hearing ACIP’s feedback about the data presented, during the discussion the WG 
also hoped to obtain:  1) feedback on whether ACIP is in agreement with the WG’s proposal to 
express a preference for the 3-dose schedule of MenB-FHbp in persons at increased risk, 
including outbreaks and healthy adolescents; and 2) whether there are additional data beyond 
data proposed for October 2016 that ACIP would like to see. 
 
Discussion Points 
 
Dr. Kempe asked whether there were plans to compare the cost-benefit for 2 versus 3 doses in 
healthy adolescents in terms of evaluating the additional potential benefit of the third dose. 
 
Ms. MacNeil indicated that the WG had not planned to perform an analysis comparing the cost-
benefit for 2 versus 3 doses, but could discuss this. 
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Regarding the preference of the 3-dose schedule for healthy adolescents, Dr. Karron asked 
whether there is clear evidence that 3 doses maximizes protection relative to 2 doses. 
 
Ms. MacNeil indicated that based on the immunogenicity data, there is a slight increase with 3 
doses versus 2. 
 
Dr. Karron asked for clarification about whether the confidence intervals overlap when the doses 
are given at 0 and 6 months, and Ms. MacNeil confirmed that they do.  Therefore, Dr. Karron 
thought ACIP should consider this as an issue as well as with regard to the wording of the 
recommendation.  She did not know that they had data to suggest that 3 doses maximizes 
protection over 2 doses in a healthy adolescent population. 
 
Dr. Reingold asked who would be left such that there would not be a preference for a 3-dose 
schedule if those at increased risk in outbreaks and healthy adolescents were subtracted out. 
 
Ms. MacNeil replied that there would be a preference for everyone for whom there is a current 
recommendation. 
 
Dr. Grogg (AOA) asked Dr. York for clarification regarding whether the subfamilies that are 
tested and give a robust response were the same strains in the vaccine.  If so, this would 
indicate to him that there is cross-protection. 
 
Dr. York responded that this was correct.  Strains were selected that would have antigens 
expressed that differed from the vaccine components.  The assumption is that there is cross-
protection.  Instead of trying to match it to show a response to a vaccine, Pfizer approached this 
to show the breadth of the ability of the antibody to recognize across a diversity of US strains. 
 
Dr. Stephens said it would be helpful to know about predicted strain coverage across US 
strains, for example.  He requested that Dr. York elaborate on those data. 
 
Dr. York indicated that Pfizer has performed exploratory analyses on outbreak strains in the US 
and France, which she presented during the last ACIP meeting.  With the 2-dose and 3-dose, it 
is really quite predictive.  Some strains are more difficult to develop in these assays, but the 
composite provides an idea of the minimum.  It varies depending on the strain, regardless of the 
FHbp antigen. 
 
Cost-Effectiveness of Meningococcal Vaccination in HIV-Infected People in the US 
 
Ismael Ortega-Sanchez, PhD 
Senior Health Economist 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
 
Dr. Ortega-Sanchez indicated that following the ACIP Guidance for Health Economics Studies, 
this study was reviewed by CDC.  The review provided important observations that were 
addressed for this presentation, with explicit responses to some comments included at the end. 
The purpose of this study was to analyze the effectiveness and cost-effectiveness of a potential 
vaccination program for persons living with HIV against meningococcal disease with a primary 
series of MenACWY followed by lifelong 1-dose boosters every 5 years.  For people less than 7 
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years of age, the booster dose would be every 3 years.  The societal perspective was used for 
this analysis. 
 
For this study, the investigators resorted to the previously constructed decision tree model to 
compare the strategies, with vaccination and without vaccination for each cohort: 
 
 
 
For the complete number of cases as well as the number of deaths and survivors with sequelae, 
the model includes nodes that describe infection and non-infection and specific outcomes.  A 
similar model was presented to this committee in the past.  To deal with key uncertainties, the 
decision tree model also is designed with a Monte Carlo simulation analysis.  This simulation 
allows for calculation of not only the most likely or base case estimate for health benefits and 
costs, but also the ranges around these estimates.  For that, an age-specific HIV+ population is 
included that is comprised of approximately 934,000 HIV+ subjects distributed by age.  Each 
age group is followed until 70 years of age, which is the timeframe.  Benefits of vaccination are 
over the age-specific life expectancy, for which a discount rate of 3% is used for both costs and 
benefits. 
 
Once the core of the model was set, the best available data were used, including the following: 
 
 
 
 
 
 
Age-specific HIV+ population (2013) 
Age- year- and Mening ACWY serogroup-specific incidence rates (2005-2014) 
Age- and Mening ACWY serogroup-specific case fatality ratios (2005-2014) 
Proportion of survivors with sequelae by condition after meningococcal disease 
The model uses data for people living with HIV by age from the HIV Surveillance Report, 2014.  
It is quite important for modeling vaccine to determine the proportion of people living with HIV in 
Stage 3.  For the lower bound, the data used was the proportion of new Stage 3 diagnoses for 
2013, while the upper bound was based on the Revised Surveillance Case Definition for HIV 
Infection, which is based on CD4 counts.  The assumption was made that the average life 
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expectancy of people living with HIV is similar to the general population for the upper bound, 
and about a 7-year reduction in people living with HIV in the lower bound. 
 
There are two important characteristics regarding the incidence data of people living with HIV 
who are in the model:  1) the proportion of cases who are HIV+ are from Active Bacterial Core 
surveillance (ABCs) and incidence data from the National Notifiable Diseases Surveillance 
System (NNDSS), with additional serogroup data from ABCs and state health departments; and 
2) incidence data for 0 to 19 years is from NNDSS, with additional serogroups data from ABCs 
and state health departments for the general population regardless of HIV status. 
 
Strategies of vaccination with MenACWY in the US are as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
≥2 years of age: 
Primary series: 0, 2 months 
Boosters: life-long boosters required 
Current booster recommendations: 3 years if age <7 years at previous dose and 5 years if 
age ≥7 years at previous dose 
<1 year of age: 
Primary series: 2, 4, 6, 12 months 
Boosters: same as above 
1-2 years of age: 
Primary series: 0, 3 months 
Boosters: same as above 
One key component is the initial VE based on CD4 counts.  The specific efficacy used in the 
model was: 
High CD4 count with 2 doses series:  75% (37% to 91%) 
Low CD4 count with 2 doses series:   37% (24% to 60%) 
The initial efficacy was based on combined efficacy from the Open-Label Trial of Safety and 
Immunogenicity of Meningococcal Groups A, C, Y, and W. 
In the same way, the coverage rate was assumed for primary series and any booster dose as 
follows:  
Primary series (2 or 3 doses):  65%   (40% to 80%) 
Booster dose (every 5 years):  45%   (30% to 65%) 
Rates of coverage for the primary series and booster assumptions were based on various 
sources. 
The second component of VE regards how initial protection wanes over time.  For preliminary 
assumptions, linear and exponential decay curves were fitted to antibody waning through 
available SBA data.  Such waning was adjusted for low and high CD4 counts and for the first 
and second dose in the series.  A key assumption in the model is that the efficacy of each and 
any booster dose is assumed to follow a similar waning protection pattern. 
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Therefore in the model, the meningococcal disease incidence and vaccination were modeled 
using the following expression: 
 
 
 
  
 
 
MDIvacc = MDIno vacc * [1-(Vcov * IntVEff * Residualt )] 
Where: 
• 
• 
• 
• 
• 
MDIvacc = Meningococcal disease incidence under vaccination 
MDIno vacc  = Meningococcal disease incidence without vaccination 
Vcov  = Vaccination coverage 
Int VEff  = Initial vaccine efficacy 
Residualt = Residual vaccine efficacy (0-100%) t years after vaccination t = 0,…,T 
No indirect effects were introduced into the model, because it is considered a vaccination 
primed to a target population.  Once the disease incidence is calculated with vaccination and 
with no vaccination, the health outcomes were estimated.  First, mortality was estimated using 
the case fatality ratios (CFRs) specific for serogroups ACWY in HIV+ persons based on NNDSS 
meningococcal cases with and without reduction as observed in ABCs data for HIV+ cases for 
the US, 2005-2014.  Second, the proportion of survivor cases with sequelae was calculated by 
type of condition.  The following table shows the rates of sequelae by type of condition, with 
point values and ranges that were used in previous analyses: 
  
 
 
 
 
 
 
 
Skin Scarring 7.6 (0 - 19) 
 
 
 
  
Single Amputation 1.9 (0.5 - 10) 
Multiple Amputations 1.2 (0.02 - 6) 
Hearing Loss* 8.8 (2 - 20) 
Significant Long-Term Neurologic Disability** 2.1   (0.02 - 11) 
 
*Edwards et al. Complications and sequelae of meningococcal infections in children. J Pediatrics 1981; 99:540-5 
**Baraff et al. Outcomes of Bacterial meningitis in children: a meta-analysis PIDJ 1993;12:389-94  
 
Once outcomes of meningococcal disease were defined, the quality-of-life lost to each of these 
complications must be assessed.  However, the baseline 1Health Utility Index must be adjusted 
to take into account the underlying HIV infection and the perceived quality-of-life among people 
living with HIV.  That is done before any meningococcal infection and the impact of the specific 
complications.  Therefore, the baseline scores for people living with HIV are adjusted using the 
marginal effects from HIV, which are taken from a study on the 2health-related quality-of-life of 
people living with HIV versus the general population.  The adjustments are done by age, 
sexuality, CD4 counts, and date of diagnosis [1Health Utilities Index, Mark 3, (HUI-3) combined 
for males and females.  Sources: (1) http://www.healthutilities.com/HUINormsKeyTable.htm (2) 
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http://www.chepa.org/Files/Working%20Papers/01-02.pdf; and 2Adjusted for Age, Sexuality, 
CD4 counts (AIDS) and Date of diagnosis. Source: Miners et al. "Health-related quality-of-life of 
people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison 
with the general population. The Lancet V1, (1), October 2014, e32–e40]: 
 
AGE 
(in years) 
Health Utility Index 
General Population1 
Marginal Effect in 
Utility Score from 
HIV2 
Health Utility Index 
People Living with 
HIV 
<24 92.2% -11.0% 81.2% 
25-34 92.2% -11.0% 81.2% 
35-44 92.3% -13.0% 79.3% 
45-54 91.5% -13.0% 78.5% 
55-64 88.1% -14.0% 74.1% 
65-74 86.4% -14.0% 72.4% 
75-84 83.9% -14.0% 69.9% 
85+ 78.5% -14.0% 64.5% 
 
 
Once the baseline for quality-of-life is adjusted for people living with HIV, the related quality-of-
life scores are applied for specific meningococcal complications as shown in the following table, 
which is done to estimate the quality adjusted life years (QALYs) lost to meningococcal to 
disease or the QALYs saved with vaccination: 
 
 
 
The following chart is intended to illustrate what goes into cost calculations for the various 
outcomes of cases of meningococcal disease in this model: 
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Finally, the vaccine costs were based on the March 2016 public and private sector prices of 
Menveo or Menactra®.  The cost of the vaccination program includes the cost of the dose, the 
cost of administration, and the proportion of waste due to vaccination problems.  Note that the 
rates of AEs included in the vaccination program were taken from the United Kingdom (UK) 
experience with meningococcal C conjugate (MCC) vaccine. 
 
Regarding the preliminary results, the baseline per age group of HIV+ persons with no 
vaccination are shown in this table: 
 
 
 
Note that because of the small numbers of people living with HIV in some age groups and 
because of the low incidence and mortality rates of meningococcal disease, the number of 
cases, deaths, and QALYs lost are very small.  The age groups with the highest meningococcal 
disease burden are observed from 20 through 24 years of age and from 50 through 59 years of 
age. 
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Once a vaccination program is implemented in the model, the total number of meningococcal 
cases and deaths averted in people living with HIV are shown below: 
 
 
 
These estimated distributions are from Monte Carlo simulation.  Based on this simulation, the 
mean number of cases averted was 122 and the mean number of deaths averted was 23. 
 
Once the vaccination program is implemented in the model, the total cost of QALYs saved in 
people living with HIV vaccinated against MenACWY are shown below: 
 
 
 
The average number of QALYs saved is 385 and the cost is about $730,000 per QALY.  
However, it is important to look more closely at which specific age groups of people living with 
HIV have high impact from vaccination.  The following table shows the base case by age group, 
the number of cases, deaths prevented, and number of QALYs saved: 
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As expected, the age groups where the highest vaccine impacts are observed are among those 
20 through 24 years of age to 50 through 59 years of age. 
 
To get an idea of the costs, the following graphic shows the base case for cost of disease with 
vaccination and the cost of vaccination program for each age group.  Also shown are the base 
case net costs by age group: 
 
 
 
The following graphic presents the cost-effectiveness analysis among all age groups.  The 
diamonds are the mean values from the Monte Carlo Simulation, and the 5th and 95th percentiles 
are the ranges in bars.  Note the U-shape when age is changing: 
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In order to see the incremental cost-effectiveness of meningococcal vaccination by age group, 
economists use the following type of graph that shows the cost per QALY in the Y-axis and the 
QALYs saved on the X-axis and draws a line to the one that has the lowest slope, which is 
considered to be the most cost-effective intervention: 
 
 
 
Based on this graph, the age groups that provide the most QALYs are those that range from 20 
through 24 to 40 through 50 to 54 years of age.  The people on the left-hand side are providing 
less QALYs saved, which is due to the small numbers in those age groups living with HIV and 
the lowest incidence and mortality rates. 
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When specific scenarios are selected and some of the variables are changed in the base case 
assumptions, changes can be seen in those assumptions and the QALYs and costs per QALY 
saved as shown in the following table: 
 
 
The following table provides a base case comparison for cost per QALY among some 
vaccination programs recommended and some not recommended:  
 
 
 
There are a number of limitations in the analysis.  Data on incidence and mortality among 
people with HIV are limited.  Data on initial VE are from serology and immunogenicity.  Data on 
duration of VE also is limited, though strong assumptions have been used to try to determine 
the best estimates. 
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 
• 
• 
 
 
 
 
 
 
 
As mentioned earlier, following the ACIP Guidance for Health Economics Studies, there were a 
number of comments / suggestions made by the reviewers inside the CDC.  The comments 
provided for Parts 1 and II, along with the responses from the investigators, were as follows: 
 
Part I 
 
Comment 1. “[C]oncerns about the numbers presented for the number of people living 
with AIDS: 
Using the “Revised Surveillance Case Definition for HIV Infection - United 
States, 2014” we re-estimated the percentage range of people living with HIV 
in stage 3, along with a scenario analysis 
 
Comment 2. The reduction in cases of disease as a result of vaccination does not seem 
to line up with the assumptions about vaccine efficacy, vaccine coverage, and waning of 
protection:  
We reviewed the model calculations for formulas and parameter values and 
health outcomes and costs were re-estimated 
Part II 
 
In Comments 3 to 9. Reviewer provided “minor” or “editorial” comments which were 
addressed in these slides and in the technical report 
In conclusion, routine vaccination of people living with HIV with a primary series plus periodic 
boosters against Meningococcal ACWY disease is relatively costly.  Disease cases, deaths 
(both with relatively low numbers), and vaccine costs of lifelong booster doses drive the 
analyses.  Although costly, additional cases could be prevented by all vaccination strategies. 
Discussion Points 
Dr. Thompson (NVAC) asked whether less waning than the base case was evaluated, and 
related to that whether people who wane, wane back to the same level as fully susceptible 
individuals with respect to their risks for the specific outcomes or sequelae. 
Dr. Ortega–Sanchez replied that the assumptions about waning were taken from the open-label 
immunization data, most of which were for children and adolescents that were extrapolated to 
the other age groups.  For the sensitivity analysis, consideration was given to what would 
happen if the waning was faster, which was following the 5th percentile.  The number of QALYs 
saved and the cost per QALY changed in the direction expected.  Only 296 QALYs saved and a 
cost of $901,000 per QALY.  The assumptions can be changed.  In fact, he has been 
performing a number of experiments with that assumption because it seems to be the one that 
drives the analysis.  Again, the data are limited and the ranges provided to each one of the 
mean points are supposed to be included in some of the uncertainty that was observed in the 
variables. 
Dr. Reingold asked for an approximate number needed to vaccine (NNV) to prevent one case, 
and a reasonable number of assumptions about duration of protection and if there is full 
coverage, approximately how many cases and deaths would be prevented per year in the US. 
Dr. Ortega–Sanchez responded that the model is allowing him to calculate the NNV and he has 
been assessing those estimates.  Some of the age groups were so small that more people than 
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in the age groups would need to be vaccinated in order to prevent one case in those age 
groups.  For example, for those less than 13 years of age, he had to determine how to distribute 
all 2415 cases among all of those 12 years, and then try to include the incidence data to come 
up with cases.  Not all 2415 would be vaccinated, because there are assumptions about 
coverage.  The NNV to prevent one case among one of these age groups was higher than the 
2415, for example.  It is basically the same for some of the other age groups.  He can provide 
those data, and some data were provided in the extra slides to support the assumptions.  He 
was not able to provide the estimate year-by-year of cases and deaths averted, because this 
cohort was followed for 70 years.  In 70 years, about 122 cases would be prevented.  That is 
approximately 45% of the total number of cases observed in the same period.  If that is 
distributed by year, the numbers are very small. 
 
Dr. Messonnier pointed out that this information was going to be discussed in the upcoming 
GRADE presentation. 
 
While Dr. Whitely Williams (NMA) thought this was an excellent effort to try to answer the 
question, the modeling did not take into account the social background and environment of this 
population.  For example, there was an outbreak of meningococcal meningitis in Chicago.  Of 
the 7 cases, 6 were HIV-infected and 1 was not.  She said she made this comment because 
eventually, had the investigation not used the infrastructure that was in place to support persons 
with HIV infection, it would have been difficult to understand what was occurring with that 
outbreak and it potentially could have spread to the general population.  Obviously, it was good 
that there was a social support and environment existed in order to be able to recognize and 
control that outbreak, she though they needed to be very careful about the modeling to come to 
a conclusion that this would be very expensive in terms of the use of this vaccine in this 
particular population. 
 
GRADE for MenACWY Vaccines for HIV-Infected Persons 
 
Monica Patton, MD 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
 
Dr. Patton presented the WG’s GRADE process for the MenACWY vaccines for HIV-infected 
persons.  She reviewed the study question and presented a modified assessment of disease 
burden data, an assessment of evidence for outcomes, and the WGs determination of overall 
evidence type.  The first step in the GRADE process is to formulate the study question.  The 
overall question for this analysis was, “Should MenACWY vaccines be administered routinely to 
all HIV-infected persons aged 2 months and older for prevention of meningococcal disease?” 
 
There are three conjugate vaccines licensed for use in the US.  Menactra® covers serogroups 
A, C, W, and Y and is licensed for use among persons aged 9 months to 55 years.  Menveo® 
covers serogroups A, C, W, and Y and is licensed for use among persons aged 2 months to 55 
years.  Menhibrix® covers serogroups C, Y, and Haemophilus influenzae type b and is licensed 
for children aged 6 weeks to 18 months. 
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The following table summarizes the outcomes that were chosen for the question: 
 
Assessment Outcome 
Modified assessment of 
disease burden data 
Cases/Incidence 
Mortality 
Quality of evidence assessed 
using standard GRADE 
approach 
Short-term immunogenicity against serogroups 
A, C, W, Y 
 -4 weeks after 1st dose (week 4) 
 -4 weeks after 2nd dose (week 28) 
Persistence in immunogenicity against 
serogroups A, C, W, Y 
 -48 weeks after 2nd dose (week 72) 
Serious adverse events 
 
The first 2 outcomes were not assessed using GRADE since they are surveillance data.  A 
modified assessment was made of these data.  The last 3 outcomes were assessed using 
GRADE.  Dr. Patton first discussed the modified assessment of disease burden data and then 
described the GRADE process for the outcomes listed. 
 
Because low disease incidence is an important consideration for meningococcal infections 
among HIV-infected persons, the WG wanted first to evaluate the quality of the meningococcal 
disease burden data.  However, because these are surveillance data and no intervention was 
tested, they could not evaluate them using the GRADE format.  Instead, the disease burden 
data were assessed for representativeness and completeness. 
 
US meningococcal incidence data come from two sources:  ABCs and NNDSS.  ABCs is an 
active laboratory and population-based surveillance system that collects data on cases of 
meningococcal disease in 10 sites that cover 43 million persons, or approximately 14% of the 
US population.  Because case reports include chart review, HIV status of cases should be 
included in ABCs data.  NNDSS is a passive surveillance system.  All states and territories 
report data for nationally notifiable diseases to NNDSS.  However, NNDSS does not contain 
HIV status.  Because cases identified in ABCs are also reportable to NNDSS, these are not 
independent surveillance systems. 
 
Between 1995 and 2014, a total of 62 meningococcal cases were reported among HIV-infected 
persons in ABCs, which is approximately 2% of all cases reported to ABCs during that time 
period.  Here we see the cases among HIV-infected person by age group in years and by 
serogroup: 
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Approximately 80% of cases occurred among HIV-infected persons aged 20 through 49 years 
and approximately 70% of cases were serogroup C, W, or Y. 
 
A chart review of ABCs data from 2000-2008 was performed in order to determine the incidence 
of meningococcal disease among HIV-infected persons in the US.  A total of 33 cases from HIV-
infected persons were included in the chart review.  However, because the population of HIV-
infected persons in ABCs was unknown due to variable HIV reporting requirements by state 
during that time period, incidence calculations were limited to the 17 meningococcal cases 
among HIV-infected persons in ABCs who met the CDC AIDS surveillance case definition 
because name-based AIDS cases were reported in all states during that time.  The analysis 
found an incidence of 3.5 per 100,000 person years among cases who met CDC AIDS criteria 
compared to 0.3 per 100,000 person years among all other cases, with a resulting relative risk 
of 12.9 [Harris CM et al. Meningococcal Disease in Patients with HIV Infection-A Review of 
Cases Reported Through Active Surveillance in the United States, 2000-2008.  Manuscript 
Under Preparation]. 
 
However, there are a few things to keep in mind with respect to the quality of data regarding 
meningococcal disease among HIV-infected persons in ABCs.  This is a map of ABC sites in 
2014: 
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However, the ABCs catchment area during 2000 to 2008 used to calculate the incidence of 
meningococcal disease among HIV-infected persons is a somewhat different picture.  For 
example, Colorado joined ABCs in 2001 and New Mexico joined in 2004.  Additionally, cases 
were excluded from Maryland in 2000 and New York during the entire study period because of 
local health information disclosure policies pertaining to HIV infection. 
  
When the proportion of the HIV-infected US population is calculated in the ABCs catchment 
area by year, the ABCs catchment area represented from 9% to 17% of the HIV-infected US 
population aged 14 years and older, and the proportion of HIV-infected US children aged 0 
through 13 years represented by the ABCs catchment area was even lower, ranging from 6% to 
9.8% per year. 
  
Additionally, when considering the quality of surveillance data to identify meningococcal disease 
among HIV-infected persons, it is important to recognize that HIV testing rates among adults 
and adolescents are suboptimal.  For example, the proportion of adults who had ever been 
tested for HIV increased from 37% in 2000 to 45% in 2008, and only 12% to 13% of adolescents 
were ever tested for HIV in 2005 and 2007. 
  
However, despite the limitations of the case / incidence data of meningococcal disease among 
HIV-infected persons in ABCs, the available estimates are supported by a number of other 
studies that have investigated the incidence of meningococcal disease in HIV-infected persons 
as shown in the following table: 
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:  
 
Most of these studies were presented to ACIP during the last meeting.  It is important to 
recognize that these studies occurred over a 4-decade time period when many advances in HIV 
testing, care, and treatment occurred, resulting in studies that span variable HIV testing rates, 
variable availability of antiretroviral therapy, and variable severity of disease.  However, the 
available studies show a 5- to 14-fold increased rate and a 5- to 24-fold increased risk of 
meningococcal disease among HIV-infected persons compared to HIV-uninfected persons that, 
taken together, suggest a possible benefit of MenACWY vaccination for persons with HIV 
infection. 
 
In terms of mortality among HIV-infected persons with meningococcal disease, case-fatality 
ratios were analyzed for HIV-infected and HIV-uninfected persons with meningococcal disease 
in ABCs in the chart review between 2000 and 2008 and overall between 1995 and 2014.  
There was no statistically significant difference in case-fatality ratios between HIV-infected and 
HIV-uninfected persons in either analysis, with a case-fatality of 13% among HIV-infected 
persons compared to 11% of HIV-uninfected persons during 2000 to 2008, and case-fatality 
ratio of 16% among HIV-infected persons compared to 11% in HIV uninfected persons overall 
from 1995 to 2014. 
 
Other studies that have assessed case-fatality ratios among HIV-infected and HIV-uninfected 
persons with meningococcal disease have demonstrated mixed results.  While the Australian 
and South African studies demonstrated higher mortality among HIV-infected persons with 
meningococcal disease compared to HIV-uninfected persons, the studies from New York and 
England demonstrated higher mortality among HIV-uninfected persons.  There are a number of 
reasons mortality may be lower among HIV-infected persons in the more recent studies, 
including the fact that many HIV-infected persons may be engaged in healthcare services where 
more rapid assessment of symptoms and referral to appropriate medical care may occur. 
Additionally, HIV-infected persons may receive antibiotic prophylaxis or be on antiretroviral 
therapy, which may improve survival from meningococcal disease. 
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Overall, the representativeness of data on cases and incidence of meningococcal disease 
among HIV-infected persons in the US is good because, while only 9% to 17% of the US HIV-
infected population is represented in ABCS, the resulting data were similar to available studies 
that assessed meningococcal disease among diverse HIV-infected individuals from multiple 
countries over a time period that spanned variable HIV testing, care, and treatment.  The 
representativeness of the mortality data is fair because of small numbers in ABC data, few other 
studies assessing mortality, and mixed results of those studies. 
 
Overall, the completeness of data on cases and incidence of meningococcal disease among 
HIV-infected persons in the US is good, but there is a potential for missed cases given the many 
limitations of surveillance data to ascertain meningococcal disease among HIV-infected 
persons, including that only 9% to 17% of the US HIV-infected population is represented in 
ABCs, NNDSS does not collect HIV status of cases, and HIV testing is suboptimal.  As a result, 
current data likely underestimate the true incidence of and risk ratio for meningococcal disease 
among HIV-infected persons.  Completeness of mortality data is fair because if cases are 
missed due to surveillance limitations, those deaths would also be missed.  Additionally, there 
are few studies investigating mortality among HIV-infected persons with meningococcal 
disease. 
 
In summary, the WG found some limitations to its meningococcal incidence and mortality data. 
However, they feel that available data likely underestimates the true burden and mortality of 
meningococcal disease among HIV-infected persons in the US. 
 
Turning to the outcomes evidence of benefits and harms, as a reminder, the study question 
was, “Should Men ACWY vaccine be administered routinely to all HIV-infected persons aged 2 
months and older for prevention of meningococcal disease?”  The following table summarizes 
the outcomes assessed using GRADE: 
 
 Outcome 
Benefits Short-term immunogenicity (4 weeks after 1st dose [week 4]) 
Short-term immunogenicity (4 weeks after 2nd dose [week 28]) 
Persistence in immunogenicity (48 weeks after 2nd dose [week 72]) 
Harms Serious adverse events 
 
The WG compiled data for MenACWY vaccines in HIV-infected persons by outcome and study 
design.  There were a total of 2 studies, both of which were observational, open-label trials.  Of 
note, both studies assessed administration of Menactra®.  One assessed administration among 
2- to 10-year old children and the other to 11- to 24-year old adolescents and young adults. 
There are no data available assessing Menveo® or MenHibrix® in HIV-infected persons. 
 
Dr. Patton reviewed the evidence findings for benefits and harms, reminding everyone that 
these data have been presented during past ACIP meetings.  Clinical effectiveness studies of 
meningococcal vaccines among HIV-infected persons are not feasible because of the low 
incidence of disease.  As a result, SBA titers are used as the immunologic correlate of 
Advisory Committee on Immunization Practices (ACIP)                                               Summary Report                                             June 22-23, 2016 
 
 
56 
 
 
protection.  Multiple studies have shown that SBA titers correlate with protection against 
meningococcal disease in healthy persons [Goldschneider I, Gotschlich EC, Artenstein MS. 
Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969 Jun 
1;129(6):1307-26; Andrews N, Borrow R, Miller E. Validation of serological correlate of 
protection for meningococcal C conjugate vaccine by using efficacy estimates from 
postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003 Sep;10(5):780-6]. 
 
Based on the body of evidence for MenACWY vaccines in HIV-infected persons, short-term 
immunogenicity is achieved for serogroups A, C, W, and Y after both the first and second 
doses.  However, immunogenicity for serogroups A, W, and Y is suppressed in HIV-infected 
adolescents aged 11 through 24 years when compared to HIV-infected children aged 2 to 10 
years after the first dose and for all serogroups after the second dose.  Additionally, 
immunogenicity in HIV-infected adolescents is also suppressed when compared to healthy 
adolescents.  Moreover, immunogenicity is suppressed further if there is a low CD4 count or 
high viral load.  Serogroup C demonstrated the lowest rates of response and immunity. 
 
When looking at persistence of immunogenicity at week 72, which is 1 year after receiving the 
second dose, there were higher levels of seroprotection among HIV-infected children who 
received 2 doses.  However, seroprotection waned rapidly in adolescents, particularly in 
adolescents with low CD4 counts.  Nevertheless, there is a boost response to the second dose. 
 
Both studies assessed SAEs, which were reported from the time of vaccination through 6 weeks 
post-vaccination.  Overall, between 2% and 7% of participants experienced an SAE event, 
including 4 laboratory events and 8 signs and symptoms including fever, headache, pain, 
psychiatric symptoms, ocular pain, and a lip lesion.  SAE event rates were inversely related to 
entry CD4 percentage.  Two deaths were reported in total, but both were unrelated to the 
vaccine.  Of all SAEs, only ocular pain was judged to be related to the vaccine. 
 
Based on the balance between the benefits and harms for using the vaccine, it can be 
concluded that the vaccine is immunogenic in HIV-infected children and adolescents in the 
short-term and is safe.  Immunogenicity persists in HIV-infected children up to 72 weeks, but 
wanes rapidly in adolescents and young adults.  Further, immune responses are suppressed 
with lower CD4 percentages or higher viral loads.  The low disease burden lowers the overall 
benefits. 
 
Regarding the determination of the evidence type for benefits and harms, in GRADE for each 
outcome, all of the available data are evaluated on the following 5 criteria and a final evidence 
type is assigned: 
 
 
 
 
 
 
Risk of Bias (methodological limitations) 
Inconsistency 
Indirectness 
Imprecision 
Other considerations (publication bias, strength of association, dose response) 
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The following table describes the algorithm used to determine the final evidence type for each 
outcome.  RCTs start out as an evidence type of 1 and observational studies start out as a 3.  
The 5 criteria are assessed to determine whether the overall evidence type is moved down or 
up: 
 
 
 
No serious concerns were found for risk of bias, and no serious concerns were found with 
inconsistency for any of the outcomes.  Short-term immunogenicity and persistence of 
immunogenicity were downgraded for indirectness because, while SBA titers are well-described 
and accepted as the immunologic correlate of protection in healthy persons, they have not been 
evaluated in HIV-infected persons.  No serious concerns were found with imprecision for short-
term immunogenicity or persistence of immunogenicity, but SAEs were downgraded for 
imprecision since the total sample size was not sufficient to detect rare events.  No serious 
problems were found for publication bias.  Short-term immunogenicity was upgraded because of 
a strong strength of association and for dose response.  Persistence of immunogenicity was 
upgraded because of a dose response.  The final evidence type turned out to be 3 for short-
term immunogenicity after 1 dose, 3 for short-term immunogenicity after 2 doses, 3 for 
persistence in immunogenicity, and 4 for SAEs.  The overall evidence type for all outcomes was 
3. 
 
In summary, available studies demonstrate that MenACWY vaccine is immunogenic in HIV-
infected children, adolescents, and young adults with immunogenicity that persists more among 
young children than among adolescents and young adults.  The overall evidence type for 
benefits and harms are Type 3 with short-term immunogenicity after 1 dose, short-term 
immunogenicity after 2 doses, and persistence in immunogenicity all being type 3 and SAEs 
being Type 4. 
 
Discussion Points 
 
Dr. Reingold asked where there is an estimate of how many cases could be prevented 
nationally if this program was fully implemented in terms of the serogroups involved, how many 
cases there are, and the NNV to prevent a case. 
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Dr. Patton replied that she did not have this information. 
 
Dr. Kimberlin (AAP) asked whether there are contemporary US data that document an 
increased risk of Men ACWY in HIV-infected children in the US. 
 
Dr. Patton responded that they do not have these data.  The only information on HIV-infected 
children in the US is from ABCs.  There were only 2 or 3 cases between 1995 and 2014 in 
ABCs data of meningococcal disease among HIV-infected children.  But again, there are very 
serious limitations to those surveillance data. 
 
Dr. Kimberlin (AAP) said he thought it was only 1 for children under 11 years of age who would 
not be receiving the vaccine anyway at the standard age of 11. 
 
Dr. Martin (SME) referred to Dr. Ortega-Sanchez’s Slide 22, which showed that the cases 
averted were 122 and the deaths averted were 23.  That it, approximately 1 million people total 
(not per year) would have to be vaccinated to avert 122 cases and 23 deaths. 
 
Dr. Cohn added that a very rough estimate based on the ABCs data, it is likely to be 
approximately 20 to 30 cases a year occurring among persons with HIV.  That is just based on 
looking at the proportion of the population covered in ABCs, and the number of years in which 
those cases occurred. 
 
Dr. Reingold said if those numbers were right, dividing by 70 would be about 1.5 cases per year. 
 
In terms of the denominator, Dr. Baker (IDSA) asked how many HIV-infected children there are 
currently. 
 
Dr. Patton replied that there are approximately 2000 HIV-infected children currently, and it is 
estimated that there are about 250 new cases of prenatally-acquired HIV per year.  One would 
hope that would be decreasing over time. 
 
Dr. Gorman (NIH) said he was struggling with the data showing the difference in mortality 
between the four countries.  He asked whether they were convinced that the healthcare 
systems were that different in the four countries in terms of the engagement of the HIV 
population with antiretroviral therapy, prophylactic antibiotics, and access to healthcare. 
 
Dr. Patton responded that they believe so, because in the two more recent studies, 80% of 
patients were on antiretroviral therapy.  In the two previous studies and the earlier studies, 
almost no patients were on antiretroviral therapy. 
  
Considerations for Use of MenACWY Vaccines in  
HIV-Infected Persons / Proposed Recommendations 
 
Jessica MacNeil, MPH 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
 
Ms. MacNeil presented a summary of the WG discussions on meningococcal disease among 
HIV-infected persons, reminding everyone that HIV is an established risk factor for several 
bacterial infections.  A growing body of evidence supports an increased risk for meningococcal 
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disease among HIV-infected persons.  ACIP does not currently include HIV-infected persons in 
the recommendations for routine vaccination of persons at increased risk for meningococcal 
disease.  However, if an HIV-infected person is vaccinated, the recommendations state that 
they should receive a 2-dose primary series. 
 
During the February 2016 ACIP meeting, the available evidence was demonstrating an 
increased risk of meningococcal disease among HIV-infected persons, MenACWY vaccine 
response in HIV-infected persons, and programmatic and other considerations for the use of 
MenACWY vaccines in HIV-infected persons were discussed.  Ms. MacNeil summarized these 
data and then explained the WG’s rationale for the proposed use of MenACWY vaccines in HIV-
infected persons and the proposed policy option language for a vote. 
 
There are now five studies which have evaluated the risk for meningococcal disease among 
HIV-infected persons.  Taken together, these studies consistently show an increased risk for 
meningococcal disease among HIV-infected persons: 
 
1) Stephens DS, Hajjeh RA, Baughman WS, Harvey RC, Wenger JD, Farley MM. Sporadic 
meningococcal disease in adults: results of a 5-year population-based study. Ann Intern 
Med. 1995: 123:937-40. 
 
2) Cohen C, Singh E, Wu HM, Martin S, de Gouveia L, Klugman KP, et al; Group for 
Enteric Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA). 
Increased incidence of meningococcal disease in HIV-infected individuals associated 
with higher case-fatality ratios in South Africa. AIDS. 2010; 24:1351-60. 
 
3) Harris CM et al. Meningococcal Disease in Patients with HIV Infection-A Review of 
Cases Reported Through Active Surveillance in the United States, 2000-2008.  
Manuscript Under Preparation. 
 
4) Miller L, Arakaki L, Ramautar A, Bodach S, Braustein S, et al. Elevated Risk for Invasive 
Meningococcal Disease Among Persons with HIV. Ann Intern Med. 2014; 160:30-38. 
 
5) Simmons RD. et al. Risk of invasive meningococcal disease in children and adults with 
HIV in England: a population-based cohort study. BMC Med. 2015; 13: 297. 
 
In addition to showing an overall increased risk for meningococcal disease in HIV-infected 
persons, these studies also demonstrate that among HIV-infected persons, low CD4 count or 
high viral load further increases risk.  Across the studies, a similar increase in risk was observed 
for both HIV-infected men and women.  One study showed that the overall risk of 
meningococcal disease in HIV-infected persons is declining along with meningococcal disease 
incidence in the US.  In HIV-infected persons, meningococcal disease is primarily due to 
serogroups C, W, and Y.  Overall, the data on case-fatality ratios for HIV-infected 
meningococcal disease cases is mixed.  However, the more recent studies show a lower case 
fatality ratio for HIV-infected persons compared to HIV-uninfected persons. 
 
As Dr. Patton reviewed earlier, seroresponse to MenACWY-D (Menactra®) in HIV-infected 
adolescents is suppressed compared to healthy adolescents and HIV-infected 2- to 10-year-
olds.  A low CD4 count or higher viral load suppresses the response even further.  In addition, 
the immune response to MenACWY-D wanes rapidly.  Although a boost response is seen to a 
second dose, duration of protection will likely be an issue in this population [Siberry GK, et al. 
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Phase I/II, open-label trial of safety and immunogenicity of meningococcal polysaccharide 
diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. 
PIDJl. 2010;29(5):391-396; Lujan-Zilbermann J, et al. Immunogenicity and safety of 1 vs 2 
doses of quadrivalent meningococcal conjugate vaccine in youth infected with HIV. J Pediatr. 
2012;161(4):676-681 e672; and Siberry GK, et al. Safety and immunogenicity of quadrivalent 
meningococcal conjugate vaccine in 2- to 10-year-old HIV-infected children. PIDJ. 
2012;31(1):47-52]. 
In addition to the evidence of increased risk for meningococcal disease in HIV-infected persons 
and meningococcal vaccine response, the WG also discussed other programmatic 
considerations for use of meningococcal vaccines in HIV-infected persons.  There are 
approximately 1 million persons living with HIV in the US1.  An additional 40,000 new HIV 
infections are diagnosed each year1.  Only about half of those diagnosed with HIV receive 
regular HIV care2.  Of those retained in care, approximately 89% are prescribed antiretroviral 
therapy and 77% achieve viral suppression2.  For HIV-infected persons in care, HIV clinics 
already may be administering other vaccines recommended for HIV-infected persons.  HIV-
infected persons in care may be more likely to have CD4 counts and viral loads favorable for 
immunogenicity [1 Centers for Disease Control and Prevention. HIV Surveillance Report, 2014. 
www.cdc.gov/hiv/library/reports/surveillance; 2 www.cdc.gov/hiv/prevention/ 
programs/pwp/linkage.html]. 
Risk for meningococcal disease among men who have sex with men (MSM) was discussed in 
detail during February’s ACIP meeting.  Of meningococcal disease cases among MSM for 
whom HIV status is known, the majority (59%) are HIV-infected.  This has made disentangling 
the relative contributions of HIV and MSM status to the increase in risk for meningococcal 
disease challenging in MSM populations.  However, vaccinating all HIV-infected persons offers 
an opportunity potentially to impact meningococcal disease risk among MSM. 
In summary, a growing body of evidence supports an increased risk for meningococcal disease 
among HIV-infected persons.  Several studies have demonstrated between a 5- to 24-fold 
increased risk for meningococcal disease in HIV-infected persons compared to HIV-uninfected 
persons.  In HIV-infected persons, risk is due primarily to serogroups C, W, and Y.  Suboptimal 
vaccine response and programmatic challenges may limit the impact of vaccination on disease 
burden in HIV-infected persons.  However, because HIV-infected persons represent a relatively 
small, defined population who receive care in a specialized medical setting, implementation of a 
recommendation in this population may be less burdensome. 
The current consideration is for use of MenACWY conjugate vaccines only because in HIV-
infected persons, risk appears to be due primarily to serogroups C, W, and Y.  No safety or 
immunogenicity data are available for the use of serogroup B meningococcal vaccines in HIV-
infected persons.  Because increased risk from HIV-infection is lifelong, routine booster doses 
would be recommended for HIV-infected persons similar to other groups at increased risk. 
There was strong support in the WG for including HIV-infected persons in the groups at 
increased risk of meningococcal disease who are recommended MenACWY vaccination.  The 
primary considerations for the WG included the evidence of increased risk of meningococcal 
disease in HIV-infected persons and the potential benefits of vaccination in this targeted group.  
However, the WG also recognized that suboptimal vaccine response and likely issues of 
duration of protection in HIV-infected persons may limit the impact of vaccination in this group.  
There were differing opinions in the WG about the age at which to begin vaccination of HIV-
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infected persons, with some favoring 2 months and others 11 years of age.  However, the 
majority of the WG members supported vaccinating HIV-infected persons beginning at 2 months 
of age. 
 
The pros and cons of including HIV-infected children 2 months through 10 years of age in the 
recommendation were discussed by the WG.  In terms of the pros, harmonizing with the current 
ACIP recommendations for use of MenACWY vaccine in persons with functional or anatomic 
asplenia or complement component deficiencies.  Because the number of HIV-infected children 
in the US is small, this likely would not be a burdensome or expensive recommendation.  
Biologically, it is unlikely that the increased risk of meningococcal disease in HIV-infected 
persons differs for children and adults.  The hSBA titers following 1 or 2 doses of MenACWY 
vaccine in HIV-infected children 2 through 10 years are higher than in HIV-infected adolescents 
11 through 24 years of age.  Regarding the cons, depending upon the timing of doses for some 
children, the schedule may not fully harmonize with ACIP and AAPs recommendations for 
routine use of MenACWY vaccines in children 11 through 12 years of age.  In addition, 
vaccination would require multiple doses over the child’s lifetime.  There are limitations in the 
current data available to document the burden of meningococcal disease in HIV-infected 
children in US. 
 
Based on the discussions of the WG, the following two policy options for use of MenACWY 
vaccines in HIV-infected persons were proposed for a vote during this session: 
 
Option 1 
Human Immunodeficiency Virus (HIV)-infected persons aged ≥2 months should routinely 
receive MenACWY vaccine* (Category A) 
 
OR 
 
Option 2 
Human Immunodeficiency Virus (HIV)-infected persons aged ≥11 years should routinely 
receive MenACWY vaccine** (Category A) 
 
[*Includes MenACWY-D (Menactra®), MenACWY-CRM (Menveo®), and Hib-MenCY-TT 
(MenHibrix®); **Includes MenACWY-D (Menactra®) and MenACWY-CRM (Menveo®)]. 
 
 
Option 1 is consistent with the current recommendations for use of MenACWY vaccines in 
persons at increased risks for meningococcal disease, including persons with functional or 
anatomic asplenia or complement component deficiencies.  Option 1 was supported by the 
majority of the WG. 
 
In addition to the recommendation language, the following guidance would be provided for use 
of MenACWY vaccine in HIV-infected persons: 
 
 
 
In HIV-infected persons aged 2 years of age and older who have not been previously 
vaccinated, two doses of MenACWY vaccine should be administered 2 months 
apart.  For children under 2 years of age, the schedules already require multiple 
doses, and additional doses would not be recommended as part of the primary 
series. 
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 HIV-infected persons who previously received 1 dose of MenACWY vaccine would 
be recommended to receive a second dose at the earliest opportunity, and then 
would be recommended to receive boosters at the appropriate interval based on their 
age at the last MenACWY dose received. 
 
Discussion Points 
 
Dr. Romero did not believe that the statement about 50% of persons diagnosed with HIV 
receiving regular HIV care would apply to children.  The diagnosis of HIV is made early among 
children, and he would surmise that about 80% are under HIV care.  He also noted that children 
who acquire this disease perinatally comprise only 0.6% of the total 40,000.  
 
Ms. MacNeil replied that those numbers were for people diagnosed with HIV overall, and 
probably were much more skewed toward adolescents and adults.  While she did not have the 
exact numbers for children under 13 years of age in care, she agreed that it is probably much 
higher.  In addition, she thought it was probably correct that children who acquire the disease 
perinatally comprise only 0.6% of the total 40,000. 
 
Dr. Moore pointed out that although it was noted that biologically, there is no difference between 
children and adults, differences are observed in rates of meningococcal disease that may have 
been attributed to exposure to different strains of meningococcal bacteria over time which is 
why attention is focused on older teens and young adults.  Based on that, there is a sensible 
argument for starting 11 years of age even though the biology of HIV is the same.  The 
behavioral risk factors associated with meningococcal disease are different. 
 
Ms. MacNeil confirmed that the highest incidence rates are among infants and young children.  
There is an increased incidence in children less than 5 years of age, so potentially some cases 
could be prevented in that age group. 
 
Dr. Belongia asked what the justification was for the different intervals for the booster dose for 
children under 7 years of age at 3 years versus 5 years. 
 
Dr. Cohn replied that this was based on waning immunity from the different schedules.  The 
schedules differ in young infants in terms of the number of doses versus older adults.  It is 
based on the 2-dose Menactra® waning immunity data, which was substantially faster than the 
waning immunity of a single dose in adolescents. 
 
It seemed to Dr. Thompson (NVAC) that there is a strong correlation between CD4 and 
antibodies.  With respect to waning, she wondered whether the WG considered the possibility of 
booster doses related to CD4 versus just an age criterion and if there are data to support that.  
In reality in the population, there is a distribution of people with different levels of progression of 
their HIV, CD4 counts, et cetera.  At some level, waning may reflect what is occurring in that 
respect.  CD4 counts are regularly monitored by clinicians. 
 
Ms. MacNeil responded that the WG did not discuss boosters related to CD4 counts, but there 
was discussion about more frequent boosters every 3 years.  The thought currently is to try to 
harmonize with the recommendations for other groups at increased risk, and to continue to 
monitor cases through surveillance.  If an issue is observed, more frequent boosters could be 
administered. 
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Dr. Kimberlin (AAP) expressed the AAP’s appreciation for the diligence with which ACIP had 
approached this issue.  AAP’s Committee on Infectious Disease (COID) has engaged in many 
discussions as well.  The focus that had been impressive to the AAP COID was listed as a con 
of dropping the age to 2 months, given the limited data to document burden of disease in HIV-
infected children in the US.  The AAP COID’s interpretation is that there are no data to suggest 
that.  Following that, without evidence of increased risk, their discussion was focused on 11 
years of age and older. 
 
Dr. Baker (IDSA) asked whether anyone could tell her the numbers of children in the US under 
11 years of age who have functional or anatomic asplenia or complement component 
deficiencies. 
 
Ms. MacNeil replied that the numbers are probably very small for both.  In general for all ages, it 
is thought that about 1% of people have a complement component deficiency and overall about 
1 million people in the US have asplenia. 
 
Dr. Baker (IDSA) pointed out that the good news is that there is a small number of perinatally-
infected children in the US.  She thought the estimate would be that greater than 90% of HIV-
infected children are in medical care.  It is biologically implausible to her that children would 
have no increased risk under 11 years of age.  While she hears people say that there is not a 
large disease burden or there are no data for children under 11 years of age, it seemed 
inconsistent with past and current policies to exclude a group.  From a programmatic point-of-
view, she thought there would be a lot of questions from the public about excluding this group at 
risk, including those at greatest risk for meningococcal disease—children less than 1 year of 
age plus HIV-infection.  She indicated that the IDSA Public Health Committee favors Option 1. 
 
Dr. Reingold was curious why one would make this recommendation for the ACWY-135 vaccine 
and not for the B vaccine.  It seemed to him that serogroup B causes about a third of the cases 
in the US. 
 
Dr. Cohn responded that the number of cases among persons with HIV are primarily serogroup 
C with some Y. 
 
Ms. MacNeil indicated that about 80% of cases are C, W, and Y in HIV-infected persons, and 
this has been increasing recently.  There are no safety or immunogenicity for MenB vaccines in 
HIV-infected people at this time.  
 
Vote:  Use of MenACWY Vaccines in HIV-Infected Persons 
 
Dr. Rubin motioned to approve Policy Option 1.  Dr. Stephens seconded the motion.  The 
motion carried unanimously with 15 affirmative votes, 0 negative vote, and 0 abstentions.  The 
disposition of the vote was as follows: 
 
15 Favored: Belongia, Bennett, Ezeanolue, Harriman, Harrison, Karron, Kempe, Moore, 
Pellegrini, Romero, Reingold, Riley, Rubin, Stephens, Walter 
  0 Opposed: N/A 
  0 Abstained:   N/A 
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VFC Resolution 
 
Dr. Jeanne M. Santoli 
Immunization Services Division 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
 
Dr. Santoli indicated that the purpose of this revision was to update the eligible groups for the 
use of meningococcal conjugate vaccines to include children 2 months of age and older who are 
infected with HIV.  Eligible groups would include the following, which reflects the addition of 
children infected with HIV: 
 
 
 
 
 
 
 
 
 
 
 
 
Children aged 2 months through 10 years who are at increased risk for meningococcal 
disease attributable to serogroups A, C, W, and Y, including: 
 
Children who have persistent complement component deficiencies (including 
inherited or chronic deficiencies in C3, C5-C9, properdin, factor H, or factor D or 
taking eculizumab [Soliris®])  
Children who have anatomic or functional asplenia, including sickle cell disease 
Children infected with Human Immunodeficiency Virus (HIV) 
Children traveling to or residing in countries in which meningococcal disease is 
hyperendemic or epidemic, particularly if contact with local population will be 
prolonged  (MenACWY vaccines only) 
Children identified to be at increased risk because of a meningococcal disease 
outbreak attributable to serogroups A, C, W, or Y 
 
All children aged 11 through 18 years of age. 
  
No changes were recommended to the following sections of the resolution: 
 
Recommended Vaccination Schedule and Intervals 
Recommended dosage   
Contraindications and Precautions 
The Serogroup B Meningococcal Vaccine component of the resolution 
 
The standard statement regarding updates based on published documents will be included: 
  
If an ACIP recommendation regarding meningococcal vaccination is published within 12 
months following this resolution, the relevant language above (except in the eligible 
groups sections) will be replaced with the language in the recommendation and 
incorporated by reference to the publication URL. 
 
Discussion Points 
 
Ms. Pellegrini requested clarification regarding whether the language on the booster doses 
would be incorporated by reference. 
 
Dr. Santoli replied that she did not discuss the links included in this resolution that are not 
changed for the 2013 statement.  All of the language is included through a link, and if there are 
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changes, those are updated by reference.  Links in the resolution point to the booster language 
and other language about administration of the vaccine. 
 
Vote:  VFC Resolution for the Use of MenACWY Vaccines in HIV-Infected Persons 
 
Dr. Rubin motioned to approve the VFC Resolution for Use of MenACWY Vaccines in HIV-
Infected Persons.  Dr. Harrison seconded the motion.  The motion carried unanimously with 15 
affirmative votes, 0 negative vote, and 0 abstentions.  The disposition of the vote was as 
follows: 
 
15 Favored: Belongia, Bennett, Ezeanolue, Harriman, Harrison, Karron, Kempe, Moore, 
Pellegrini, Romero, Reingold, Riley, Rubin, Stephens, Walter 
  0 Opposed: N/A 
  0 Abstained:   N/A 
 
 
 
 
Arthur Reingold, MD 
University of California, Berkeley 
Chair, ACIP Evidence-Based Recommendations Work Group 
 
Dr. Reingold indicated that the purpose of the Evidence-Based Recommendations WG is to 
provide a forum for discussion of best practices for the evidence-based recommendation 
process, including development and use of evidence tables and an evidence to 
recommendation framework to ensure consistency and enhance transparency in the 
development of ACIP recommendations, with the goal of developing a uniform approach to 
evaluation and use of the evidence base for ACIP recommendations. 
 
The aims of the WG are potentially to modify and / or propose additional guidance for the ACIP 
evidence-based recommendation process, including GRADE and subsequent use of an 
evidence to recommendation framework, specifically to: 
 
 
 
 
 
Identify areas for improvement and harmonization regarding development and use of 
GRADE evidence tables among ACIP WGs 
Propose criteria that should be considered when determining whether GRADE evidence 
tables should be prepared for vaccine recommendations 
 
Develop a more transparent process outlining the formulation of recommendations that 
defines methods for the incorporation of additional factors that contribute to decision-
making, as well as GRADE evidence tables generated by systematic review 
  
Evidence-Based Recommendations Work Group Update 
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Th
 
 
 
 
 
 
 
 
 
 
 
• 
• 
• 
 
 
 
 
 
 
• 
• 
e WG will develop the following: 
Guidance outlining proposed modifications and/or additions to the Evidence-Based 
Recommendations approach for consideration and approval by ACIP 
 
When developing the guidance, processes used by other nationally and internationally 
recognized groups also charged with formulating clinical and prevention policies will be 
considered  
A toolkit for use by ACIP Work Groups when formulating evidence-based recommendations 
 
A summary of any changes to the Evidence-Based Recommendations approach used by 
ACIP for publication (e.g., in MMWR) 
 
Potential topics for the Evidence-Based Recommendations WG to address include the 
following: 
Quality Assessment of Evidence: 
Determine the optimal way to consistently include the following data when evaluating 
the evidence using GRADE: 
immunogenicity data  
post-licensure safety and effectiveness assessments 
data addressing the population-level impact of vaccine use 
Evaluate methods to systematically and consistently evaluate burden of disease and 
outline how these data should be utilized during the process of recommendation 
development 
Recommendation Development: 
Develop guidance providing additional structure for the evidence to recommendation 
process, including incorporation of the following: 
 
population-level impact of vaccine use  
values and preferences (audience, methods to elucidate such as provider 
surveys, et cetera) 
 
 
 
Arthur Reingold, MD 
University of California, Berkeley 
Chair, ACIP Hepatitis Work Group 
 
Dr. Reingold emphasized that ACIP believes it is very important to update recommendations on 
a regular basis.  It has been almost 10 years since the last recommendation, although there 
have been updates in the interim.  Hepatitis A recommendations were published in the MMWR 
Hepatitis Vaccines Update 
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Recommendations and Reports in 2006 and Hepatitis B recommendations were published in 
MMWR Recommendations and Reports in 2005 and 2006.  While there may not be a lot of new 
information or new vaccines available, the WG thinks it is important at least to update the 
statements and bring them current through 2016.  The basic plan is for the WG to create two 
new documents, one on Hepatitis A and the other on Hepatitis B that will combine all of the 
information into single document that incorporates any new information.  
 
As a reminder, the ACIP Hepatitis WG Term of Reference are as follows: 
 
 
 
• 
• 
• 
• 
 
 
• 
• 
• 
• 
 
• 
• 
Update ACIP recommendations for Hepatitis A vaccine 
  
Current ACIP recommendations 
ACIP Routine Recommendation for Hepatitis A Vaccine.  MMWR 2006 May 
19;55(RR-7):1-23.  
Update: Prevention of hepatitis A after exposure to hepatitis A virus and in 
international travelers. Updated recommendations of the ACIP. MMWR 2007 
Oct 19;56(41):1080-4. 
FDA Approval of an Alternate Dosing Schedule for Twinrix®.  MMWR 2007 
Oct 12;56(40):1057. 
Updated recommendations from the ACIP for use of hepatitis A vaccine in 
close contacts of newly arriving international adoptees.  MMWR 2009 Sep 
18;58(36):1006-7.  
 
Update ACIP recommendations for Hepatitis B vaccine 
 
Current ACIP recommendations 
ACIP Routine Recommendation for Hepatitis B Vaccine (Infants/Children). 
MMWR 2005 Dec 23;54(RR-16):1-33.  
ACIP Routine Recommendation for Hepatitis B Vaccine (Adult).  MMWR 
2006 Dec 8;55(RR-16):1-33. 
FDA Approval of an Alternate Dosing Schedule for Twinrix®.  MMWR 2007 
Oct 12;56(40):1057. 
Use of hepatitis B vaccination for adults with diabetes mellitus: 
recommendations of the ACIP.  MMWR 2011 Dec 23;60(50):1709-11. 
 
Current CDC Guidelines 
CDC guidance for evaluating health-care personnel for hepatitis B virus 
protection and for administering postexposure management.  MMWR 2013 
Dec 20;62(RR-10):1-19. 
Update: Shortened Interval for Postvaccination Serologic Testing of Infants 
Born to Hepatitis B-Infected Mothers.  MMWR 2015 Oct 9;64(39):1118-20. 
 
From May 2014 to April 2015, the WG considered Hepatitis A disease burden and population 
protection and catch-up vaccination for children / teens 2 through 18 years of age.  From 
February 2016 to present, the WG has been considering immunogenicity and safety of 
HEPLISAV-B, a 2-Dose Hepatitis B Vaccine Series for Adults; and updating the ACIP 
recommendations for Hepatitis B vaccination.  The ultimate goals is to develop the revised 
vaccine statements over the course of the next 6 to 12 months.  They will then be presented to 
ACIP for evaluation and hopefully concurrence. 
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Dr. Jeanne M. Santoli 
Immunization Services Division 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
During this session, Dr. Santoli presented an update on diphtheria, tetanus, and pertussis 
(DTaP)-containing vaccines Pentacel® and Pediarix®, and Merck vaccines in prefilled syringes. 
In December 2015, Sanofi Pasteur announced a manufacturing delay with Pentacel® vaccine. 
As a result, Sanofi Pasteur is only able to meet approximately 70% of historical Pentacel® 
vaccine demand.  At this time, sufficient supplies of the relevant individually administered 
vaccines DAPTACEL®, ActHIB®, and IPOL® are available to address the anticipated gap in 
Pentacel® supply.  Sanofi Pasteur anticipates resolution of this Pentacel® delay during the 
second half of 2016. 
GlaxoSmitnKline (GSK) is experiencing a delayed release of its Pediarix® vaccine.  This delay is 
anticipated to resolve in late June to early July 2016.  At this time, sufficient supplies of GSK’s 
individually administered vaccines (DTaP and HepB) are available to address the gap in 
Pediarix® supply.  In addition, Sanofi Pasteur has indicated it has sufficient supplies of IPV and / 
or Pentacel® vaccine to address the gap in Pediarix® supply. 
The following prefilled syringes are currently unavailable: 
 
 
 
 
Gardasil 9 (HPV) 
Pediatric Recombivax (Hep B) 
Adult Recombivax (Hep B) 
Pediatric Vaqta (Hep A) 
Merck anticipates return to availability in the second quarter of calendar year 2017.  In the 
interim, Merck has sufficient supplies of the vial presentations for each of these vaccines to 
meet historical demand for both vial and prefilled syringe presentations. 
CDC’s Vaccine Supply/Shortage Webpage can be found 
at: www.cdc.gov/vaccines/vac-gen/shortages/default.htm 
Vaccine Supply 
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Introduction 
 
Ruth Karron, MD 
Chair, Influenza Work Group 
 
Dr. Karron reported that since the February 2016 ACIP meeting, the Influenza WG has 
considered recent data pertaining to vaccine safety, FluLaval™ Quadrivalent vaccine evaluated 
in 6 through 36 months of age, the newly licensed Flucelvax Quadrivalent® vaccine, and vaccine 
effectiveness data for live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine 
(IIV).  She indicated that the topics for this session would focus on vaccine safety for 2015-
2016; FluLaval™ Quadrivalent; Flucelvax Quadrivalent®; vaccine effectiveness data for 2015-
2016, including effectiveness of LAIV and IIV, from the US Influenza Vaccine Effectiveness (US 
Flu VE) Network and MedImmune; and proposed recommendations for use of influenza 
vaccines. 
 
FluLaval™ Quadrivalent 
 
Bruce L. Innis, MD, FIDSA 
Research and Development Program for Influenza Vaccines 
GSK Vaccines 
 
Dr. Innis presented the immunogenicity and safety data for FluLaval™ Quadrivalent in children 
6 through 35 months of age.  He reminded everyone that original IIVs were administered to 
young children at a reduced dose to diminish their immunogencity1-3.  Most contemporary split 
or subvirion vaccines are less reactogenic in young children, but have variable immune 
responses in the age group below 3 years4-5. 
 
In the US, Fluzone™ is the sole IIV licensed for children 6 through 35 months of age.  Its 
approved dose is 0.25 mL containing 7.5 µg of purified hemagglutinin (HA) for each of the 
strains contained in the vaccine.  This is half the dose that is approved for children 3 years of 
age and older.  In this development program, GSK used a 0.5mL dose containing 15µg of 
purified HA per strain of FluLaval™ Quadrivalent in the anticipation that this would improve its 
immunogenicity [1Wright PF, Thompson J, Vaughn WK, et al. J Infect Dis 1977;136:S731-41; 
2Gross PA, Ennis FA, Gaerlan PF, et al. J Infect Dis 1977;136:623-32; 3Gross PA. J Infect Dis 
1977;136:S616-25; 4Englund JA, Walter EB,Gbadebo A, et al. Pediatrics 2006;118:e579-85; 
5Walter EB, Rajagopal S, Zhu Y, et al. Vaccine 2010;28:4376-83l]. 
 
As a reminder, FluLaval™ Quadrivalent (Q-QIV) received FDA approval in August 2013 for use 
in persons 3 years of age and older.  The vaccine is available in pre-filled syringes or a multi-
dose vial.  In January 2016, GSK submitted a Supplemental Biologics License Application 
(sBLA) to extend the indication to 6 through 35 months of age.  The expected FDA action date 
is November 26, 2016.  The dose will be 0.5mL and will contain 15µg HA from each of the 
recommended A/H1N1, A/H3N2, B-Victoria, and B-Yamagata strains.  The proposed indication 
follows:  
 
Influenza 
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FLULAVAL™ QUADRIVALENT is a vaccine indicated for active immunization for the 
prevention of disease caused by influenza A subtype viruses and type B viruses 
contained in the vaccine. FLULAVAL™ QUADRIVALENT is approved for use in persons 
6 months of age and older  
 
The sBLA contained immunogenicity and safety data generated in three small Phase 1 or 2 
studies and one very large Phase 3 trial.  The development program began in 2010 and ran 
over a period of four immunization seasons.  This allowed GSK to acquire safety and 
immunogenicity data on approximately 2000 subjects who were all actively monitored for safety 
for 6 months post-vaccination.  Dr. Innis focused on the large pivotal Phase 3 study during this 
presentation, but emphasized that the relevance of the earlier studies is that they established 
that the profile of FluLaval™ immunogenicity and safety were consistent over multiple annual 
strain updates. 
 
The Phase 3 study was an observer-blind randomized Fluzone™ QIV controlled trial conducted 
in 69 centers in the US and Mexico from October 2014 through June 2015.  There were 2424 
children 6 through 35 months of age enrolled who appear in the total vaccinated cohort (TVC).  
Children received one or two doses according to their vaccine priming status in accordance with 
the ACIP recommendation.  The strain composition of both vaccines was identical, including: 
 
 
 
 
 
A/California/7/2009 (A/H1N1) 
A/Texas/50/2012 (A/H3N2) 
B/Massachusetts/2/2012 (B/Yamagata) 
B/Brisbane/60/2008 (B/Victoria) 
 
Blood samples were collected pre-vaccination and 28 days after the last vaccine dose.  
Reactogenicity data, including body temperature that was assessed using a standard digital 
thermometer, were reported by parents on a diary card daily for 7 days after dosing.  Additional 
safety data were collected by the investigators at each subsequent visit with the parent or 
guardian of the study subject. 
 
The primary protocol objective was to evaluate the immunogenic non-inferiority of FluLaval™ 
QIV versus Fluzone™ QIV in terms of geometric mean titers (GMTs) and seroconversion rates 
(SCRs) as determined by a standardized and validated hemagglutination inhibition (HI) assay 
approximately 28 days after completion of dosing in children 6 through 35 months of age.  The 
secondary objectives were to: 
 
 
 
 
 
Evaluate immunogenicity of FluLaval™ QIV based on Center for Biologics Evaluation and 
Research’s (CBER’s) acceptance criteria for seroconversion and seroprotection 
Describe safety and reactogenicity 
Describe immunogenicity 
Describe relative risk of fever for FluLaval™ QIV compared to Fluzone™ QIV within 2 days 
post-vaccination 
 
There were no notable demographic differences in terms of age, gender, ethnicity, or 
vaccination priming status.  The average age was 19.5 months.  There were slightly more males 
than females.  Most of the subjects were of non-Hispanic ancestry.  There were approximately 
200 participants from Mexico, while the rest were from the US.  There was baseline medical 
history indicating the presence of at least one risk factor that could predispose a subject to 
complications of influenza infection in 6.8% and 6.2% of subjects respectively for Fluzone™ 
Advisory Committee on Immunization Practices (ACIP)                                               Summary Report                                             June 22-23, 2016 
 
 
71 
 
 
versus the comparator.  The most frequent risk factor was chronic pulmonary disease, mostly 
asthma.  There were 102 subjects in the younger age stratum of 6 through 17 months of age, 
and 1,422 in the older stratum.  Of the subjects, 1,110 were vaccine unprimed. 
 
While pre-vaccination titers were low and similar between the groups for all strains, the vaccine 
response for the double dose FluLaval™ treatment appeared to be slightly higher for the two B 
strains included in the vaccine.  The primary confirmatory objective was to demonstrate the 
immunogenic non-inferiority of FluLaval™ QIV compared to the comparator, which was met.  
The success criteria included a GMT ratio of ≤ 1.5 for each strain and an SCR of ≤ 10% for each 
strain. The GMT ratios were < 1 for all strains in favour of the double dose treatment, although 
more so for the B strains than for the A strains.  The SCR was < 6% in favour of the double 
dose FluLaval™ treatment, again notably more so for the B versus the A strain.  Conformance 
with the CBER acceptance criterion for inactivated vaccines was assessed and was exceeded 
by both treatment groups, but more so for FluLaval™.  The CBER acceptability criterion for 
seroprotection was 70% of subjects who met or exceeded a titer of 1:40 by HI test following 
immunization.  Both products met this criterion for 3 of the 4 strains, but neither met the criterion 
for B Victoria.  The pre-immunization titers were quite low, with less than 5% of this cohort 
having a titer of 1:40 or greater.  While this is presumably the explanation, Dr. Innis believes that 
the response to this strain also illustrates the potential benefits of having a double dose in the 
vaccine for this age group, because the difference is particularly notable when baseline titers 
are low. 
 
The higher titers observed in the double dose FluLaval™ group relative to the standard of care 
prompted the investigators to perform a post-hoc analysis comparing the immune response 
elicited by the vaccine in all children and then according to age group and according to priming 
status.  The post-hoc superiority analysis was performed of FluLaval™ over Fluzone™ using a 
conventional superiority criterion articulated by CBER; that is, superiority was indicated when 
the lower bound of the 95% confidence interval was > 1.5.  Two important subgroups’ influenza 
B responses were superior in the double-dose FluLaval™ group:  1) children 6 through 17 years 
of age, regardless of their vaccine priming status; and 2) all children under 3 years of age who 
were not previously vaccinated.  In terms of the SCR difference, in this case the superiority 
criterion for superior immunogenicity was that the lower limit of the 95% confidence interval was 
>10%.  That was met again in these same two groups for the response to the influenza B 
components of the vaccine.  The comparative immunogenicity data acted as a surrogate for 
vaccine efficacy. 
 
In terms of reactogenicity data, in terms of incidence rates per subject over 7 days following 
vaccination, there were no notable differences between the treatments (any symptoms, injection 
symptoms, general symptoms) for all symptoms or Grade 3 symptoms.  In addition, there were 
no notable differences between all pain, redness, and swelling and Grade 3 pain, redness, and 
swelling between the treatments.  With regard to solicited general AEs for All versus Grade 3, 
because the children were young they were monitored for drowsiness, fever, irritability, and loss 
of appetite.  Again, there were no notable differences.  The rates of unsolicited AEs, shown in 
the following table, were equal among the treatment groups as expected and this supports the 
excellent safety profile of the new vaccine relative to what has been the standard of care for the 
last 16 years: 
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  FluLaval™ QIV Fluzone™  QIV 
 [follow up period] N = 1207 N = 1217 
Any unsolicited AEs, n (%) 
[28 days after vaccination] 549 (45.5%) 537 (44.1%) 
Medically attended AEs, n (%) 
[entire study] 727 (60.2%) 719 (59.1%) 
Potential immune mediated disease, n (%) 
[entire study] 1 (0.1%) 1 (0.1%) 
Any SAEs, n (%) [n related] 
[entire study] 22 (1.8%) [0] 21 1.7%) [0] 
 
With respect to relative risk of fever, rates were similar between groups and the relative risk of 
fever ≥38°C was 0.97. 
 
In conclusion, the primary objective was met.  Immunogenic non-inferiority of FluLaval™ QIV to 
Fluzone™ QIV was demonstrated for all four strains in terms of GMTs and SCR.  The use of 
0.5mL dose (15µg per strain) of FluLaval™ QIV was not only immunogenically non-inferior to 
the standard of care, but also it elicited superior immune responses to both influenza B strains 
in children 6 through 17 months of age or in children 6 through 35 months of age who had not 
been vaccinated previously.  Despite its double dose and injection volume, the FluLaval™ QIV 
reactogenicity and safety profile was equal to that of Fluzone™ QIV.  As HI antibody titer post-
vaccination is positively correlated with protection from influenza illness, GSK believes that 
double-dose FluLaval™ QIV may improve protection against influenza B, which is a potentially 
serious and life-threatening illness in young children.  At the same time, the use of a 0.5mL 
dose (15µg per strain) FluLaval™ QIV will reduce complexity and cost in mounting the annual 
immunization campaign by allowing the same vaccine dose to be used for all persons who are 
eligible regardless of their age. 
 
Discussion Points 
 
Regarding fever, Dr. Walter inquired as to whether any of the children received other vaccines 
simultaneously and whether the investigators specifically assessed pneumococcal conjugate 
vaccine (PCV13). 
 
Dr. Innis responded that simultaneous vaccination was permitted.  Though this study did not 
assess PCV13, GSK has evaluated PCV13 in the past for Fluarix® and FluLaval™.  The risk of 
fever is increased with these products and PCV, but not remarkably so.  This is an acceptable 
combination. 
 
Referring to Slide 18, Dr. Kempe noted that there was a relative risk of high fever of almost  
almost 6 and almost 3.  She wondered whether the reason that was not significant was because 
there were small numbers of cases.  She also inquired about the total N. 
Dr. Innis replied that there were very small numbers of cases.  For the relative risk of 6, there 
were 4 cases in the FluLaval™ group and 1 case in the Fluzone™ group.  The total N is 
approximately 1200 subjects per group. 
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Flucelvax Quadrivalent® (ccIIV4) 
 
Dr. James Mansi 
Seqirus™ A CSL Company 
 
Dr. Mansi provided an update on Flucelvax Quadrivalent® (ccIIV4), the Seqirus™ quadrivalent 
inactivated cell culture influenza vaccine.  This is Seqirus’s™ first influenza quadrivalent 
influenza vaccine.  Flucelvax Quadrivalent® was approved by the FDA on May 23, 2016 for 
individuals 4 years of age and older. 
  
Using the cell-based technology or culture platform as the Seqirus™ currently licensed 
Flucelvax Trivalent® cell culture vaccine; whereby, influenza virus is propagated in Madin Darby 
Canine Kidney (MDCK) cells, a continuous cell line.  This platform provides an alternative to 
traditional influenza vaccine passage through eggs, and allows for a flexible high volume 
process without reliance on eggs.  Moreover, given that the process is closed and semi-
automated, the risk is reduced for external contamination. 
 
The licensure of Flucelvax Quadrivalent® was based on the immunogenicity, safety, and 
tolerability results from two pivotal Phase III trials, both of which were conducted in the United 
States (US) during the 2013-2014 Northern Hemisphere Influenza season.  The first study 
evaluated ccIIV4 in adults 18 years of age and older, while the second study evaluated ccIIV4 in 
children 4 through 17 years of age.  Across both studies, ccIIV4 was shown to be immunogenic 
against all four influenza strains and demonstrated a safety profile similar to the trivalent cell 
culture vaccine, while being equally well-tolerated. 
 
The following diagram represents the study design and subject dispensation for the adult study: 
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Approximately 2600 adults 18 years of age and older were stratified into two age groups, either 
18 through 65 years of age or 65 years of age and older.  They were randomized in a 2:1:1 
fashion to receive either ccIIV4 or one of two ccIIV3 vaccines, the first having all three of the 
World Health Organization (WHO)-recommended strains for that season and the second having 
the two recommend A strains with the alternate B strain, B/Victoria.  Baseline blood specimens 
were drawn at Visit 1 and again 3 weeks following immunization. 
 
The preliminary objective of the study was to demonstrate non-inferiority of the antibody 
response from ccIIV4 compared to both ccIIV3 vaccines by the GMT ratios as well as the 
seroconversion rates.  The secondary objective was to evaluate the immunologic response of 
ccIIV4 and to demonstrate superiority of the ccIIV4 on the alternate B strain.  Safety data was 
collected through 6 months post-immunization. 
 
With respect to the immune response, non-inferiority across all four vaccine strains was met by 
both seroconversion rates, whereby the upper bound of the 95% confidence interval did not 
exceed the pre-defined non-inferiority margin of 10.  Similarly, for the GMT ratios, the upper 
bounds of the 95% confidence interval of each of the four strains did not exceed the pre-defined 
non-inferiority margin of 1.5.  All of this confirms that the addition of the fourth influenza strain to 
the trivalent formulation did not negatively impact the immune response or the antibody 
response of the three other strains.  Additionally, ccIIV4 demonstrated superiority to the 
alternate B strain compared to ccIIV3.  
 
In terms of the antibody response, overall the immune response was similar between ccIIV4 and 
ccIIV3, with the antibody response being more robust in the younger age group of 18 through 65 
years as compared to the older age group of 65 years and older.  This can be attributed to age-
related immunosenescence.  The Center for Biologics Evaluation and Research (CBER) 
immunogenicity criteria were met against all strains for both HI titers >40 and the percent of 
subjects achieving sero-protective levels in the adult population of 18 through 65 year olds.  In 
the adult population 65 years of age older, the CBER immunogencity criteria were met for all 
four strains for HI titers.  The criteria was met for seroconversion only for the H1N1 strain.  The 
lower antibody response has been observed previously in older adults in other influenza vaccine 
studies. 
 
With respect to safety and the tolerability profile of ccIIV4 in the adult population, a similar 
percentage of subjects reported solicited AEs across all three of the vaccine groups.  Overall, 
the solicited AEs were reported in a lower percentage of older adults 65 years of age and older 
as compared to the younger cohort of adults 18 through 65 years of age.  The most common 
local AE was pain at the injection site, while the most common systemic AE was headaches.  
Across the entire study group, the percentage of subjects reporting unsolicited AE were few, 
with similar rates across each of the three vaccine groups.  SAEs were reported in about 1% of 
subjects, with none found to be related to the vaccine.  Thus, the reactogenicity and safety 
profile of Flucelvax Quadrivalent® were consistent with those of the Seqirus™ trivalent cell 
culture vaccine in the adult population, and similar to what is observed in other influenza 
vaccines in this adult population. 
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The pediatric study included approximately 2300 children 4 through 17 years of age who were 
stratified into two age groups, children 4 through 8 years of age and children 9 through 17 years 
of age shown in the diagram below: 
 
 
 
Within these strata, subjects were randomized to receive vaccine in a 2:1:1 fashion to receive 
either ccIIV4 or one of two ccIIV3 vaccines, the first having all three of the WHO-recommended 
strains for that season and the second having the two recommend A strains with the alternate B 
strain, B/Victoria.  Previously vaccinated children received one dose; whereas, influenza 
vaccine naïve children received two doses one month apart.  Baseline blood samples were 
taken at Visit 1 and again 1 month following the last dose of study vaccine.  Similar to the adult 
study, a primary objective of this study was to demonstrate non-inferiority of ccIIV4 against the 
GMT ratio and seroconversion rates compared to ccIIV3.  The secondary objectives included 
the antibody response of ccIIV4 compared to ccIIV3 according to CBER and the Committee for 
Medicinal Products for Human Use (CHMP) criteria, and demonstration of superiority of ccIIV4 
to the alternate B strain.  Once again, safety was followed up through 6 months following the 
last dose of study vaccine. 
 
The immune response to the cell culture vaccine was shown to be non-inferior for both the 
seroconversion rates, where the confidence intervals for each of the four influenza strains were 
below the pre-defined non-inferiority margin of 10.  For GMT ratios, all four of the vaccine 
strains were shown to be non-inferior below the pre-defined non-inferiority margin of 1.5.  Once 
again, superiority of ccIIV4 was demonstrated in the population of children 4 through 18 years of 
age against the alternate B strain in the vaccine.  In terms of the antibody response, overall the 
immune responses were similar between ccIIV4 and each of the trivalent cell culture vaccines.  
The CBER criteria for immunogenicity based on seroconversion and HI titers >40 were met in 
children 4 through 18 years of age for all four of the influenza strains in the vaccine.  The 
European CHMP criteria were equally met for seroconversion and HI titers. 
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With respect to safety and tolerability of ccIIV4 in this pediatric population, overall the safety 
profile was similar to that of the comparator trivalent cell culture vaccines and to what has been 
observed in other influenza non-cell culture vaccines, including similar reactogenicity profiles.  
The reported solicited AEs were generally mild to moderate in nature and of a limited duration, 
resolving in less than 7 days.  The most common local AEs reported were tenderness and 
injection site pain across all of the vaccine groups in equal proportions.  The most common 
systemic AEs reported were sleepiness, fatigue, and headache across all three of the vaccine 
groups.  Unsolicited AEs were reported in about 24 percent of subjects equally across each of 
the three vaccine groups.  None of those were judged by the investigators as possibly related to 
any of the vaccines, and were comparable across all three.  SAEs were reported in about 1% of 
all subjects and were equally distributed across each of the three vaccine groups, and none 
were judged by the investigators as vaccine-related. 
 
In conclusion, the cell culture-based platform represents an alternative to traditional egg-based 
vaccine platforms, allowing for a flexible, high-volume process without relying on eggs.  Given 
that it is a closed, semi-automated process, risk for external contamination is limited.  What has 
been shown in the clinical trials for ccIIV4 is that from an immune perspective, ccIIV4 was able 
to illicit an immune response that was non-inferior to the comparator ccIIV3 and provided a 
superior immune response to the alternate B vaccine.  The safety profile of MDCK cell-derived 
QIV was similar to that of TIVc vaccines, including a similar reactogenicity profile.  No 
unexpected safety signals or concerns occurred throughout the study across the various ages. 
  
Discussion Points 
 
Dr. Gorman (NIH) requested an estimation of the time advantage over egg-based 
manufacturing processes in terms of a pandemic, and an estimation of Seqirus™ production 
capacity. 
 
Dr. Mansi replied that the cell-based platform allows for more flexible and rapid production of 
influenza vaccine, particularly in a pandemic.  They have run estimates on pandemic readiness, 
which he indicated he would share with ACIP.  In terms of production capacity, Seqirus™ is able 
to meet current demands.  
 
Dr. Belongia said he thought it was important to acknowledge that although manufacturing 
occurs in cell culture, it begins with egg-adapted viruses as a source and does not eliminate the 
problem of using eggs completely.  Mutations can occur during egg adaptation.  For the adult 
study, he wondered whether Dr. Mansi had any data on the proportion of participants who 
received vaccine the previous year and if so, whether there was a distribution of some people 
who were and were not vaccinated in the prior year. 
 
Dr. Mansi noted that the full potential of the cell-based platform would be reached once they 
reach the starting point with the virus in the cell basing.  The majority of adults were previously 
vaccinated, so a high number of adults had seroprotective levels at baseline, particularly in the 
older adult population that was equally distributed among the three vaccine groups. 
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Vaccine Safety Update 
 
Tom Shimabukuro, MD, MPH, MBA 
Immunization Safety Office 
Centers for Disease Control and Prevention  
 
Dr. Shimabukuro shared the following table depicting the influenza vaccine products utilized 
during the past season, pointing out that IIV is commonly used when speaking of inactivated 
products collectively or some group of inactivated products, while all LAIV is quadrivalent. 
 
Vaccine Abbreviation 
Trivalent inactivated influenza vaccine IIV3 
Quadrivalent inactivated influenza vaccine IIV4 
Quadrivalent live attenuated influenza vaccine LAIV4 
High-dose trivalent inactivated influenza vaccine IIV3-HD 
Intradermal trivalent and quadrivalent inactivated influenza vaccines IIV3-ID IIV4-ID 
Cell culture-based trivalent inactivated influenza vaccine ccIIV3 
 
Recombinant trivalent inactivated influenza vaccine  
 
RIV3 
 
He reminded everyone that the Vaccine Adverse Event Reporting System (VAERS) is a passive 
reporting system that is administered by the CDC and FDA.  The strengths are that it includes 
national data, is good for rapid signal detection, and can detect rare AEs.  The limitations are 
the limitations inherent to passive surveillance in general, including reporting bias, inconsistent 
data quality and completeness, lack of unvaccinated comparison group.  Because of this, 
whether a vaccine caused an AE generally cannot be assessed from VAERS data. 
 
Included for this season were US influenza vaccine reports received in VAERS through May 27, 
2016 for individuals vaccinated July 1, 2015 through May 6, 2016.  Signs, symptoms, and 
diagnoses are coded using the Medical Dictionary for Regulatory Activities (MedDRA) terms.  
Clinical review of reports, which includes review of medical records when available, were 
performed for the following: 
 
 
 
 
All serious reports after IIV4, IIV4-ID, LAIV4, ccIIV3, RIV3 
All anaphylaxis reports in persons with a history of egg allergy 
Pregnancy reports for spontaneous abortion, stillbirth, congenital anomalies, and serious 
pregnancy reports 
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Empirical Bayesian data mining was also conducted.  Serious reports are based on the Code of 
Federal Regulations and include death, life-threatening illness, hospitalization or prolongation of 
hospitalization, or permanent disability. 
 
Following IIV3, IIV4, LAIV4, and IIV3-HD in 2015-2016, serious reports were 5% to 6% and non-
serious reports were 94% to 95%.  Keeping in mind that VAERS is a passive system, the 
percentage of serious reports is the percentage of all reports that met the regulatory definition 
for “serious” that were submitted to VAERS.  It is not the rate of SAEs after influenza 
vaccination, which is very low based upon the clinical trials.  These percentages of breakdowns 
for serious and non-serious events are similar to other vaccines in the VAERS database.  
Guillain-Barré Syndrome (GBS) reports comprised a very small percentage of total reports from 
0.5% to 1% for these products.  That is similar to what was observed last year.  Anaphylaxis 
reports are rare in VAERS, ranging from 0.3% to 0.6%.  There were two reports of anaphylaxis 
following LAIV4 in persons with a history of egg allergy.  One was in an adult who received 
LAIV4 alone, while the other was in a child who received multiple other vaccines during the 
same visit.  There were no data mining findings for GBS or anaphylaxis.  Following ccIIV3, 
RIV3, IIV3-ID, and IIV4-ID overall similar observations were made.  There were no data mining 
findings for GBS or anaphylaxis for these influenza products either. 
 
There was a total of 58 reports of pregnancy in VAERS for the season following IIV3 or IIV4.  
The median maternal age was 32 years, with a range of 14 through 44 years of age.  
Gestational age was reported in 17 (29%) cases.  The median gestational age was 20 weeks, 
with a range of 4 to 38 weeks.  The breakdown for the 17 reports was approximately one-third 
for each trimester.  Of the 58 reports, 8 included pregnancy-specific outcomes or 14% of the 
total reports.  There were 5 spontaneous abortions, 1 stillbirth, and 2 cases of vaginal bleeding.  
The overwhelming majority of reports either were non-pregnancy specific such as injection site 
reactions and other non-pregnancy specific events, or no AE report.  There was a total of 7 
LAIV4 reports, none of which included any pregnancy-specific events.  In fact, 5 of the 7 had no 
AE. 
 
In summary of VAERS surveillance for the 2015-2016 influenza season, no new safety 
concerns were detected for IIVs, LAIV4, ccIIV3, or RIV3.  Surveillance for the 2016-2017 
influenza season will include enhanced safety monitoring for the following: 
 
 
 
 
 
Adjuvanted influenza vaccine (Fluad®)  
IIV4-ID (Fluzone® Intradermal Quadrivalent) 
Pregnancy reports 
Anaphylaxis reports in persons with a history of egg allergy 
 
Turning to FDA near real-time surveillance, for GBS following influenza vaccination in Medicare 
beneficiaries for the 2015-2016 influenza season,  
 
FDA conducts near real-time surveillance for GBS following influenza vaccination every 
influenza season in collaboration with CMS.  
Weekly statistical testing compares GBS rates in the current season with rates in the prior three 
seasons in the Medicare database.  During 2015-2016 season, there were 15.4 million IIV 
administrations.  This includes all IIV products combined comprised primarily of standard dose 
IIV3, IIV4, and High-Dose IIV. 
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FDA’s 2015-2016 season surveillance showed a GBS rate increase following IIV of small 
magnitude, with 7.25 cases/million IIV vaccinees in comparison to an average of 5.45 
cases/million IIV vaccinees for the past three seasons.  The limitations of surveillance include 
the fact that it was a comparison of current to historical data, this is a claims-based analysis, 
there was a change from ICD-9 in the previous seasons to ICD-10 in the 2015-2016 season, 
and there was no control for confounders.  End-of-season analysis using self-controlled designs 
has been initiated. 
 
As a reminder, the Vaccine Safety Datalink (VSD) was established in 1990 and is a 
collaboration between CDC and 9 integrated healthcare plans.  VSD collects data on over 9 
million persons per year, which is approximately 3% of the US population.  VSD links 
vaccination data to health outcome data.  VSD includes vaccination records; health outcomes 
from hospitalizations, emergency department (ED) visits, and outpatient encounters; and 
information on patient characteristics.  These are all linked by unique identifiers into a large 
linked database that CDC uses for surveillance and epidemiologic studies. 
 
The outcomes assessed for the end-of-season analysis for 2015-2016, which are the same as 
assessed last season, are shown in the following table: 
 
Pre-Specified 
Outcome Age Group 
Risk Window 
(days) 
Control Window* 
(days) 
Anaphylaxis >6 mos 0-2 7-9 
Bell’s palsy 
>6 mos to <18 yrs 
18-49 yrs 
>50 yrs 
1-42 -56 to -15 
Encephalitis >6 mos 1-21 -56 to -15 
Guillain-Barré 
syndrome  >6 mos 1-42 43-84 
Seizures 6-23 mos 24-59 mos 
0-1 for IIV 
0-14 for LAIV 
14-20 for IIV 
15-29 for LAIV 
Transverse myelitis >6 mos 1-21 -56 to -15 
 
In terms of the number of Dose 1 doses administered in the VSD for this season, there were 
roughly 3.2 million IIV doses and relatively small amounts of vaccine doses administered for the 
other products.  Because of this, the end-of-season focused on IIV3.  There is not enough data 
on the other products to achieve meaningful results. 
  
Because of the transition from ICD-9 to ICD-10 in 2015, VSD analysis was limited to analysis of 
ICD-10 data, specifically IIV3 doses administered after October 1, 2015.  A self-controlled risk 
interval (SCRI) analysis was conducted.  There was a concern about the transition from ICD-9 
to ICD-10 and how that might impact the analysis, so the decision was made to assess ICD-10 
data only for the current season using an SCRI design, which avoids the problems of the current 
versus historical ICD-10 versus ICD-9 issues.  GBS was the signaling outcome in the 2015-
2016 season.  The risk window for GBS in this analysis was Days 1 through 42 (the biologically 
plausible risk interval) and the comparison window was days 43 through 84.  The incident 
definition was “first occurrence in a year.”  The SCRI design assesses vaccinated cases only, 
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each patient serves as his or her own control, and the goal is to look for events in the risk 
window and events in the comparison window. 
 
For those greater than 6 months of age, there were 27 cases in the risk window and 4 in the 
comparison window.  That is a relative risk of 3.38, which is statistically significant.  In those less 
than 65 years of age (6 months through 64 years of age), there were 14 cases in the risk 
window and 4 cases in the comparison window.  That is a relative risk of 3.5, which is 
statistically significant.  In individuals 65 or more years of age, there were 13 cases in the risk 
window and 4 cases in the comparison window.  That is a relative risk of 3.25, which is 
statistically significant.  The next model assessed inpatient or ED encounters for all individuals 
greater than 6 months of age.  There were 18 cases in the risk window and 6 in the comparison 
window.  The relative risk is 3, which is statistically significant.  A quick chart review was 
performed for inpatient or ED encounters in those greater than 6 months of age.   The quick 
chart review included an electronic medical record review to confirm a case as an incidence 
case, with a diagnosis by a neurologist.  The relative risk was 3.67, which was statistically 
significant.  In terms of the general results from the 2014-2015 season for all ages, there were 
18 cases in the risk window and 13 in the comparison window.  The relative risk was 1.38, 
which was statistically significant.  The take-home message is that, for the current season 
assessing the risk of GBS associated with IIV using various models with different ages and 
different settings and conducting a quick chart review, a statistically significant relative risk is 
consistently being observed of 3 to 3.6 in this preliminary analysis. 
 
The following chart reflects the GBS SaTScan™ clustering results in the VSD using automated 
data for the 2015-2016 influenza season: 
 
 
 
In summary, VSD identified a significantly elevated relative risk of 3.67 (95% CI: 1.02, 13.14) 
using the SCRI method in the quick chart review analysis.  The corresponding attributable risk 
for GBS following IIV3 is approximately 2.6 additional GBS cases per million doses 
administered.  VSD will continue to further evaluate the association by conducting chart reviews 
of all GBS cases (inpatient, emergency department and outpatient), and by conducting a case-
centered analysis that adjusts for seasonality of both IIV3 administration and of GBS and other 
potential confounders. 
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To summarize influenza safety monitoring for the 2015-2016 season, no new safety concerns 
were detected in VAERS surveillance. FDA surveillance for GBS following influenza vaccination 
in Medicare beneficiaries showed a GBS rate following IIV of 7.25 cases per million compared 
to an average of 5.45 for the prior three seasons.  Further assessment using self-controlled 
methods is in progress.  For CDC VSD end-of-season analysis, a signal was identified for GBS 
following IIV3 in the SCRI design.  Estimated attributable risk is 2.6 GBS cases per million IIV3 
doses administered.  Signal assessment using detailed chart review and case-centered analysis 
is in progress.  The preliminary GBS risk estimate appears consistent with that observed in 
some previous influenza seasons. 
  
In conclusion, the association between IIV and GBS is not new.  This has been observed in the 
past.  The data have been variable across seasons.  If there is an increased risk, it is small on 
the order of 1 to 2 additional cases per 1 million doses administered.  The preliminary risk 
estimates observed for this season is similar to what has been observed in some past seasons.  
The CDC and FDA need to perform additional assessments on these signals.  The findings 
need to be placed in the context of the known benefits of influenza vaccination in preventing 
disease and complications from influenza.  Influenza disease is actually a risk factor for GBS. 
 
Discussion Points 
 
Noting that introduction of newer vaccines such as the quadrivalent high-dose might have some 
safety implications, Dr. Kempe asked what percent of the FDA data included quadrivalent or 
high-dose. 
 
Dr. Shimabukuro responded that CDC monitors those vaccines, but the data are so sparse 
there are not meaningful results.  He did not have the breakdown of that information for the 
FDA, but indicated that he could follow up with them. 
 
Dr. Karron asked for a reminder of the risk associated with GBS as associated with influenza 
infection. 
 
Dr. Shimabukuro said that while he did not have exact numbers, there are pretty well-
established risk factors for GBS, including upper respiratory illnesses, of which influenza is one; 
gastroenteritis, specifically campylobacter; surgery; age; pregnancy; and others. 
 
Dr. Bennett asked if there was an estimation of what percentage of GBS cases might be 
associated with influenza vaccine. 
 
Dr. Shimabukuro said that while he did not know specifically, when studies have controlled for 
influenza disease, it has basically lowered the risk.  The risk went away. 
 
Dr. Stephens asked whether the question with ICD-9 and ICD-10 was a sensitivity issue. 
 
Dr. Shimabukuro responded that his understanding was that it is a one-to-one, or a single 
outcome compared to a single outcome.  The ICD-9 diagnosis was acute infective polyneuritis, 
while the ICD-10 diagnosis is GBS.  If anything, the ICD-10 should be a better code.  Based on 
the preliminary work done, this does not seem to be impacting the surveillance.  CDC has work 
underway to assess the impact in general of the ICD-9 to ICD-10 transition. 
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Dr. Moore said that from work done in her state and others, in efforts to correlate claims data 
with actual medical records, there is not good correlation between the diagnosis according to 
the claims data and the medical record review.  She noted with pleasure that the final results 
involve actual record reviews to confirm the diagnosis of GBS in doing these assessments.  
Obviously, with such small numbers over millions of doses administered, it can swing one way 
or the other very easily.  She asked when those data would be available. 
 
Dr. Shimabukuro replied that he was uncertain when the results would be available.  He will 
have to follow-up with FDA.  CDC is in the process of reviewing the cases, but he did not have a 
specific hard date on when the reviews and the case-centered analysis would be completed. 
 
Dr. Walters asked whether the years in which the association had been seen happened to track 
with any predominant strains circulating that year.  He wondered whether it pertained to 
circulating disease or the vaccine strain. 
 
Dr. Shimabukuro responded that the last time an increased risk was observed was during the 
pandemic, which was with monovalent H1N1.  However, it was not observed in seasonal 
vaccine that year.  This is the first time since the pandemic that an increased risk has been 
observed for GBS.  It is the first time an increased risk has been observed with H1N1-containing 
seasonal vaccines.  Therefore, options are being explored to determine how to further assess 
multiple years of data.  There was a strain change in the past season.  It was the same for the 
two prior seasons.  There was a strain change in the As and one of the Bs for this season.  The 
vaccine changes year-to-year, and it is not unreasonable to think that there may be differences 
in reactogenicity based on changes in the vaccine.  However, it is not clear whether these 
findings could be attributed to any strain change. 
 
Dr. Gorman (NIH) noted that the increased number of cases in the 2009 monovalent was 
approximately 1 case per million doses, so about half.  Recognizing all of the confounders 
already mentioned, he thought that they were in the same range for monovalent. 
 
Dr. Shimabukuro responded that several studies showed increased risk.  In the meta-analysis, it 
was 1.6 and this is 2.6.  If there is an increased risk, it is on the order of 1 to 2 additional cases 
per million doses administered. 
 
Dr. Gorman (NIH) asked when the diagnosis of GBS is made—the day the symptoms start or 
the day the diagnosis is made for attributing the diagnosis. 
 
Dr. Shimabukuro replied that there are automated analysis and chart confirmed analysis.  For 
automated analysis, it is really based on the dates in the administrative database.  When a chart 
confirmation is done, an effort is made to pinpoint symptom onset to determine if that is an 
incident case. 
 
Dr. Gorman (NIH) pointed out that GBS, like most diseases, has a distribution of seriousness.  
He asked whether Dr. Shimabukuro had any sense of whether GBS after influenza vaccination 
is more or less severe than GBS in general. 
 
Dr. Shimabukuro responded that there is not a difference in the severity of course regardless of 
whether it occurs after vaccination or is a spontaneous case. 
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Dr. Middleman (SAHM) thought there was a similar issue of GBS that was initially associated 
with meningococcal vaccination, and then it was found that the campylobacter season was 
playing a role.  She asked whether Dr. Shimabukuro felt that by using self-controlled analysis 
this is a potential risk in that vaccination was probably given during that same kind of season 
and that by using self-controls, they may have left the campylobacter season. 
 
Dr. Shimabukuro replied that there is seasonality to GBS.  One reason CDC is conducting the 
case-centered analysis is because that controls for seasonality of GBS.  It is possible that 
seasonality is a confounder, but that is part of the assessment. 
 
Dr. Thompson (NVAC) asked how reports are made to the VSD and whether there is a potential 
that things that happen later in the context of a patient’s time since the vaccine might have less 
likelihood of being reported, or whether there was no concern about reporting bias to the VSD. 
 
Dr. Shimabukuro responded that VAERS is a spontaneous reporting system that depends upon 
people to send in reports.  VSD is a large linked database that utilizes electronic health records, 
so no one is actually reporting into VSD.  These data are captured in the health systems 
administering people’s health insurance programs.  While there may be biases to VSD data. 
Reporting bias should not be one of them. 
 
Vaccine Effectiveness Update 
 
Dr. Brendan Flannery 
Influenza Division 
Centers for Disease Control and Prevention  
 
Dr. Flannery reviewed end-of-season estimates of influenza vaccine effectiveness for the 2015-
16 season from the US Flu VE Network, and presented data comparing LAIV and IIV 
effectiveness among children and adolescents aged 2 through 17 years during the season. 
 
In terms of the end-of-season estimates, the percentage of visits for influenza-like illness (ILI) by 
week from the Influenza-Like Illness Surveillance Network (ILINet) over the past 6 seasons 
since the 2009-2010 season shows the late increase in ILI activity observed in the 2015-2016 
season, with peak ILI activity occurring in March.  This is one of the few seasons that has had a 
peaked in March.  Influenza A/H1N1pdm09 virus predominated with circulation of both B virus 
lineages. 
 
The US Flu VE Network, funded by CDC, conducts annual studies of influenza vaccine 
effectiveness at five sites within the US, shown in on the following map along with the Principal 
Investigators (PIs) at each site: 
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Of note, the same sites have participated in the US Flu VE network over the past 5 influenza 
seasons.  To briefly review methods for the VE estimates presented during this session, US Flu 
VE network sites enroll outpatients 6 months of age and older who present with an acute 
respiratory illness with cough of 7 or fewer days duration.  This analysis includes patients 
enrolled from November 2, 2015 through April 15, 2016.  All enrolled patients are tested for 
influenza by reverse transcription-polymerase chain reaction (RT-PCR).  VE estimates are 
based on the test-negative design, comparing vaccination odds among influenza PCR-positive 
cases versus PCR-negative patients as the control group.  For this analysis, vaccination is 
defined as receipt of at least one dose of any 2015-2016 influenza vaccine and includes partially 
vaccinated children.  Vaccination status was determined from medical records, immunization 
registries, or self-report with plausible timing and location of immunization, referred to as 
plausible self-report, for patients aged 9 years and older.  VE is estimated as 1 minus the 
adjusted odds ratio times 100%.  Odds ratios were adjusted for study site, age, self-rated 
general health status, race/Hispanic ethnicity, interval (days) from onset to enrollment, and 
calendar time. 
 
A total of 7,563 patients were enrolled during the season, of whom 82% were influenza negative 
(controls) and 18% were influenza positive.  The predominant influenza virus among enrolled 
patients was A/H1N1pdm09, with cases due to both B lineages and only 6% of confirmed cases 
due to A/H3N2, the predominant virus during the 2014-2015 season.  All viruses from enrolled 
patients that were antigenically characterized were similar to vaccine reference viruses, with 
limited genetic variability among H1N1pdm09 or B viruses, and mixed circulation of two clades 
of H3N2 viruses, all characterized as vaccine-like. 
 
The overall adjusted VE estimate for all vaccines was 47% with 95% confidence interval from 
39% 53%.  VE estimates were statistically significant for patients of all ages with the exception 
of adults aged 50 through 64 years.  Restricting to inactivated vaccines only, adjusted VE was 
49%, very similar to the estimate for all vaccines.  The adjusted VE against illness associated 
with A/H1N1pdm09 virus was 41%, with 95% confidence interval from 31% to 51%.  Again, VE 
was statistically significant for all ages except adults aged 50 through 64 years.  Restricting to 
inactivated vaccines, adjusted VE was 44%.  For all ages combined, adjusted VE against 
A/H3N2-related illness was 45% with confidence intervals from 9% to 66%.  For B Yamagata 
viruses, adjusted VE was 55% with confidence intervals from 41% to 66%, and for B Victoria 
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lineage viruses, adjusted VE was 55% with confidence intervals from 38% to 68%.  Estimates 
restricted to inactivated vaccines were similar to overall estimates. 
 
Over 2000 children were included in the analysis of LAIV and IIV effectiveness among children 
2 through 17 years of age by influenza virus type and subtype.  Of these, 18% were influenza 
positive and almost half of the influenza cases were H1N1pdm09, with somewhat higher 
numbers of B/Victoria lineage viruses than B/Yamagata.  Regarding the methods for this 
analysis, vaccination was defined as at least one dose, including partially vaccinated children.  
Only documented doses were considered for children 2 through 8 years of age.  Documented 
doses and plausible report of vaccination were considered vaccinated for those 9 through 17 
years of age.  Vaccine type was determined from medical record or parent report if the record 
had no information.  Odds ratios were adjusted for study site, age, and listed variables, including 
calendar time in biweekly intervals.  Of note is that because of the importance of this analysis 
this season, all analyses were independently confirmed by Jessica Pruszynski at Baylor Scott & 
White Health.  A total of 154 enrolled children were excluded from this analysis, primarily 
because their illness onset occurred prior to confirmed influenza circulation at that site, or illness 
onset occurred within 14 days of vaccination. 
 
In terms of adjusted VE estimates for LAIV and IIV among children 2 through 17 years of age 
against any influenza A or B and for A/H1N1pdm09-related illness and by B lineage, estimated 
LAIV effectiveness against any influenza was 3% with confidence intervals including zero. 
Estimated IIV effectiveness was 63% with a confidence interval from 52% to 72%.  Estimates for 
LAIV effectiveness against A/H1N1pdm09 and B viruses were not statistically significant, while 
estimates for IIV were similar to the VE estimate against any influenza.  Among children 2 
through 8 years of age, no significant VE was demonstrated against any influenza, 
A/H1N1pdm09 or influenza B.  The lowest point estimates were observed against 
A/H1N1pdm09 viruses.  Similarly, estimates of LAIV effectiveness were not significant among 
patients 9 through 17 years of age, although the point estimate for VE against A/H1N1pdm09 
was higher than among children 2 through 8 years of age.  The adjusted odds of influenza was 
also estimated of influenza among LAIV versus IIV vaccinated children similar to an analysis or 
relative effectiveness, excluding unvaccinated children.  In this analysis, children who received 
LAIV had significantly higher odds of influenza due to any virus type or due to A/H1N1pdm09 
compared to IIV vaccinated children.  Odds ratios greater than 1 favor IIV.  The result for 
influenza B was not statistically significant. 
 
In addition to US Flu VE data, data also were received from the Department of Defense (DoD) 
laboratory-based influenza surveillance system.  These data include military dependents 2 
through 17 years of age who presented to participating facilities during the 2015-2016 season 
with ILI.  Laboratory testing by clinical indication was by RT-PCR or culture, and the study used 
a test-negative design with RT-PCR negative controls.  Vaccination status was determined from 
electronic medical records.  The estimates were adjusted for two age groups and 3 time periods 
during the season.  Regarding adjusted VE estimates for military dependents 2 through 17 
years of from the DoD laboratory-based influenza surveillance system, estimated VE against 
A/H1N1pdm09 associated illness for LAIV was 15% with confidence intervals including zero.  
Estimated VE for IIV against A/H1N1 was 68% and was statistically significant.  Numbers of 
influenza positive cases among vaccinated children were small for A/H3N2 and B, but estimated 
VE against influenza B was statistically significant for both LAIV and IIV in this system [Lt. Col. 
Susan Federinko, US Air Force]. 
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This analysis is subject to limitations.  First, the final end-of-season analyses are pending, since 
prior season vaccination status is pending for one site and chronic conditions were not included 
in adjusted estimates.  However, data were received from all five sites for prior end-of-season 
vaccination and chronic conditions.  Those will be included in updated analyses, which have 
been run already and did not change the results presented during this session.  In previous 
seasons, final analyses have been similar to preliminary end-of-season results.  Secondly, there 
is limited precision for some VE estimates due to small numbers of influenza cases in some 
strata. 
 
In summary, the 2015-2016 influenza season was a late season, with peak enrollment at US Flu 
VE network sites in March and mixed circulation of A/H1N1pdm09 and B viruses.  Overall 
vaccine effectiveness for any vaccination was 47% against influenza A and B.  Point estimates 
were 41% for A/H1N1pdm09 and 55% for B viruses.  Vaccine effectiveness for LAIV was 
significantly lower than IIV among children 2 through 17 years of age.  No significant LAIV 
effectiveness was observed against A/H1N1pdm09 or B viruses.  Relative effectiveness 
significantly favored IIV over LAIV against A/H1N1pdm09-associated illness. 
 
2015-16 US Influenza Vaccine Effectiveness 
Influenza Clinical Investigation for Children (ICICLE) Study 
 
Chris Ambrose, MD 
Vice President, Infectious Disease 
US Medical Affairs, MedImmune 
 
The Influenza Clinical Investigation for Children (ICICLE) VE study demonstrated significant 
overall VE for LAIV4 and IIV in US children 2 through 17 years of age in 2015-2016.  For LAIV4, 
VE was 46% (95% CI: 7, 69) and for  IIV VE was 65% (95% CI: 48, 76).  Supporting those 
results are similar results in a 2015-2016 in a test-negative VE study in the United Kingdom 
(UK) and a large cohort study in Finland.  Including the DoD study just presented, these LAIV4 
VE estimates are similar to VE observed with IIV in children in recent seasons (e.g., 2011-2012 
and 2012-13)1-3 
 
Reduced effectiveness has been observed this last season relative to IIV vaccine for LAIV.  But 
the range of the point estimates in these studies is within the range observed in other seasons.  
There is no explanation at present for the difference between these studies compared to the 
CDC LAIV4 VE estimate, particularly because the CDC and ICICLE study methods are very 
similar and in past seasons have reached similar estimates of effectiveness.  The differences 
may relate to a limited sample size (less than 150 children have received LAIV), statistical 
power, or limitations of observational study design [1Ohmit et al, CID 2013; 2McLean et al, JID, 
2014; 3Flannery B. ACIP presentations. 2014].  Similar to the CDC VE study, ICICLE is an 
observational, test-negative design.  Community-dwelling children 2 through 17 years of age 
were enrolled at the following US sites: 
 
 
 
 
 
 
 
 
Marshfield Clinic, Wisconsin (Edward Belongia)* 
Baylor Scott & White Health, Texas (Manjusha Gaglani)* 
Vanderbilt University, Tennessee (Marie Griffin) 
Wake Forest University, North Carolina (Katherine Poehling) 
Akron Children’s Hospital, Ohio (Blaise Congeni) 
HealthPartners Como Clinic, Minnesota (Poornina Kavathekar) 
Kaiser Permanente, Oregon (Allison Naleway) 
Advisory Committee on Immunization Practices (ACIP)                                               Summary Report                                             June 22-23, 2016 
 
 
87 
 
 
 University of Florida, Gainesville (Kathleen Ryan) 
 
Children are enrolled who are seeking outpatient care for febrile acute respiratory illness with 
onset <5 days.  Like the CDC study, subjects are excluded who were vaccinated <14 days 
before symptom onset.  Nasal swabs are tested by PCR using a respiratory viral panel.  This is 
a subtle difference from the CDC study in that MedImmune knows the outcome for influenza 
and other respiratory viruses, which allows them to perform an important secondary analysis 
comparing cases being influenza positive to controls being positive with another respiratory 
virus.  That was in addition to the study requested by the FDA, because this is an FDA post-
marketing commitment study.  Sites are monitored up to 3 times per season to confirm data 
accuracy.  That is important to ensure good clinical practice and because it is an FDA post-
marketing commitment.  Like the CDC study, the Medimmune study results were independently 
analyzed [*Also participate in CDC VE study but at different clinic sites, so the same patients 
are not being enrolled]. 
 
The ICICLE study enrolled 1,238 children from November 30, 2015 to April 15, 2016.  Of these, 
226 were excluded from analysis for the following reasons: 
 
 
 
 
 
Enrolled before or after influenza circulation: n=215 
Vaccination <14 days before illness: n=7 
Missing documentation of vaccination date and/or type: n=3 
Lack of signed consent: n=1 
 
This resulted in 1,012 subjects being retained for analysis.  Of these, 594 were unvaccinated 
children, 101 were LAIV4 recipients, and 317 were IIV recipients. 
 
The 2015-2016 ICICLE population characteristics by vaccine group are delineated in the 
following table: 
   
No Vaccination 
(n=594) 
LAIV4 
(n=101) 
IIV 
(n=317) 
2 to 4 years 
5 to 8 years 
9 to 17 years 
28% 
36% 
36% 
33% 
47% 
20% 
36% 
36% 
28% 
Privately insured 45% 56% 53% 
Chronic condition 16% 6% 26% 
Prior vaccination in 2014-2015 32% 73% 77% 
 
This is an observational study, so there are differences in the children who were unvaccinated 
versus those whose parents elected to receive LAIV4 versus those who elected to receive IIV.  
Some of the greatest differences are illustrated in the table in terms of age, insurance status, 
chronic conditions, and prior vaccination. 
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In terms of the overall adjusted estimates of effectiveness for the two vaccines, overall 
effectiveness of LAIV4 was 46% with similar estimates for H1N1 A and B.  Over 60% of isolates 
detected were H1N1, so there would not have been an overall statistically significant 
effectiveness if there was not a trend of effectiveness for H1N1.  For IIV, the estimates were 
65%, 71% for H1N1, and 56% for B.  With the greater sample size, the IIV estimates are much 
more precise.  For children receiving any vaccine or at least one dose of vaccine, secondary 
analyses confirmed that the results are similar for those fully vaccinated, excluding those 
negative for any respiratory virus, and excluding those with high-risk conditions.  The point 
estimates are all the same.  When those with high-risk conditions are excluded, for LAIV the 
estimate of H1N1 VE is statistically significant. 
 
Regarding overall VE for LAIV4 and IIV by calendar time, an interim analysis was performed at 
the end of February that showed an estimate of high effectiveness.  As time went on and more 
subjects were enrolled and more cases were identified, the point estimate of VE decreased to 
46%.  Waning immunity is a possibility, or it could just be gaining additional precision as more 
subjects are enrolled and more cases are identified. 
  
Clearly, the ICICLE results differ from CDC’s results for LAIV.  Supporting the ICICLE results is 
a 2015-2016 VE study by Public Health England (PHE).  The PHE study is a test-negative VE 
study in UK children 2 through 17 years of age (N=279).  2015-2016 is the third year of the UK 
vaccination program.  LAIV4 is the predominant vaccine used in UK children without 
contraindications.  Vaccine uptake has been achieved in each of the three years of 
approximately 40%.  The estimated overall LAIV4 VE was 57.6% (25.1, 76), which was 
statistically significant [Public Health England statement, June 22, 2016 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/530756/Influenza_vaccine
_effectiveness_in_primary_care_in_children.pdf].  The UK is aware of the data from the US and 
Finland, and is proceeding with their program for the upcoming season. 
 
A 2015-16 VE study by the Finland National Institute for Health and Welfare (THL) was 
presented at the Nordic Vaccine Meeting in April 2016.  This is a cohort study in Finland of 
58,857 children 24 through 35 months of age.  They are using the comprehensive healthcare 
utilization and administrative databases that exist in Finland to comprehensively track outpatient 
visits, influenza positive tests, and vaccinations.  Like the US and UK, the predominant A strains 
were H1N1.  The overall unadjusted VE of LAIV was 46% (22, 63) and was statistically 
significant, and IIV was 60% (27, 78).  Most of the cases were A strains, and the estimates were 
similar for LAIV at 48% and 78% for IIV. 
  
The PI was consulted because these were unadjusted early estimates.  However, the initial 
adjustments have been made and the estimates are very similar, changing by only a single 
percentage point and still being statistically significant.  Finland routinely vaccinates children 6 
through 35 months of age, up to 60% of the LAIV recipients were previously vaccinated 
[Nohynek et al., Nordic Vaccine Meeting, April 2016.  Confirmed by personal communication 
June 21, 2016].  The overall VE for all three studies is statistically significant with the estimates 
being 46% for US ICICLE, 58% PHE, and 46% Finland THL. 
 
Based on data from recent seasons for LAIV and IIV across the different subtypes, highly 
variable results have been observed for H1N1pd09 for both vaccines, but especially for LAIV.  
In 2009, CDC described the high effectiveness of LAIV, albeit on a very small sample, and low 
effectiveness of IIV.  In 2010-2011 with the trivalent formulation and 2013-2014 quadrivalent 
formulation, the reverse was observed in the CDC and ICICLE studies.  Interestingly, in Canada 
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in 2013-2014, there was high effectiveness of LAIV that was confirmed by a cluster randomized 
study conducted there in elementary school-aged children.  Clearly, there have been highly 
variable results for the LAIV H1N1pdm09 strains.  All of these studies were conducted with the 
A/California strain. 
 
These variable results led to the investigations of the stability of that strain, which was found to 
be heat unstable.  It was confirmed in the laboratory that real-world exposures that were 
confirmed to have occurred could negatively impact the potency of the vaccine upon 
administration.  This led to the replacement of that strain with a more heat-stable H1N1pdm09 
LAIV strain, the A/Bolivia strain that was used in the 2015-2016 vaccines.  In light of the recent 
data, there is clearly still a biological phenomenon that is reducing the effectiveness of the H1N1 
LAIV strains. 
  
Significant research is underway to better understand the biology of the strains so that they can 
be further optimized in the future.  For 2010-2013 VE of IIV and LAIV against Matched H3N2 in 
children, there was comparable effectiveness of LAIV and IIV with something of a trend toward 
higher effectiveness with LAIV perhaps.  The 2010-2015 VE of IIV and LAIV against influenza B 
in children was very comparable. 
 
Data from a CDC evaluation of seasonal effectiveness of LAIV and IIV in children 2 through 17 
years of age were summarized in a publication and are shown here: 
 
 
 
Consistent with what Dr. Ambrose presented, the trend of favoring IIV for H1N1pdm09, but in 
some cases trending toward favoring LAIV for H3N2 and B [Chung et al, Pediatrics, 2015]. 
 
Any presentation of these studies requires a presentation of the limitations.  There is a potential 
for bias in observational studies because the treatment is not being randomly assigned.  Also, 
VE estimates can be imprecise and vulnerable to random effects.  This is particularly true in this 
season where there is a small number of recipients in all of the studies (<150) in the CDC and 
ICICLE study, which makes it vulnerable to random effects.  In addition to what is expected from 
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cohort studies and others, multiple assumptions must be met to ensure study validity of the 
case-control approach.  Those are well-summarized by Jackson et al in Vaccine.  These are 
hard to check, but are the underlying assumptions for the framework of these studies providing 
valid estimates [Jackson et al., Vaccine. 2013]. 
 
In conclusion, three studies (four if the DoD study is included) demonstrated similar, statistically 
significant overall VE of LAIV4 in 2015-2016 in children 2 through 17 years of age of 46% to 
58%.  These estimates are similar to VE observed with IIV in children in recent seasons1-3, 
although in the last season, lower effectiveness is being observed with LAIV compared to IIV.  
The differences from these four estimates compared to the CDC VE LAIV4 estimate may be 
due to limited sample, statistical power, and limitations of observational study design.  
MedImmune agrees that healthcare providers (HCP) should be made aware of these data so 
they can make informed decisions and have informed discussions with their patients in the 
upcoming season.  AstraZeneca/MedImmune will share available 2015-2016 VE data with US 
HCPs to inform discussions of 2016-2017 vaccine options with patients.  Research is underway 
to improve LAIV A/H1N1pdm09 strains in future seasons [1Ohmit et al, CID 2013; 2McLean et al, 
JID, 2014; 3Flannery B.  ACIP presentation.  December 2014]. 
 
LAIV Versus IIV Effectiveness:  Summary of Evidence Since 2009 
 
Dr. Brendan Flannery 
Influenza Division 
Centers for Disease Control and Prevention 
 
As background for discussion, Dr. Flannery presented a brief review of LAIV and IIV 
effectiveness data in children and adults since 2009.  To summarize the two presentations 
during this session for the 2015-2016 season:  
 
1) Data from the US Flu VE network indicate no LAIV effectiveness against A/H1N1pdm09 but 
significant VE for IIV 
2) Data from the US Department of Defense test-negative study indicate no LAIV effectiveness 
against A/H1N1pdm09 but significant VE for IIV 
3) In a Medimmune presentation of data from the ICICLE test-negative study, the VE estimate 
against A/H1N1pdm09 was not significant despite a higher point estimate, but this study 
also identified significant VE for IIV.   
4) All studies reported higher VE for IIV than LAIV although point estimates varied 
 
CDC received information from researchers from other countries where LAIV is used.  All 
countries used quadrivalent LAIV this season.  From a test-negative VE study in the UK, 
preliminary data indicate significant adjusted VE for LAIV against any influenza A or B among 
children 2 through 17 years of age.  A national observational cohort study conducted in Finland 
reported significant unadjusted estimates of LAIV effectiveness against influenza A, mainly 
H1N1pdm09, among 2-year olds.  Point estimates were higher for IIV, but confidence intervals 
overlapped.  There was no estimate of LAIV effectiveness in children from the Canadian test-
negative study this season, nor was there an estimate from Israel where LAIV was not available 
this season. 
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For each of the last three seasons, the US Flu VE Network has identified no significant 
effectiveness of LAIV against medically attended influenza.  In two of these seasons, the 
predominant influenza virus was A/H1N1pdm09 and in one season, antigenically drifted A/H3N2 
viruses predominated.  In the first three seasons, LAIV was trivalent.  Quadrivalent LAIV 
replaced LAIV3 in 2013-2014.  It was not possible to separate any effects of quadrivalent 
vaccine during the last three seasons from factors related to the circulating viruses during those 
seasons.  In the US Flu VE network, three seasons since 2009 had enough A/H1N1pdm09 
circulation to estimate LAIV and IIV effectiveness.  None of the estimates for LAIV were 
significant, and relative effectiveness significantly favored IIV in all three of these seasons.  In 
three seasons since 2009, LAIV and IIV showed similar effectiveness against influenza A/H3N2, 
and in 2014-2015, as previously mentioned, neither LAIV nor IIV provided significant protection 
against the predominantly drifted H3N2 viruses.  Against influenza B viruses, estimates of LAIV 
and IIV effectiveness were similar during three seasons since 2009.  For the 2015-2016 season, 
the estimate for LAIV effectiveness against influenza B viruses was not statistically significant, 
while significant effectiveness was found for IIV.  The relative effectiveness analysis did not find 
a significant difference between IIV and LAIV against influenza B viruses in 2015-2016. 
 
For the 2013-2014 season, all LAIV in the US was quadrivalent and all LAIV outside the US was 
trivalent.  There were three observational VE studies conducted in the US during 2013-2014: 
US Flu VE study, MedImmune’s ICICLE post-marketing study, and the DoD-led study among 
military dependents.  None of the three studies identified significant VE for quadrivalent LAIV 
against the predominant H1N1pdm09 virus, while all found significant VE for trivalent inactivated 
vaccine against H1N1pdm09.  These data led to a change in the LAIV H1N1pdm09 HA 
component from A/California to A/Bolivia.  The 2015-2016 season is the first season in which 
LAIV contains the updated H1N1pdm09 construct.  Finally, there was one CDC-funded 
household cohort study conducted by the University of Michigan that found a high point estimate 
of 82% for LAIV effectiveness, but did not find significant VE for either LAIV or IIV due to small 
numbers of influenza cases in the cohort. 
 
During 2013-2014, CDC began conducting a relative effectiveness analysis of US Flu VE data 
as part of the GRADE consideration for the preferential recommendation of LAIV.  The analysis 
is modeled after the LAIV-IIV comparative efficacy studies conducted before 2009, comparing 
odds of influenza in vaccinated children.  Relative effectiveness against H1N1pdm09 
significantly favored IIV in two seasons, 2010-2011 and 2013-2014.  There were no significant 
differences in LAIV versus IIV against A/H3N2 or B viruses in the seasons indicated. 
 
During 2013-2014, several studies of trivalent LAIV were conducted outside of the US.  Two 
observational studies conducted outside the US during the 2013-2014 seasons, one in the UK, 
and one in Canada, did not find statistically significant effectiveness of trivalent LAIV despite 
high point estimates in the observational VE study in Canada.  Of note, although the UK study 
did not find effectiveness for trivalent LAIV against the A/H1N1pdm09 virus, an ecologic 
analysis observed a trend toward reduced influenza incidence in LAIV pilot areas in which about 
50% of school children in the target age range received LAIV.  In addition, in a cluster-
randomized trial of trivalent LAIV compared to trivalent IIV, influenza incidence was significantly 
lower in LAIV vaccinated students and their contacts compared to students vaccinated with IIV 
and their contacts during the 2013-2014 season when H1N1pdm09 predominated. 
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In terms of data comparing LAIV and IIV effectiveness in adults from the DoD Global 
Laboratory-based Influenza Surveillance System, these data are from published estimates of 
LAIV and IIV effectiveness among active military aged 18 years and older for 2010-2011 
through 2013-2014.  Estimates for 2011-2012 include dependents and children.  The VE 
estimates are from test-negative studies using the laboratory-based surveillance system, and 
are against all influenza types A or B.  Nonsignificant estimates were reported for LAIV 
effectiveness against any influenza in the 2010-2011 and 2013-2014 seasons, and for IIV in 
2013-2014. Adjusted estimates were similar for LAIV and IIV during 2011-2012 and 2012-2013 
[Eick-Cost 2012; MacIntosh 2013; Eick-Cost 2013; Cost 2014]. 
 
Finally, there are limited data on the serologic response to the A/H1N1pdm09 LAIV vaccine 
component or shedding of vaccine virus.  One small Norwegian study of 38 children vaccinated 
with trivalent LAIV showed reduced antibody response measured by HI titer increase to the 
H1N1pdm09 component compared to H3N2.  Serologic studies by US Flu VE network sites 
have shown limited increase in H1N1pdm09 titers following quadrivalent LAIV vaccination even 
among children with low pre-vaccine baseline HI titers.  Another small study demonstrated that 
shedding of A/H1N1pdm09 vaccine virus following LAIV was reduced after repeat LAIV 
vaccination, but found no influence of pre-vaccination serum antibody titer on H1N1 vaccine 
virus shedding.  Unfortunately, serologic and viral shedding data may provide little information to 
identify problems with the A/H1N1pdm09 vaccine component without a better understanding of 
correlates of protection for LAIV [1 Mohn, JID 2014; 2US Flu VE network (unpublished); 
3Ilyushina, JID 2014]. 
 
To summarize the available data for LAIV effectiveness since 2009, preliminary US Flu VE 
Network data for 2015-2016 indicated that quadrivalent LAIV offered no significant protection 
against influenza A (H1N1)pdm09 in children aged 2 through 17.  Poor VE for quadrivalent LAIV 
was observed during two preceding flu seasons in children aged 2 through 17: 
 
 
 
 
2013-2014: No significant VE for LAIV4 against A(H1N1)pdm09 
2014-2015: No significant VE for LAIV4 or IIV3/4 against drifted A(H3N2) viruses 
During previous seasons, most evidence demonstrated that LAIV3 worked as well as IIV3 
against A(H3N2) and B viruses in children aged 2 through 17.  There was poor VE for LAIV3/4 
against A(H1N1)pdm09 in active military. 
 
The reason for poorer overall performance of LAIV compared to IIV, particularly with regard to 
the A(H1N1)pdm09, over the last few seasons is not well-understood and is a subject for further 
study.  How well the influenza vaccine works can vary by season, virus type/subtype, the 
vaccine, and age and other host factors of the people being vaccinated.  While the causes of 
the low estimate of 2015-2016 VE in the US VE Network studies are not clear, some 
possibilities include: 
 
 
 
 
Suboptimal performance of the A/Bolivia/559/2013 (H1N1) HA vaccine strain. 
Potential interference among viruses in the quadrivalent vaccine [i.e., additional B 
vaccine component effects viral replication of A(H1N1)pdm09 virus]. 
Reduced immunogenicity of LAIV (or replication in nasal passages?) resulting from a 
more highly vaccinated population in recent years; compared with populations of earlier 
studies, in which it is likely that a higher proportion of children were vaccine-naïve. 
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Discussion Points 
 
Dr. Stanley Plotkin (Audience Member) noted that while they had heard a great deal of 
epidemiologic data, what struck him was the lack of immunologic data.  LAIV is more 
complicated than IIV in the sense that one needs to assess serum responses intranasal, IgA 
secretory responses, and even cellular responses that have all been associated as correlates of 
protection.  He asked whether there were any data on the recent vaccine. 
 
Dr. Ambrose replied that he was not aware of any data on the 2015-2016 vaccine, including the 
A/Bolivia strain, in terms of cellular or antibody responses.  As Dr. Flannery summarized, there 
are studies with the A/California H1N1pdm09 strain and a few others that generally show that 
there is shedding, antibody responses, or T-cell responses.  But, they are lower than what is 
generally seen for other strains.  It is very difficult with IIV to pinpoint an exact correlate.  It is 
consistent with the more moderate effectiveness in that the responses are more in the moderate 
range. 
 
Dr. Karron thought it had been quite challenging to find a correlate of protection for LAIV, and it 
is not for lack of looking.  In many of the studies, there was a lot of effort to look at correlates of 
protection.  In fact, vaccine shedding is probably a better correlate.  She wondered what data 
exist, if any, about the relative shedding of various components.  Regarding licensure of LAIV 
and related to Dr. Plotkin’s question, at the time it was licensed it was based on immunogenicity 
equivalents.  But, the serum antibody responses to the trivalent and the quadrivalent vaccine 
were very modest.  At that time, the FDA specifically called for effectiveness studies to look at 
this issue of effectiveness of the quadrivalent preparation.  Given these data about 
effectiveness, she wondered what the FDA’s plans were. 
 
Regarding shedding, Dr. Ambrose said that when they reviewed the comprehensive data 
following the 2013-2014 data, it was mixed.  One study of the trivalent formulation showed 
relatively high shedding of the H1N1pdm09 A/California strain close to 60%.  In a subsequent 
quadrivalent study, it was lower in the 10% to 20% range.  Frustrating about that study was that 
the first sample was on Day 4 to 7 post-vaccination, which is after the peak shedding would 
occur. 
 
Dr. Sun (FDA) said that the data are obviously of concern to the FDA.  FDA has been working 
with CDC and MedImmune since the 2013-2014 findings.  They also recognize that influenza is 
a very complex disease and that there are occasional surprises.  The FDA always approaches 
these types of matters with deliberateness, especially given the fact that all of the study results 
have not been fully reviewed.  He thought it was fair to say that the studies are not completely 
consistent.  It is also important to recognize that the LAIV approach has offered advantages in 
the past for influenza over IIV, especially among certain age groups.  LAIV continues to be an 
important alternative in the armamentarium against influenza.  As part of the evolutionary 
process, changes have been made in order to try to address this problem.  Obviously, more 
work needs to be done.  There are additional studies that FDA would like to see from 
MedImmune and others.  At this point, FDA is not ready to undertake a requirement for 
changing the prescriber’s information.  FDA wants to continue to work with MedImmune to find 
out the root cause of this phenomenon.  They are also engaged in internal discussions about 
what else can be done. 
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Dr. Harriman noted that the ICICLE study was in US children while the UK and Finland studies 
were in different populations.  She wondered if there was any thought that those two are more 
likely to be influenza vaccine naïve. 
 
Dr. Flannery responded that the ICICLE, MedImmune, and US Flu VE studies, the percentages 
of previous vaccination are very similar as would be expected in the US population at between 
70% and 80%.  They do not have the actual numbers from the UK and Finland.  The sense is 
that the UK has had uptake in several years of a pilot program that has been expanded, so 
there has been relatively less exposure in that population.  In the Finnish study, about 60% of 
the children have received vaccine.  Finland does not have a universal infant vaccination 
program, so the LAIV and IIV program beginning in 2 year olds, a lot of those children are 
receiving vaccines early on in the schedule, but this is the beginning of their vaccination 
program.  For that cohort, if they were 2 year olds and received prior vaccination, they would not 
have been expected to see more than just that one prior vaccination. 
 
Dr. Bresee (SME) asked whether Dr. Ambrose knew what the VE against the H1 strain 
specifically is. 
 
Dr. Ambrose responded that in the Finland study, the predominant strains were A strains and 
H1N1 strains.  This is where there was 47% for LAIV that was statistically significant, and 78% 
for IIV that was statistically significant.  In the UK program, he had only the overall vaccine 
effectiveness.  His understanding was that their epidemiology last year was very similar to the 
US in which the predominant strain was H1N1 and they had B/Victoria strain circulating as well. 
 
Dr. Gorman (NIH) asked whether the study in Canada was conducted on naïve children or if 
children had been previously vaccinated with LAIV. 
 
Dr. Flannery responded that there was a very low vaccination rate in that cohort, so they 
conducted a trial.  2013-2014 was the second season, so some children were vaccinated over 
the two seasons.  In one group, it is school vaccinations. 
 
Dr. Romero noted that the Influenza VE Net and ICICLE studies had overlapping centers:  
Marshfield and Baylor Scott & White.  The two sites in the ICICLE study account for one quarter 
of the sites, while Flu VE Net is one third of the sites.  He wondered whether any comparison 
had been done of the VE at both of these sites, and if the analyses for the differences in VE 
hold up when that group alone was assessed. 
 
Dr. Ambrose responded that for the two sites in the ICICLE study, the estimates of VE were 
very similar, almost identical, to the overall vaccine effectiveness observed in the entire study.  
 
Dr. Flannery indicated that there was an extra slide, 33, in the slide set that may be helpful in 
terms of answering the questions related to what the differences are in the studies and at the 
sites.  The two sites contributed LAIV-vaccinated children, but they did not have a large number.  
CDC’s data for those two sites are very similar to the MedImmune data overall.  The other sites 
contributed LAIV vaccinated children as well as H1N1 cases or failures in LAIV children.  There 
were about 150 total LAIV recipients versus about 753 children enrolled who had received 
inactivated vaccine.  CDC is not comfortable breaking down the LAIV data by site.  There is 
some site-to-site variability, but CDC sees the overall estimate as a reflection of the whole.  
There are more similarities than differences in the two studies.  An effect modification has not 
been observed of prior season vaccination.  There is no explanation for prior vaccine as an 
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effect modifier of what is seen as low VE for LAIV.  The MedImmune study enrolls children with 
an ILI definition of fever specifically.  Overall estimates do not change when children are 
restricted to those who have cough and fever and / or sore throat.  If patients are restricted who 
are enrolled within 5 days of illness onset, very similar estimates are observed. 
 
Dr. Kempe noted that there was a percentage that relied on report, which might differ between 
getting a shot or inhaled vaccine.  She heard that in the CDC presentation not the others.  She 
asked what percent that was and if that issued had been studied. 
 
Dr. Flannery responded that about two thirds of their children are two to eight year olds, all of 
which is by document.  There is no self-report.  For a small number of children, there was 
parent-report of vaccination that was outside of the health system that provided the documents.  
So, it is plausible because they were able to provide a location outside the system and a date, 
but that really is a small number of children.  If the analysis is limited to documented vaccination 
only for both of those age groups, the overall estimates are still the same for LAIV and IIV. 
 
Proposed Recommendations Summary / Vote  
 
Lisa Grohskopf, MD 
Influenza Division 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
 
Dr. Grohskopf reminded everyone that what was discussed and approved during the February 
2016 meeting was reiteration of the core recommendations that annual influenza vaccination is 
recommended for all persons 6 months of age and older.  There was a minor change in timing 
of vaccination language and changes to the egg allergy recommendations allowing use of LAIV 
and removing the 30-minute post-vaccination waiting period that had been recommended 
previously.  There was also some additional specific language about the specific case of 
individuals with a history of severe egg allergy. 
 
New Licensures that that will be listed in the Available Products table include:  1) Fluad®, the 
MF59-adjuvanted inactivated influenza vaccine trivalent from Seqirus™, which is for persons 65 
years of age and older; and 2) Flucelvax Quadrivalent®, which is the cell-culture-based 
inactivated influenza vaccine, which has been available previously as trivalent and now will be 
available as quadrivalent for persons years of age and older.  ACIP has had the opportunity to 
hear presentations on these.  Potential upcoming licensures, which also have been presented at 
ACIP, which will not be in the table as they are not yet licensed, but will be acceptable options to 
existing products for appropriate age groups if licensed:  1) Flublok Quadrivalent®, which is a 
recombinant quadrivalent influenza vaccine for persons 18 years of age and older; and 2) 
Flulaval Quadrivalent®, which is an inactivated influenza vaccine for persons 6 months of age 
and older.  Again, those will not be in the table but will be mentioned as potential upcoming 
licensures and will be viable options for existing products in the relevant age groups once 
licensed. 
 
In terms of LAIV efficacy, the WG had the opportunity to hear presentations of the data heard 
during this session and an opportunity to discuss it.  One of the considerations that went into the 
discussion was the importance of ensuring that policy reflects understanding of the latest VE 
data, which in this case indicates that at least in the US data, IIV is more effective than LAIV 
against influenza A(H1N1)pdm09, which was the predominant circulating virus this year.  There 
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is also an understanding that there is an uncertainty about LAIV4 effectiveness against A(H3N2) 
and B viruses, which has been available since the 2013-2014 season.  Most notably, there has 
not yet been an opportunity to see how well the quadrivalent performs against A(H3N2) in a 
season where there is good match.  2014-2015 was an H3N2 predominant season, but there 
was drift of H3, so there was poor match and the inactivated vaccine did not perform well either.  
There is a conviction that policy should encourage use of the most effective vaccines available, 
and a conclusion in general that LAIV should not be used in routine practice though there was 
not consensus regarding the exact language surrounding that.  There was also discussion that 
there is a need to specify that changes in the recommendations are interim, if there are 
changes, for the 2016-2017 season, as data may be different in future seasons. 
 
There was discussion of a number of programmatic implications should the recommendations 
change.  There was a lot of discussion regarding the potential impact on vaccine supply if LAIV 
is not recommended for use.  It is projected that there should be a maximum produced 171 to 
176 million total maximum doses projected for all influenza vaccines.  This information was 
presented at the Adult Influenza Vaccination Summit in May.  Among these doses, about 14 
million are projected LAIV doses, which is about 8% of the total.  There was recognition that 
providers may have difficulty purchasing other products and also understanding of the fact that 
not all products are licensed for all age groups.  There are other vaccines, inactivated and 
otherwise, which are not licensed for children for example.  CDC has contacted manufacturers 
regarding the likelihood of mitigating any potential shortages.  A second concern raised was that 
this may impact school-based programs, many of which primarily use LAIV.  One recent 
publication indicates that this is not a large number of children.  In recent seasons, an estimated 
5% of children were vaccinated at school, 55% of whom received LAIV according to that study. 
 
If LAIV were not to be used, there would be no alternative for those who refuse injectable 
vaccine if LAIV is not recommended for use.  This may impact vaccine coverage. 
Communicating to providers and parents the rationale for the policy change was felt to be 
critical to maintaining a strong influenza vaccine program.  There was also concern that any 
change in the LAIV recommendations may potentially result in decreasing LAIV use, which may 
in turn preclude evaluation of LAIV effectiveness in future seasons because there will not be the 
same numbers witnessed in recent seasons.  With that in mind, two basic options were raised:  
 
Option A:  
 
 
 
 
 
 
 
LAIV should not be used in any setting 
More definitive response to the available data 
May be more clear to communicate message 
 
Option B: 
LAIV may be used in settings where otherwise an individual may not be 
vaccinated 
Leaves flexibility in the program for certain situations 
Iterative step, may be easier to transition back to LAIV if the vaccine is 
reformulated 
May limit the programmatic impact of change 
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The potential language posed for each option follows: 
 
Option A:  Interim Recommendation That LAIV Should Not Be Used 
 
“In light of the evidence for poor effectiveness of LAIV in the U.S. over the last three 
influenza seasons (2013-14 through 2015-16), for the 2016-17 season, ACIP makes the 
interim recommendation that LAIV should not be used.” 
 
Option B:  Interim Recommendation for Limited Use of LAIV 
 
“In light of the evidence for poor effectiveness of LAIV in the U.S. over the last three 
influenza seasons (2013-14 through 2015-16), for the 2016-17 season, ACIP makes the 
interim recommendation that LAIV should not be routinely used.  Use of LAIV may be 
considered in certain circumstances.” 
 
Examples may include (clinical guidance to be developed by CDC):  
 
 
 
 
Refusal of injectable vaccine 
Shortage of age-appropriate IIV or RIV 
School based programs with no alternative vaccine 
 
Discussion Points 
 
Regarding the WG’s thoughts about this information, Dr. Karron indicated that this was very 
much a rapidly evolving situation so some of the language shown differed from what the WG 
saw.  In the initial discussion with the WG, there was also the option of not making any change 
to the recommendation, for which there was no enthusiasm.  The WG was very clear that some 
change was needed.  There was division as to whether it should be a recommendation that 
LAIV should not be used, or should be used under certain circumstances.  For those who felt 
that perhaps it should be used under certain circumstances, most of the concerns were 
programmatic in nature and related to implementation. 
 
Dr. Moore pointed out that the way the language was written, it implied that LAIV was 
particularly bad for the last three seasons.  Given that no formulations had good effectiveness in 
the 2014-2015 season, it might be fairer to state something to reflect that the problems were 
different during that season and that it was not the fault of any vaccines. 
 
Dr. Reingold asked whether the current statement was preferential for IIV and if not, whether 
any consideration had been given to a statement that would state a preference for IIV. 
 
Dr. Karron replied that the existing statement has no preference for one over the other.  The 
statement considered in the WG regarded stating a preference for IIV.  She invited the WG to 
comment.  The original statement the WG considered was a reverse preferential 
recommendation in favor of IIV, but the WG was divided on this. 
 
Ms. Pellegrini requested further information regarding why the full membership was seeing such 
different recommendations from the ones the WG originally considered as the IIV preference. 
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Dr. Bresee (SME) said he thought what the WG was commenting on demonstration of data that 
indicated a lack of effectiveness of one of the choices, so the word “preference” seemed to 
connote the difference between a good vaccine and a better vaccine.  The wording that it had 
“limited use” seemed more aligned with what the data are showing. 
 
Dr. Kimberlin (AAP) extended gratitude to the Influenza WG and to MedImmune for responding 
quickly to a rapid developing and changing sequence.  This has a major impact on pediatric 
practices.  A number of emergency calls have been conducted that assessed the pediatric 
practice equivalence of programmatic changes and impacts.  However, everything kept circling 
back to the science for the AAP.  The science simply shows that one product has not worked for 
the last three years; whereas, IIV has.  Thus, AAP prefers Option A for that reason. 
 
Dr. Savoy (AAFP) pointed out that many people have likely ordered their vaccine for the 
upcoming year, and it is probably too late to change that.  If she were to see this 
recommendation, she would want to know explicitly whether ACIP was telling her not to give 
that vaccine or that she should give it but should know that it might not work as well.  People are 
going to need to make some practical decisions about this. 
 
Dr. Wharton responded that this would depend upon what ACIP recommended as well as the 
clinical guidance developed subsequently.  If language like Option B were used, she thought it 
would suggest that if some amount of LAIV had been purchased, it might be appropriate to use 
in limited circumstances but not the way it was used last year.  Regarding the issue of supply, 
the manufacturers could make statements about what vaccine remained available.  However, 
even if all the numbers were reassuring, there still is likely to be some difficulty for individual 
providers if they did need to obtain influenza vaccine to identify vaccines that might be age-
appropriate for their patients.  This might require a higher level of efforts, and all providers may 
not be prepared to do this.  The end result is that some providers might not end up with 
influenza vaccine for their patients. 
 
Dr. Gorman (NIH) asked whether the determination regarding the poor effectiveness was driven 
primarily by the A strains and the H1N1 strains. 
 
Dr. Karron said she thought the data were clear for H1N1 and the data for other strains were 
less clear, but concerning.  Certainly, there was poor effectiveness of the vaccine last year with 
a mismatched year.  In prior years with H3N2 and mismatching, there has been variation in 
efficacy or effectiveness.  She wondered if they had ever seen zero or negative even if there 
was a very bad mismatch.  That certainly was a concern in the WG. 
 
Dr. Ambrose showed the following graphic of the three observational, test-negative studies 
conducted in 2014-2015 for LAIV4 and IIV.  The CDC study on the left efficacy was 17% for IIV 
and -8% for LAIV4.  The ICICLE study was 40% for IIV that was significant, and 30% for LAIV4 
that was not significant.  The UK PHE results were very similar.  The additional data available 
were from a randomized placebo controlled study conducted in Japan in children 7 through 18 
years of age.  Many of these children were previously vaccinated with inactivated vaccine.  In 
that study, efficacy was 23% against completely mismatched strains and that was statistically 
significant; whereas, in the UK and US observational studies some matched strains were 
circulating.  There was evidence that LAIV was working, albeit at a low level against those 
mismatched strains, which was not detected by the CDC study but would be consistent with 
what was observed in the ICICLE and UK PHE study.  In terms of how this relates to past data, 
in the original Belshe study in 1997-1998 demonstrated 86% against mismatched strains.  
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According to CDC classification, those were four-fold different.  Similar high relative efficacy was 
seen compared to inactivated vaccine when there were four- to eight-fold different viruses in 
2004-2005.  But there was an 8- to 16-fold difference in 2014-2015, the absolute efficacy 
estimates were in the 20% to 30% range.  Essentially, the randomized trial and much of the 
observational data, at least from ICICLE and PHE, were consistent with what has been 
observed before with the trivalent formulation against severely mismatched by a 16-fold 
difference in H3N2.  Statements being made that no effectiveness is demonstrated are not 
correct.  This is the classic “absence of evidence is not evidence of absence.”  There is no 
evidence of zero percent effectiveness of LAIV.  There is just evidence of low effectiveness that 
is not significant. 
 
 
 
Dr. Messonnier thanked the ACIP membership, recognizing the complexity of this discussion.  
As everyone must have gathered, Dr. Frieden saw these data before joining them earlier in the 
morning.  He tried to focus on the need to make decisions based on imperfect data.  As a 
science-driven group, ACIP must make a decision about whether they have actionable data.  
Her understanding from the WG deliberations was that despite the fact that there are 
discrepancies in the data, the WG felt strongly that these data are actionable.  Where they fell 
out of consensus regarded whether it was absolute that the vaccine should not be used, as AAP 
supports, or whether because of some of the programmatic issues, which AAFP pointed out, 
there should be some space such that if clinicians had no other option, it would be better to give 
LAIV versus nothing.  She asked the group to deliberate these issues, remember that someone 
ultimately will have to offer clinical guidance to individuals, clinicians, and parents faced with this 
decision. 
 
Dr. Lett (CSTE) thought it would be helpful to know more about how binding pre-books would be 
in the private and public sectors. 
 
Dr. Wharton responded that on the public sector side, CDC would take their cue from and would 
implement what ACIP advised.  In terms of the private sector, individual providers are likely to 
have various purchase agreements which they would have to deal with themselves. 
 
As a member of the WG, Dr. Zahn (NACCHO) commented that for Option B, the discussion was 
that LAIV would be given if the option of IIV was not available.  While he appreciated Dr. 
Bresee’s point that they did not want it to appear preferential, having multiple bullet points about 
various situations felt more preferential than simply stating to give IIV unless there was no other 
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choice as a provider than to give LAIV.  There was some conversation among the WG members 
about avoiding saying too much to providers, because providers have many other issues with 
which they must deal. 
 
Dr. Bennett said she thought the changing in wording from the use of the word “preference” to 
the use of “should not be routinely used” and “may be considered in certain circumstances” 
addressed what Dr. Zahn was saying. 
  
Dr. Moore said that as an Immunization Manager and member of the committee, what struck 
her as important pertained to who H1N1 disproportionately affects with more severe disease.  
Younger adults and children tend to have more severe disease with H1N1, which also happens 
to be the group for whom LAIV is targeted.  Knowing that it will not work against H1N1 or that 
there is no evidence of effectiveness, she would not feel comfortable giving a child that vaccine 
because if it is an H1N1 year, it would leave them vulnerable.  Programmatically, LAIV 
comprises 8% of the total supply available.  This can be figured out.  However, she worried also 
about sending the message that whomever receives LAIV has gotten an inferior product.  That 
has another layer of communication complications.  The public looks to ACIP to make 
recommendations for the best possible vaccines. 
 
Not being a member of the WG, Ms. Pellegrini found this to be a lot of information to absorb on 
short notice and about which to make a very important decision.  She said she was struggling 
with the differences in effectiveness data among the strains, and among the strains from year-
to-year.  She found the difference among the results in different countries to be particularly 
confounding.  She wondered what it was about the US that the vaccine did not work, while the 
same vaccine seemed to work in other places.  Setting aside 2014-2015 as a season of 
mismatch, they were looking at two different vaccines because the A strains were California and 
Bolivia.  It is still H1N1, but is a slightly different vaccine.  Also setting aside 2014-2015, she felt 
like there were two data points.  A couple of years ago, ACIP preferentially recommended LAIV 
based on one really strong data point and they regretted that.  She was not much happier 
dealing with what felt like to her to be two data points to make the opposite recommendation.  
On the basis of all of this, she said she would like the committee to consider postponing a vote 
until the next morning to give the members time to review and process the information. 
 
Dr. Karron said she felt Ms. Pellegrini’s pain in terms of the data.  She clarified that the GRADE 
analysis performed for a preferential recommendation of LAIV was not based on a single data 
point.  It was based on several RCTs.  Unfortunately, those were for a different vaccine 
essentially—the trivalent vaccine.  She found the fact that the H1N1 components had been 
changed but the results were the same to be especially disturbing and concerning in terms of 
the efficacy of this vaccine against H1N1.  There may be issues of viral interference.  There may 
be issues connected to the fact that the US has a more highly immunized pediatric population 
against influenza than anywhere else in the world, which may contribute to differences observed 
in the US versus other populations.  Less is known about H3N2 and B, but she thought that the 
data for H1N1 were quite compelling. 
 
Dr. Messonnier acknowledged that ACIP was being rushed.  Unfortunately, CDC felt a great 
sense of urgency to make some sort of recommendation.  Putting it off until the morning might 
mean that other things could not proceed.  No decision would basically be a decision, so no 
vote would not be helpful. 
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Echoing Dr. Karron and responding to Dr. Messonnier, Dr. Schaffner (NFID) suggested that this 
issue should not depend at all on programmatic issues.  ACIP should decide whether LAIV is an 
ineffective or insufficiently effective vaccine.  If that was the decision, Option A was clear.  He 
suggested that Option A was the clear choice. 
 
Dr. Baker (IDSA) thought this was great because CDC is filled with very capable people who 
can interpret data without an advisory committee.  However, this is why CDC has an ACIP.  She 
appreciated Dr. Messonnier bringing them back to Dr. Frieden’s comment.  Things change.  The 
one thing she has learned about influenza is that it changes all of the time—the virus, the policy, 
et cetera.  She thought that the science made this actionable, and that they did not have a 
choice.  She said she had great sympathy for doing something with Option B in terms of all of 
the programmatic issues, but the science suggested that Option A was correct.  She was not 
sure whether overnight would be helpful, but she thought a decision must be made. 
 
Dr. O’Leary (PIDS) indicated that the Pediatric Infectious Disease Society (PIDS) would like to 
support Option A for many of the reasons articulated.  Moreover, there are good data to show 
that IIV is effective though it varies from year-to-year.  However, there were enough 
unanswered questions about LAIV that he did not think they could recommend in good 
conscience its use in children. 
 
Dr. Gorman (NIH) pointed out that if Option A was approved and the recommendation went to 
Dr. Frieden and he agreed, he wondered whether insurances would be freed of their 
responsibility of paying if providers administered an FDA-approved vaccine to those children. 
 
Dr. Bennett requested input from Dr. Wharton, pointing out that this was also why the VFC vote 
had been tabled.  There are a number of financial implications that must be better understood. 
 
Dr. Wharton responded that it is difficult to predict what exactly insurers would do.  In general, it 
is not expected that insurance coverage would change immediately following an ACIP 
recommendation.  Generally changes are phased in over time. 
 
Dr. Bennett added that it usually takes a year from the time ACIP makes a recommendation. 
 
Having been a private practitioner for 20 years, Dr. Gorman (NIH) noted that it took a year to 
start paying.  He did not think it would take a year to stop paying.  
 
Vote:  Influenza Vaccine Recommendations 
 
Dr. Harrison motioned to approve Option A.  Dr. Walter seconded the motion.  The motion 
carried with 13 affirmative votes, 1 negative vote, and 1 abstention.  The disposition of the vote 
was as follows: 
 
13 Favored: Bennett, Ezeanolue, Harriman, Harrison, Karron, Kempe, Moore, Romero, 
Reingold, Riley, Rubin, Stephens, Walter 
  1 Opposed: Pellegrini (due to insufficient time to review the data) 
  1 Abstained:   Belongia (due to conflict of interest) 
 
 
Although they voted “yes,” many ACIP members expressed regret.  Dr. Bennett lamented that it 
was a very sad day for the influenza vaccination program.  However, she stressed that “if you’ve 
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seen one influenza year, you’ve seen one influenza year” and that they might be back next year 
reaching a very different conclusion. 
 
VFC Vote:  Influenza Recommendation 
 
Dr. Jeanne M. Santoli 
Immunization Services Division 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
 
Dr. Santoli indicated that the purpose of this resolution was to update the resolution to remove 
LAIV from the VFC program.  No changes were proposed to the IIV component of the 
resolution. 
 
The other sections of this component of VFC resolution will not be changed.  The following 
statement will be included regarding updates based on published documents: 
 
If an ACIP recommendation regarding influenza vaccination is published within 6 months 
following this resolution, the relevant language above (except in the eligible groups 
sections) will be replaced with the language in the recommendation and incorporated by 
reference to the URL. 
 
Discussion Points 
 
Dr. Thompson requested clarification regarding the implications of approving this resolution in 
terms of payment for physicians for VFC-ordered vaccines if they have already ordered / paid 
for them.  She also asked for clarification of the implications of the timing of the resolution in 
terms of current influenza season vaccinations. 
 
Dr. Santoli responded that providers receive VFC vaccines at no charge.  CDC provides 
contracts and makes doses available to states for the VFC program.  This indicates that CDC 
will make vaccines available for children who are covered by the VFC program, and those are 
the vaccines to which providers of the VFC program will have access and will be able to 
administer.  They do not bill for these vaccines, although they do bill for the administration fee.  
That will occur as normal, but the resolution will limit the formulary for influenza vaccines that 
CDC will make available through the VFC program this year.  
 
Vote:  VFC Influenza Vaccine Recommendation 
 
Dr. Kempe motioned to approve the VFC Influenza Vaccine Recommendation.  Dr. Rubin 
seconded the motion.  The motion carried with 13 affirmative votes, 1 negative vote, and 1 
abstention.  The disposition of the vote was as follows: 
 
13 Favored: Bennett, Ezeanolue, Harriman, Harrison, Karron, Kempe, Moore, Romero, 
Reingold, Riley, Rubin, Stephens, Walter 
  1 Opposed: Pellegrini (due to insufficient time to review the data) 
  1 Abstained:   Belongia (due to conflict of interest) 
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No public comments were offered during this session. 
 
 
 
 
 
 
Introduction 
 
Ruth Karron, MD 
Chair, Respiratory Syncytial Virus Vaccine Work Group 
 
Dr. Karron said that she was delighted to introduce the Respiratory Syncytial Virus (RSV) WG, 
both because RSV is such an important pathogen in young children and the elderly and also 
because so much has been accomplished in terms of vaccine development; therefore, it is time 
to constitute an ACIP WG. 
 
RSV was discovered almost 60 years ago in 1957.  It is a major cause of lower respiratory tract 
illness (LRTI) in infants, young children, and older adults.  In the US, there are approximately 
150,000 hospitalizations each year in US infants and children and approximately 180,000 
hospitalizations in US elderly.  In the US, these represent the “tip of the iceberg,” and there is a 
substantial outpatient disease burden in both populations.  RSV is a global pathogen and it is a 
leading cause of hospitalization and serious LRTI in children throughout the world.  Despite 
having been recognized as a human pathogen 59 years ago, a vaccine does not exist.  There is 
a monoclonal antibody (mAb) called palivizumab, but that is given as a monthly injection, is 
quite expensive, and is recommended for only a subset of high-risk infants. 
 
The following graphic represents the RSV vaccine landscape in 2003, with just a couple of 
companies and NIH involved in developing vaccines: 
 
Day 1:  Public Comment 
Respiratory Syncytial Virus Vaccine  
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Contrast that with the current state of affairs shown in the following graphic of 2016 mAb and 
RSV vaccine development: 
 
 
 
There are approximately 60 products in development, of which 3 are in Phase 3 development.  
Two of the vaccines in Phase 3 development are manufactured by Novavax.  One is currently 
being evaluated in mothers for maternal immunization to protect young infants, and one has 
completed enrollment in the elderly.  There are a number of other products, but the products in 
particular that are meant for the elderly are further along in clinical development than the 
products meant to protect young children, either through maternal immunization or through 
active immunization of the infant. 
 
For that reason, at this time, the WG was constituted to focus primarily on the elderly because it 
is anticipated that a vaccine could be licensed as early as 2017-2018.  The current terms of 
reference for this WG are to consider recommendations for the use of RSV vaccine in adults 60 
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years of age and older and in adults with underlying medical conditions.  The current tasks of 
the WG are to: 
 
 
 
 
 
Review the epidemiology of RSV infection and burden of RSV disease in older adults; 
 
Review efficacy, immunogenicity, safety, and cost-effectiveness of RSV vaccine(s) in older 
adults and adults with underlying medical conditions as these data become available; 
 
Provide evidence-based recommendations regarding use of RSV vaccine(s) in older adults; 
and 
 
Identify areas in need of further research for informing potential future vaccine 
recommendations. 
 
Because it is anticipated that over time, there also will be vaccines to consider for protection of 
infants and children, the terms of reference and the membership of the WG may evolve over 
time to accommodate these additional needs.  With the exception of the liaison members, the 
WG initially was constituted with the focus on elderly adults in mind. 
 
This session included an overview of RSV and RSV vaccines with regard to obstacles and 
progress in RSV vaccine development, targeted vaccine populations, and considerations for 
RSV vaccine use.  Future presentations will include presentations on burden of RSV in older 
adults, clinical trial results, and cost-effectiveness. 
  
Overview of RSV Vaccines 
 
Lindsay Kim, MD, MPH 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
 
Dr. Kim began by acknowledging Dr. Karron’s mentorship and leadership in the standing up of 
this ACIP WG.  She explained that RSV is a common cause of acute respiratory infections (ARI) 
in infants and young children.  By the first year of life, 50% are infected, with virtually all children 
infected with RSV by 2 years of age.  RSV is the most common cause of LRTI among infants, 
and it frequently manifests as bronchiolitis or pneumonia.  It can present with apnea in infants 
less than 6 weeks of age.  There is a questionable relationship between RSV infection during 
early childhood and subsequent development of reactive airway disease and wheezing. 
 
In adults, RSV can cause repeat infections after being exposed and infected during infancy and 
early childhood.  It most often causes upper respiratory tract illnesses, but sometimes can be 
asymptomatic.  When it does cause symptoms, they are more severe than the common cold 
with less fever and fewer systemic symptoms compared to influenza.  LRTI also can occur, 
especially among the immunocompromised, those with underlying cardiopulmonary disease, 
and the elderly.  Frequently, RSV can also manifest as exacerbations of chronic medical 
conditions such as chronic obstructive pulmonary disease (COPD), asthma, and congestive 
heart failure.  In some case series of immunocompromised persons, RSV can manifest as 
pneumonia and sinusitis, with mortality rates of 50% or more reported. 
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This table shows frequency of symptoms among adults aged 65 years and older: 
  
 
The most frequent symptoms reported by persons with RSV infection were new or worsening 
cough (92%), headache (82%), fatigue (80%), and nasal congestion (72%).  RSV and influenza 
often are thought of commonly as similar pathogens, but they do have different 
symptomologies.  As seen in the above slide, fever is reported more frequently in influenza A-
infected persons at 72% versus 56% in RSV in adults. 
 
In terms of the burden of RSV in older US adults, the importance of RSV infections in adults 
was first recognized as a result of outbreaks in long-term healthcare facilities in the 1970s.  One 
population based study estimated that RSV infection causes 177,000 hospitalizations and 
14,000 deaths annually1.  Another study found that the average annual RSV hospitalization rate 
was 15 per 10,000 residents2.  What was striking was that the investigators also found a similar 
rate of hospitalization for influenza.  Another study published in 2014 found that there were 154 
medically attended RSV episodes per 10,000 persons in adults 50 years and older with 
increasing incidence with age.  This was a prospective study over 4 respiratory seasons in 
community-dwelling older adults who were seeking care for ARI3.  For a higher risk group of 
adults 65 years and older, another study found that RSV caused approximately 18 
hospitalizations per 1000 persons and 5 deaths per 1000 persons with chronic lung disease 
using retrospective data from the Tennessee Medicaid database4 [1Falsey 2005; 2Widmer 2012; 
3McClure 2014; 4Griffin 2003].  So, there is a burden of RSV in older US adults. 
 
In terms of the virus itself, RSV is an enveloped ribonucleic acid (RNA) Paramyxoviridae virus 
with 2 major subgroups, A and B, which are based on the surface proteins.  The viral genome 
consists of 10 genes that encode 11 proteins, two of which are named F and G.  The Fusion (F) 
and attachment (G) surface glycoproteins are the most important in their ability to induce 
neutralizing antibodies.  The F protein is highly conserved between the RSV subgroups, making 
it a promising vaccine target.  Humans are the only source of transmission, and RSV is spread 
by direct or close contact through large droplets or fomites on objects and surfaces.  These can 
last from 30 minutes to 6 hours.  The incubation period is 4 to 6 days, with a range of 2 to 8 
days.  Viral shedding can occur for 3 to 8 days, but can last up to 4 weeks. 
 
There are several methods for testing for RSV or diagnosing it.  Laboratory diagnosis of RSV 
can be done by rapid tests of respiratory specimens (midturbinate, nasal swab, or wash).  
These include antigen assays, which are highly sensitive in young children, with reports of 80% 
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to 95% sensitivity.  However, they have much lower sensitivity in adults of about 14% to 39% 
due to low virus shedding.  Therefore, this is not the optimal way to diagnose RSV in adults.  
Reverse transcriptase polymerase chain reaction (RT-PCR) assays are now more widely 
available and have a much higher sensitivity in adults, with some reports approaching over 
90%.  Viral isolation from respiratory specimens in cell culture can also be performed to 
diagnose RSV; however it can take 1 to 5 days, is more expensive, and is less sensitive than 
current methods of RT-PCR.  Sensitivity can also be affected by which laboratory is performing 
that method.  Serology is used mainly for seroprevalence studies and not for patient care; 
however, the added benefit of serology is that it can add to case finding in adults as studies that 
use both PCR and serology can detect more RSV than virus isolation or PCR alone. 
 
The goal for RSV vaccine development is to safely induce sufficient immunity to protect against 
serious RSV infections like LRTI and possibly apnea in infants.  The induction of sterilizing 
immunity is not required and actually might not be feasible.  In the late 1960s, a formalin 
inactivated vaccine underwent clinical trials in children 2 months to 7 years of age.  
Unfortunately, there were some devastating results that impacted the development of RSV 
vaccines for several decades.  The trials ended when seronegative vaccine recipients had more 
severe RSV-associated LRTIs than non-recipients when they acquired natural infection during 
the subsequent RSV season.  Of vaccine recipients, 80% required hospitalization compared to 
5% of controls who never received vaccine.  There were 2 deaths in the vaccine recipient group. 
  
Data assessing vaccine recipients with serious outcomes from this trial and rodent models 
found that the vaccine caused a vaccine-enhanced disease syndrome in RSV-naïve infants or 
those who had not yet had primary infection.  This was due to two main reasons.  First, the 
vaccine did not induce enough neutralizing antibody, and second, it induced a Th2- and CD4-
biased immune response leading to more inflammation, more cytokine release, and more 
obstruction and worse outcomes in infants and children.  There are many implications of the 
formalin-inactivated vaccine trial, including the fact that vaccine development / production 
slowed down due to the need to know more about the immunology of RSV disease and immune 
responses.  Because of the enhanced disease seen during the vaccine trials, non-replicating 
vaccines are unlikely to be used in RSV-naïve infants.  Therefore, different vaccines types are 
now being used for different target populations.  These include replicating or vectored vaccines 
for active immunization of RSV-naïve infants and children, subunit vaccines with or without 
adjuvant for maternal immunization to protect the very youngest infants, and subunit vaccines 
with or without adjuvant to protect the elderly and boost their already-existing immunity. 
 
Recently, there has been quite some movement in RSV vaccine development as shown on the 
graphic earlier by Dr. Karron.  There are more than 60 different products in development by 
several manufacturers.  There are different types of vaccines ranging from live-attenuated to 
subunit to those with gene-based vectors.  The furthest along is the RSV Fusion protein vaccine 
using recombinant nanoparticle technology developed by Novavax, which will be the first 
vaccine that the ACIP will consider.  This vaccine recently completed Phase 3 clinical trials. 
 
There are four RSV vaccine priority groups, which are comprised of the populations at risk of 
severe disease: 
 
 
 
 
 
Neonates and Young Infants 
Older Infants and Children 
Pregnant Women  
Older Adults 
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Neonates and young infants have the greatest potential benefit due to having the highest 
burden of disease and mortality among all age groups; however, there are a couple of obstacles 
to think about when developing a vaccine for this age group.  They have immature immune 
systems and the presence of pre-existing maternal antibody can make active immunization in 
this age group challenging.  Therefore, the most promising strategy for the youngest infants is 
maternal vaccination or administration of an extended half-life monoclonal antibody. 
  
Older infants and children face similar issues to young infants, but have more mature immune 
systems and lower levels of maternally acquired antibodies.  This should lead to better 
responses to vaccines.  Currently, development is focusing on live-attenuated virus and 
vectored vaccines with several candidates in Phase 1 clinical trials. 
 
Pregnant women are also a high risk population.  The use of a vaccine for pregnant women has 
several objectives including protecting the young infant by inducing high levels of neutralizing 
antibodies that are transferred to the fetus, preventing maternal to infant transmission of 
infection, and protecting the pregnant woman herself from infection.  Pregnant women would not 
be at risk for enhanced disease, given that as infants / children they were already naturally 
exposed and infected.  RSV F subunit vaccines are in development, and these candidates are 
in Phase 1, 2, and 3 clinical trials. 
 
Lastly, older adults have a substantial disease burden.  However, immunosenscence might be a 
challenge to overcome.  Several subunit vaccines are currently in development.  Vaccine 
candidates are in Phase 1, 2, and 3 trials.  The RSV F subunit nanoparticle vaccine will be the 
first RSV vaccine to be considered for FDA licensure and use, and it is the focus of the current 
ACIP RSV WG. 
 
In August 2015, news media reported early indications of vaccine efficacy of the Novavax 
vaccine targeted for older adults.  Early indications show it to be efficacious for RSV in older 
adults.  More data will be forthcoming as Phase 2 and 3 trial results become available, and 
these will be presented to ACIP. 
 
As ACIP deliberates the use of an RSV vaccine in older adults, several issues will be 
considered including disease burden, appropriate outcome measures, immunogenicity and 
correlates of protection, duration of protection, the cost-effectiveness of the vaccine, 
implementation issues, and education of stakeholders (particularly among family practitioners 
and other providers who would be administering the vaccine, and the public who would be 
receiving the vaccine).  The proposed ACIP timeline will include a review of the epidemiology 
and burden of RSV in older adults in 2016; vaccine manufacturer presentations on clinical trial 
results in 2017; discussions regarding correlates of protection, immunogenicity, and cost-
effectiveness in 2017; and implementation considerations, the GRADE evidence, and a 
potential vote in 2018. 
 
 
 
Introduction and Enhanced Surveillance of Tdap Vaccine Safety in Pregnancy in VAERS 
 
Pedro L. Moro, MD, MPH 
Safety of Maternal Tetanus, Diphtheria, Acellular Pertussis (Tdap) Immunization 
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Dr. Moro reminded everyone that there were two recent ACIP recommendations.  The first was 
in 2011, which indicated that unvaccinated pregnant women should receive a dose of Tdap to 
provide infants with maternal transplacental passive antibody protection against pertussis during 
the early postnatal months1.  The next recommendation was a year later, in 2012, to administer 
Tdap during every pregnancy, irrespective of prior history of receiving Tdap 2.  The optimal 
timing for administration is between 27 to 36 weeks gestation.  At the time of the 
recommendations, limited data were available on the safety of Tdap vaccination in pregnancy 
[1CDC. MMWR. October 21, 2011 / 60(41); 1424-1426. Available at 
www.cdc.gov/mmwr/preview/mmwrhtml/mm6041a4.htm; and 2CDC. MMWR. February 22, 
2013 / 62(07);131-135.  Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a4.htm. 
During the 2012 deliberations, ACIP expressed the need for enhanced monitoring and safety 
studies of Tdap in pregnancy.  The CDC Immunization Safety Office (ISO) implemented a 
comprehensive vaccine safety monitoring effort for maternal Tdap safety1.  That included 
enhanced surveillance in VAERS, a clinical review of all Tdap pregnancy reports, epidemiologic 
studies in the VSD, and clinical research in the Clinical Immunization Safety Assessment (CISA) 
Project.  In 2015, Tdap vaccination coverage during pregnancy among women who had a live 
birth was 42.1% versus 27% in 20142  [1Moro et al. Hum Vaccin Immunother. 2015;11(12):2872-
9; and 2Pregnant Women and Tdap Vaccination, Internet Panel Surveys, United States, April 
2014 and April 2015 (unpublished data)]. 
In terms of the safety of Tdap in pregnancy in VAERS, surveillance in VAERS from October 
2011 through June 2015 showed no new or unexpected vaccine safety concerns among 
pregnant women who received Tdap or their infants.  These findings were presented at the 
February 2014 ACIP meeting and have been published [Moro PL, et al. Vaccine. 2016 Apr 
29;34(20):2349-53]. 
There were three studies in the VSD on Tdap in pregnancy, which are reflected in the following 
table, along with the safety data: 
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Dr. Moro reminded everyone that VAERS is a passive reporting system that is administered by 
the CDC and FDA.  The strengths are that it is capable of rapid signal detection, can detect rare 
AEs, generates hypotheses, encourages reports from healthcare providers and accepts reports 
from patients and others, and makes data available to the public.  The limitations include 
reporting bias, inconsistent data quality and completeness, inability to assess whether a vaccine 
caused an AE, lack of an unvaccinated comparison group, and no field for pregnancy status, 
making it difficult to search for reports.  Because there is no denominator, it is not possible to 
calculate the incidence or prevalence of an AE or to estimate the risk of an AE. 
 
Surveillance was initiated on November 26, 2012.  The VAERS database was searched for 
reports of pregnant women after administration of Tdap vaccinated from 10/11/2011 through 
5/6/2016.  Medical records were requested and reviewed for all pregnancy reports associated 
with Tdap.  The reporter / patient was also queried for prior administration of tetanus-containing 
vaccine. 
 
VAERS received a total of 464 pregnancy reports after Tdap.  In 54% of reports, the 
manufacturer was the reporter.  The majority (85%) of Tdap doses were give alone.  There were 
26 (5.6%) reports of repeat doses.  For a majority of the reports (80%), Tdap was given during 
the third trimester.  In terms of pregnancy-specific AEs, the two most commonly reported 
conditions were premature delivery (< 37 weeks) and stillbirth.  Regarding fetal or infant AEs, 
one neonatal demise was reported to VAERS.  Four major birth defects were reported:  ectopic 
kidney in newborn, hypoplastic left heart syndrome, Trisomy 12, and clubbed foot.  The 
predominant non-pregnancy specific AEs included injection site reactions and systemic 
reactions.  Regarding reports of repeat Tdap doses among pregnant women, 26 were reported 
to have received a previous dose of Tdap.  The interval between current and previous Tdap was 
7 days to 9.4 years, with a median of 1.8 years.  Thirteen reports did not describe an AE.  AEs 
in 13 reports included: 
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 
 
 
4 reports of injection site or arm pain 
2 reports each of oligohydramnios, intrauterine growth restriction / poor fetal growth, and 
elevated blood pressure / abdominal pain 
1 report each of stillbirth with trisomy 12, maternal urinary tract infection, and maternal 
systemic reactions (e.g., fever, chills) 
 
In conclusion, in VAERS no new unexpected vaccine safety concerns were noted among 
pregnant women who received Tdap or their infants.  A limited number of pregnancy reports 
with repeat Tdap doses were received by VAERS.  CDC will continue to monitor the safety of 
Tdap vaccine during pregnancy. 
 
Discussion Points 
 
Dr. Hayes (ACNM) asked what the rate of GBS is in the general population who received Tdap 
compared to the maternal vaccination group. 
 
Dr. DeStefano (SME) responded that he did not think they had those specific rates.  Pregnancy 
is a risk factor for GBS, but there are no data to suggest that maternal receipt of Tdap 
vaccination is associated with GBS.  
 
Maternal Pertussis Vaccination and Structural Birth Defects in Offspring 
 
Lakshmi Sukumaran, MD, MPH  
Immunization Safety Office 
Centers for Disease Control and Prevention 
 
Dr. Sukumaran indicated that she would be presenting the VSD study on behalf of the Health 
Partners Institute VSD team.  Tdap vaccine has been recommended for routine use in pregnant 
women not previously vaccinated since 2010 in California and since 2011 across the US.  In the 
fall of 2012, ACIP recommended that Tdap be administered during every pregnancy, with a 
preference for it to be given between 27 through 36 weeks gestation.  Many other countries also 
have implemented maternal Tdap vaccination programs. 
  
The objective of the Health Partners Institute VSD team study was to examine risks for 
structural birth defects following maternal Tdap vaccination within the VSD.  The study 
outcomes were any birth defect, major structural defects, and microcephaly.  Microcephaly in 
particular was chosen as an outcome because in Brazil, there is a maternal Tdap immunization 
program and there was some speculation initially that increases in microcephaly were due to 
maternal Tdap vaccine and not Zika virus. 
 
The 7 VSD sites that contributed data to the study on Tdap in pregnancy included the following: 
 
 
 
 
 
 
 
 
 
Group Health Cooperative 
Northwest Kaiser Permanente 
Kaiser Permanente Northern CA 
Kaiser Permanente Southern CA 
Kaiser Permanente Colorado 
HealthPartners 
Marshfield Clinic 
Advisory Committee on Immunization Practices (ACIP)                                               Summary Report                                             June 22-23, 2016 
 
 
112 
 
 
In a study of coverage data on maternal Tdap vaccination in live births between 2007 and 2013 
within the VSD that was published earlier this year, there was a steady background rate of first 
trimester vaccinations during the study period.  This usually represents women who did not 
realize that they were pregnant at the time of vaccination.  However, it is an important for this 
study because most birth defects occur in the first trimester.  There was a large increase in 
vaccinations in 2010 related to the California vaccine recommendations and in 2013 following 
the ACIP recommendations [Kharbanda et al.  Vaccine 2016]. 
 
An observational cohort study was conducted of pregnant women and their infants from the 7 
VSD sites.  Pregnancies ending in a live birth between January 1, 2007 and September 1, 2013 
were studied.  Pregnancies were identified through a validated algorithm based on 
administrative electronic health record and birth certificate data [Naleway et al.  Vaccine.  2013].  
Pregnant women were included who had continuous insurance enrollment from 6 months prior 
to their last menstrual period (LMP) through 6 weeks postpartum, with at least 1 outpatient visit 
during pregnancy.  Infants were required to have birth weight and gestational age available.  If 
they survived to 12 months of age, they were required to have 4 months of insurance 
enrollment, with 1 outpatient visit during the first year of life.  For infants who died during the first 
year of life, these insurance and health utilization criteria were not applied.  
 
Exclusions were identified from International Classification of Diseases (ICD)-9 codes and 
pharmacy files.  Multiple gestation births and live births with a known exposure increasing their 
risk for a structural birth defect were excluded, including receipt of a live virus vaccine during 
pregnancy, pre-existing diabetes, use of a teratogenic medication,  infant congenital TORCH 
infections (toxoplasmosis, other, rubella, cytomegalovirus, and Herpes simplex), and infant 
chromosomal abnormalities.  Maternal Tdap administrations were identified using claims and 
EHR data found in standardized VSD files.  Three exposure windows were assessed:  
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 
 
 
 
 
First trimester, defined as <14 weeks gestation, which is the most biologically plausible 
time period for a birth defect to occur 
27 to 36 weeks gestation, which is consistent with current ACIP recommendations for 
optimal timing of maternal Tdap administration 
Any week during pregnancy, since Tdap can be given at any time during pregnancy 
 
Three neonatal outcomes were examined that were identified from inpatient, outpatient, or 
emergency visits during an infant’s first year of life.  “Any structural birth defect” was defined by 
the presence of 2 or more ICD-9 codes from 740.0–759.9.  For selected major structural 
defects, there was a list of over 50 defects that affect an infant’s life expectancy, health status, 
or physical or social functioning.  The major structural birth defects were selected a priori based 
on outcomes monitored in US and European birth defect surveillance systems, and outcome-
specific algorithms were developed and applied to increase the specificity for identification of 
major structural defects:  For microcephaly, there was also a specific algorithm, which Dr. 
Sukumaran showed an example of as follows: 
 
 
 
In general, for major structural birth defects there was a specific code with different outpatient 
and inpatient diagnoses required based on validation work that was done.  For microcephaly, 
the code 742.1 would be required with 1 inpatient diagnosis or 2 outpatient diagnoses or 1 
outpatient diagnosis and death in the first year. 
 
For the statistical analysis, baseline characteristics between vaccinated and unvaccinated 
women were compared.  Logistic regression was used to estimate aggregate propensity scores 
to adjust for multiple risk factors.  The propensity scores included maternal demographic factors, 
healthcare utilization during pregnancy, and maternal comorbidities.  Prevalence differences 
were estimated using Poisson distribution with identity link and robust variance.  Prevalence 
ratios were estimated using generalized linear models with Poisson distribution. 
 
After applying exclusion criteria, 324,463 pregnancies were included.  Of these, 13% were 
Tdap-exposed and 87% were Tdap-unexposed.  Over 3,000 women were vaccinated before 14 
weeks gestation and over 20,000 women were vaccinated between 27 and 36 weeks gestation.  
In terms of baseline characteristics of the cohort, maternal age, race, and ethnicity were similar 
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between the groups.  Most vaccinated women were 15 through 24 years old.  A slightly higher 
percentage of vaccinated women received adequate prenatal care and Tdap vaccinated women 
were more likely to receive another vaccine during pregnancy.  Rates of smoking and 
hypertension were similar between the groups. 
 
Regarding the results of the analysis for any structural birth defect following maternal Tdap, 
when Tdap vaccine was given before 14 weeks gestation, the rate of any structural birth defect 
was 6.3% compared to 6.2% in unexposed women.  For 27 through 36 weeks gestation, 7% of 
Tdap-exposed and Tdap-unexposed had a structural birth defect.  For Tdap at any time during 
pregnancy, 6.8% compared to 6.2% of unexposed had a structural birth defect.  These 
differences were not statistically significant. 
 
For major structural birth defects, when Tdap was given before 14 weeks gestation, the rate 
was 1.8% compared to 1.6% in unexposed women.  For Tdap between 27 through 36 weeks 
gestation, the rate was 1.7% compared to 1.6% in unexposed women.  For Tdap at any time 
during pregnancy, the rate was 1.7% compared to 1.6% in unexposed women.  These 
differences are not statistically significant. 
 
For microcephaly, when Tdap was given before 14 weeks gestation, the rate was 12/10,000 in 
Tdap-exposed and 12/10,000 in Tdap-unexposed.  For Tdap administered at 27 through 36 
weeks gestation, the rate was 10/10,000 in Tdap-exposed compared to 12/10,000 in Tdap-
unexposed.  For Tdap at any time in pregnancy, the rate was 9/10,000 in Tdap-exposed 
compared to 12/10,000 in Tdap-unexposed.  These differences were not statistically significant. 
  
There are some limitations to the study.  Birth defects were identified through diagnostic codes 
using the outcome-specific algorithms rather than clinical exam or direct review of charts.  There 
is a potential for missing diagnoses in children if they had lapses in their insurance coverage.  
Also, the study was limited to live births.  Therefore, it was not possible to study stillbirths, 
elective terminations, and spontaneous abortions. 
 
In summary, maternal Tdap vaccination during pregnancy was not associated with increased 
risk for birth defects, including microcephaly, among live birth offspring.  These results support 
the safety of maternal Tdap vaccination for the infant outcomes evaluated. 
  
Discussion Points 
 
Dr. Harrison inquired as to why a record review was not done for at least a subset of the ICD-9 
codes. 
 
Dr. Sukumaran replied that a record review was done when the algorithms were being 
developed for identifying the birth defects to make sure that the codes were valid, and to make 
sure that the background rates in the VSD were similar to national background rates.  That 
algorithm was then applied to the larger dataset. 
 
Dr. Reingold was curious as to why the investigators did not assess the effect of giving vaccine 
in the interval between 15 through 26 weeks.  Given that ACIP is considering the potential for 
recommending the vaccine earlier in pregnancy, it might be of interest to do that calculation and 
show it. 
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Dr. Sukumaran responded that this group was included in the “Tdap given at any time during 
pregnancy” group.  If the recommendation changes for the timing of administration, this group 
can be assessed more carefully. 
 
Given the furor in the discussion about the 2011-2012 recommendations by many ACIP 
members and liaisons at that time, Dr. Baker (IDSA) congratulated the investigators on 
performing this study.  The second trimester will be assessed and evaluated, and that 
information will be needed moving forward.  She found these data to be beautiful and very 
reassuring. 
 
Dr. Sukumaran responded that they do have the data on the second trimester, so it is possible 
to evaluate this closely as well. 
 
Reactogenicity and Immunogenicity of Tdap Vaccine in Pregnant Women 
 
Kathryn Edwards, MD 
Vanderbilt University School of Medicine 
 
Dr. Edwards provided an overview of the clinical study of Tdap safety during pregnancy, and 
preliminary results from the reactogenicity and immunogenicity analyses.  ACIP has 
recommended that providers administer a dose of Tdap during each pregnancy, with the optimal 
timing being 27 to 36 weeks gestation.  Available data support the safety of Tdap in pregnant 
women, but data on the safety of repeat Tdap doses are limited.  As part of a comprehensive 
monitoring to evaluate the safety of Tdap in pregnant women, a clinical study was implemented 
in the CDC CISA Project.  The primary study aim was to compare rates of injection-site and 
systemic reactions after Tdap in pregnant women versus non-pregnant women.  The secondary 
study aim was to explore differences in injection-site and systemic reactions in pregnant women 
who received Tdap before the current pregnancy versus pregnant women receiving their first 
Tdap dose.  There also were two exploratory aims funded by a Bill and Melinda Gates 
Foundation grant to Vanderbilt, which were to: 
 
 
 
 
Measure antibody levels to pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin 
(PRN), fimbria (FIM)  and diphtheria and tetanus toxoids prior to and one month after 
administration of Tdap vaccine in both pregnant and non-pregnant women; and  
 
Compare levels of cytokines in women (pregnant and non-pregnant) with severe local or 
systemic reactions after Tdap with those without reactions, using measurements of 
cytokines before, during, and after the reactions. 
There are additional studies in progress to: 
 
 
 
 
 
 
 
Assess the rates of preterm and small for gestational age (SGA) births in women who 
received Tdap during pregnancy; 
Assess the rates of additional obstetrical and infant outcomes in pregnant women receiving 
Tdap (e.g., pregnancy related hypertension); and 
Describe the health outcomes and growth parameters through 6 months of life among 
infants born to women who received Tdap during pregnancy. 
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In terms of the methods, this is a prospective observational study of women 18 through 45 years 
of age receiving Tdap as first or repeat doses at Vanderbilt and Duke University clinics. 
Pregnant women ≥ 20 and ≤ 34 weeks gestation were enrolled in the study.  These women 
received Tdap as part of their routine care.  The goal of this part of the study was to enroll 375 
pregnant women.  Non-pregnant women receiving Tdap for usual care or as part of a research 
procedure and followed through 1 month after vaccination also were enrolled.  The goal was to 
enroll 225 non-pregnant women.  Prior Tdap, Td, or TT history was assessed by subject report, 
medical record review, or state registry to document vaccine receipt.  Rates of local and 
systemic reactions were assessed during Days 0 through 7 after Tdap using memory aid with 
severity scales.  Blood was collected on Days 0 and 28 after Tdap.  Pertussis serology studies 
were performed at Vanderbilt, while the diphtheria/tetanus toxoid serologies were performed at 
Duke. Blood was collected in women with severe local and systemic reactions and in controls 
without the reactions for cytokine analysis on Day 0, the day of the reaction, and Day 28.  
Pregnancy outcomes were assessed via chart review, and infant outcomes were assessed by 
phone interview and chart review at 3 and 6 months of life. 
 
The major statistical analysis was directed at non-inferiority analysis for reactogenicity because 
the study was really looking at the safety of the vaccines.  For this purpose, comparisons were 
made of the proportions with moderate to severe and severe reactions during 0 to 7 days post-
vaccination between pregnant women and non-pregnant women receiving Tdap, and between 
pregnant women who received prior Tdap and those with no prior Tdap receipt.  The primary 
hypothesis was that the rates of moderate to severe reactions in pregnant women receiving 
Tdap would be non-inferior to non-pregnant women receiving Tdap.  One sided statistical tests 
were used, with a non-inferiority margin of 10% for moderate to severe and 5% for severe 
reactions. 
 
The mean age, gestational age, and gestational weeks at delivery at both study sites were 
comparable and the same as seen in other studies presented during the morning.  There was 
also prior Tdap receipt in about 50% of the pregnant women at Vanderbilt, about 65% at Duke, 
and indeed a higher percentage had received prior Tdap, Td, or TT.  In addition, because of 
vaccine availability at pharmacies, almost all vaccine administered was Sanofi Pasteur’s 
Adacel® vaccine.  A small proportion received Boostrix® vaccine.  By and large, these women 
had participated in other vaccine studies and received other vaccines prior to the Tdap vaccine.  
For the non-pregnant women at the study sites, the mean age was very similar.  Prior Tdap 
receipt was 60% at Vanderbilt and almost 80% at Duke.  The non-pregnant women often were 
under the care of healthcare providers, which may explain their higher rate of prior Tdap receipt.  
Tdap, Td, and TT receipt was also very high in this group.  All of the women in the non-pregnant 
group at Vanderbilt received Adacel® and about two-thirds at Duke did as well.  Again, many of 
these women had received influenza vaccine the previous year. 
 
Regarding local reactions within the 7 days after vaccination in pregnant versus non-pregnant 
women, the following definitions were used: 
 
 
 
 
 
Moderate: Induration and erythema: 10-34 mm; Pain/tenderness: Interferes with activity but 
did not necessitate medical visit or absenteeism 
Severe: Induration and erythema: >=35 mm; Pain/tenderness: Prevents daily activity and 
resulted in medical visit or absenteeism 
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 Non-inferiority criteria met for moderate/severe and severe local reactions in pregnant vs. 
non-pregnant women, except moderate/severe pain 
 
The rates of pain were greater in the pregnant women.  The rates of tenderness, swelling, and 
redness did not differ between the pregnant and non-pregnant groups.  Very few severe 
reactions were observed in the pregnant or non-pregnant women, and did not differ in their 
rates. 
 
Comparing the proportion difference between pregnant and non-pregnant women, moderate to 
severe pain did reach the 10% or higher level in pregnant women.  The biology that would 
explain this is not clear.  In terms of systemic symptoms after vaccination, moderate fever was 
defined as ≥ 100.4 to < 102.2° F and other symptoms that interfered with activity but did not 
necessitate medical visit or absenteeism.  Severe fever was defined as ≥ 102.2° F and other 
symptoms that prevented daily activity and resulted in medical visit or absenteeism.  The rates 
of moderate to severe systemic reactions were comparable in the pregnant and non-pregnant 
groups for fever, feverishness, malaise, body aches, and headaches. 
 
All comparisons for moderate to severe or severe reactions met non-inferiority criteria 
among pregnant women with and without prior Tdap receipt.  There were no significant 
differences, and no indication that prior Tdap vaccination would predispose one to more 
reactions.  For systemic and local reactions, when women are compared who had Tdap before 
to those who did not, there were no significant differences in any of the reactions at the 10% for 
moderate or severe reactions.  It is reassuring that repeated Tdap does not appear to program 
one for more severe local or systemic responses.  No women sought medical care for a vaccine 
reaction, and no SAEs were reported. 
 
In terms of the serologic studies, for each of the pertussis antigens in both the pregnant and 
non-pregnant women, the antibody responses were significantly higher post-vaccination for all 
of the antigens.  When the ratio of the pre and post-vaccination antibody titers (non-pregnant: 
pregnant women) was compared for all the pertussis antigens, some differences were shown.  
The ratio was significantly > 1.0 for PT and FHA titers post-vaccination and for FIM and PRN 
pre-vaccination. This means that non-pregnant women had significantly higher antibody titers at 
28 days after vaccinations for PT and FIM and had significantly higher antibody titers at Day 0 
for FIM and PRN when compared to pregnant women.  The non-pregnant women had higher 
rates of prior immunizations and may have explained why they had higher pre-vaccination titers 
for FIM and PRN. Why they had higher post-vaccination titers for PT and FIM is not clear.  
 
Comparing the ratio of those antibody titers to those who had not received Tdap before and 
those who had, for all of the pre-antibody titers, the no Tdap before had a lower ratio, meaning 
that the antibody titers in no Tdap before for pre-titers were all significantly less.  Again, this may 
have reflected the higher titers in the women who received Tdap before reflected in their pre-
titers.  What is interesting, however, is that for the FIM and PRN, the antibody titers were higher 
in those who had not had prior Tdap.  It is not clear whether that reflects immune suppression or 
is a statistical fluke.  But again, all of them had antibody rises. 
 
Regarding the cytokine study, 6 subjects had severe reactions.  They were seen at the time of 
the severe reactions.  They were matched to 6 controls who did not have severe reactions who 
were seen at that same time, and were matched by pregnancy status.  There were 5 cases at 
Vanderbilt, 2 of whom were pregnant and 3 of whom were not.  There was 1 non-pregnant case 
at Duke.  They were matched for their pregnancy status.  For each of the cytokine levels at each 
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of the determinations, there were no significant differences between the cases and the controls.  
Also, there were no differences in the cases before and after vaccination or the time of local or 
systemic reactions for IL-6, IL-8, IL-10, TNF-α, and IL-5. 
 
In conclusion, Tdap was well-tolerated in both pregnant and non-pregnant women.  Moderate 
and severe injection-site pain occurred more frequently among pregnant women, but rates were 
consistent with clinically reported rates for the Tdap vaccine (16% per Adacel® package insert) 
and did not lead to medical visits.  Of the pregnant women, 53% received a prior Tdap vaccine 
and rates of moderate and severe reactions were similar in pregnant women receiving the first 
or repeat Tdap vaccine.  Both pregnant and non-pregnant women had significantly higher 
antibody titers to all antigens after vaccination.  Obstetric and fetal outcome data are being 
collected. 
 
Discussion Points 
 
Dr. Karron wondered whether the antibody responses had been analyzed by gestational age. 
 
Dr. Edwards responded that they did assess this.  Unfortunately, they were so adherent to the 
study criteria, there was little variability in when women received the vaccine.  Therefore, this 
cannot be addressed adequately. 
 
Dr. Reingold asked whether there were any women in the study for whom it was a third 
pregnancy and who were receiving a third dose of Tdap. 
 
Dr. Edwards replied that they did not have these data. 
 
Dr. Baker (IDSA) asked whether Dr. Edwards could comment on the possibility of differences in 
circulating pertussis in the community among the two groups, and whether the study was 
performed at a time when pertussis activity was high, medium, or low. 
 
Dr. Edwards responded that at the time of the study, the investigators did not appreciate that the 
issues regarding circulation of pertussis were occurring at either site.  They did not have 
ongoing serologic studies that might have evaluated that.  They have not assessed duration of 
antibody in this particular study, although they are in the process of analyzing data funded by 
NIH in which antibody titers were assessed over two years in women who were vaccinated post-
partum.  The antibody titers drop off very fast, which is very curious because for tetanus and 
diphtheria they do not.  This is very interesting.  Even in those patients, at two years there were 
still some antibody titers for some of the antigens.  Some of these women were vaccinated 
within a year or so in the non-pregnant group.  It is hard to say, but the investigators do not 
believe that there was natural transmission.  Pertussis is a complicated problem. 
 
Ms. Stinchfield (NAPNAP) noted that Dr. Edwards had used the words “reaction” and 
“response.”  When vaccinating pregnant women and they get local redness and swelling, a 
pregnant woman might hear “a vaccine reaction equals I can’t have another one in the future.”  
To turn that to a positive, that is a robust immune response. 
 
Dr. Edwards said that for many years, an attempt has been made to determine whether having 
a more vigorous local immune response translates to a better serologic response.  That is not 
always consistently seen with all antigens.  It would be difficult to say whether having a better 
response means having higher antibody.  The most reassuring thing she could say about this 
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would pertain to cytokine data.  Only 6 people had severe reactions, which is very reassuring.  
Even at the time of the peak local reactions, there were not systemic cytokine responses that 
were elevated.  This is very reassuring.  It is not clear exactly what will happen in terms of 
repeated Tdap.  They did conduct a study a number of years ago that also was funded by the 
CISA Project in which children were assessed at 4 to 6 years who had large local reactions after 
their fourth dose of DTaP at 18 to 24 months, and in general those children did have slightly 
more local responses after their fifth dose than they did at the fourth.  However, it was not 
remarkable and there were no severe reactions and no inhibition of activities. 
 
Dr. Sun (FDA) wondered whether anything was found in the assessments of infants at 3 and 6 
months by telephone and chart review. 
 
Dr. Edwards indicated that those are still in the process of being analyzed.  All of the patients 
have not reached that mark, but these data should be available soon.  Empirically speaking, 
there were no AEs of note. 
 
Pertussis Vaccines WG Update 
 
Art Reingold, MD 
Chair, ACIP Pertussis Vaccine Work Group 
 
Dr. Reingold reminded everyone that the Pertussis Vaccine WG was originally formed in April 
2009.  Since then, there have been some changes to the composition of the WG.  As of June 
2015, the WG had completed all but one remaining term of reference: 
  
Review existing statements on infants and young children (1997), adolescents (2006), 
adults (2006), and pregnant and postpartum women and their infants (2008) and 
consolidate into a single statement. 
 
This consolidated statement was drafted, has been reviewed by WG members, and is making 
its way through CDC clearance. 
  
Since 2013, the ACIP recommendation for pregnant women has been as follows: 
 
Health-care personnel should administer a dose of Tdap during each pregnancy, 
irrespective of the patient’s prior history of receiving Tdap. 
 
The guidance for use states the following: 
 
To maximize the maternal antibody response and passive antibody transfer to the infant, 
optimal timing for Tdap administration is between 27 and 36 weeks gestation. 
 
Since then, several studies from other countries have looked at the immunogenicity of 
vaccinating pregnant women primarily from 27 through 36 weeks gestation.  But one study 
prompted the request by CDC to reconvene the WG. 
  
Three recently published studies with relevant data show equal or higher antibody 
concentrations among infants whose mothers were vaccinated in the second trimester 
compared to those whose mothers were vaccinated in third trimester1; higher PT antibody levels 
in mothers vaccinated at 28 through 32 weeks compared to those vaccinated 33 through 36 
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weeks2; and no differences in titers of neonatal antibodies between mothers vaccinated in the 
late second trimester and during the third trimester3 [1Eberhardt CS, et. al. Clin Infect Dis. 2016 
Jan 20.;  2Naidu MA, et al. Am J Obstet Gynecol. 2016 Mar 9. [Epub ahead of print]; and 
3Vilajeliu A, et. al. Vaccine. 2015 Feb 18;33(8):1056-62]. 
 
The UK Joint Committee on Vaccination and Immunization changed its recommendation in 
February 2016 such that they now recommend that women receive the vaccine as early as 16 
weeks of gestation, but after the mid-pregnancy ultrasound.  Presumably then if there are any 
abnormalities, they cannot be blamed on a dose of Tdap that has recently been given. 
 
The next steps for the WG are to review new data related to Tdap in pregnancy regarding timing 
of vaccination during pregnancy, Tdap effectiveness of preventing pertussis in infants, safety, 
and programmatic considerations.  The plan for the October 2016 ACIP meeting is to present 
the consolidated ACIP statement and have additional discussion regarding the timing of 
maternal Tdap vaccination, summarizing the existing data and receiving suggestions from ACIP 
about keeping the timing the same or changing it in the US. 
 
 
 
Olen Kew, PhD 
National Poliovirus Containment Coordinator (NPCC) 
 
Dr. Kew presented a status report on Poliovirus Type 2 containment in the US.  The last wild 
poliovirus (WPV2) in the US was eradicated before 1965, WPV3 around 1968, and WPV1 
around 1970.  Globally, WPV2 was last detected in October 1999.  Although vaccine strains of 
Type 2 have been detected through the present, indigenous WPV has not been detected since 
that time.  Globally, it appears that WPV3 also has been eradicated though WHO is not 
prepared to declare that yet.  The last case was in 2012 in Nigeria.  WPV1 is barely hanging on.  
Thus far in 2016, there have been about as many cases as occurred in 30 minutes when this 
program began.  As of 14 September 2016, there have been 25 cases in only three endemic 
countries: Pakistan has reported 14 cases, with the most recent being 27 July;  Afghanistan has 
reported 8 cases, with the most recent occurring 8 August; and Nigeria has reported 3 cases, 
with the most recent detected in 6 August. 
 
The goal of the WHO Global Action Plan on Poliovirus Containment, Third Edition (GAPIII) is to 
minimize poliovirus facility-associated risk after type-specific eradication of WPVs and 
sequential, type-specific cessation of oral poliovirus vaccine (OPV) use.  The original hope was 
to eradicate all three serotypes in such a close time span that there could be a coordinated, 
concurrent containment of all three poliovirus serotypes.  However, because of the long lag after 
the eradication of Type 2 and the occurrence of repeated outbreaks associated with Type 2 
circulating vaccine-derived polioviruses, it became clear that Type 2 had to be contained 
specifically.  Therefore, implementation is in three phases.  Phase I was Global Coordination 
and Readiness, Phase II is Poliovirus Type 2 Containment by 2016, and Phase III is Complete 
Poliovirus Containment (all three serotypes) at least three years after the last WPV 
case/infection.  The date for completion of Phase III depends on the timeline of WPV eradication 
in the remaining endemic countries.  All “infectious” and “potentially infectious” poliovirus 
materials were requested to be inventoried by the end of 2015, although this was not 
accomplished.  Not only WPV and OPV/Sabin of all three serotypes, but also vaccine-derived 
Laboratory Containment of Poliovirus Type 2 
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polioviruses (which are phenotypically indistinguishable from WPVs).  Some vaccine-derived 
polioviruses have circulated in communities for as long as 10 years. The objective is to reduce 
the number of facilities handling poliovirus to a minimum.  The following graphic depicts the 
phases of GAPIII.   
 
 
One of the key events was the withdrawal of OPV Type 2 from the vaccine by May 2016.  The 
last dose of trivalent OPV was given before mid-May 2016, and a shift was made to a bivalent 
Type 1 and 3 vaccine.  That poses a biological imperative to containing Type 2 in the US, and 
particularly in developing countries.  The long-term plan is to cease the use of bivalent OPV as 
well and shift to IPV.  Within that, WPV and vaccine-derived Type 2 poliovirus must be 
contained in what are known as “Poliovirus Essential Facilities” in 2016.  An approach is being 
used that will phase in the strategy.  “Containment” means to act on three options: 1)destroy 
and document destruction of all unneeded poliovirus infectious or potentially infectious 
materials, 2) transfer important materials to a Poliovirus Essential Facility, or 3) become a 
Poliovirus Essential Facility by implementing facility and personnel performance standards 
required by GAPIII. 
 
In terms of the US role in global containment, Dr. Walter Dowdle initiated a survey in 2002–2003 
that showed that 34% of all facilities worldwide storing WPV infectious or potentially infectious 
materials were in the US.  CDC has the largest WHO Global Polio Reference Laboratory.  The 
US is home to many leading poliovirus research institutions.  There is no polio vaccine 
production in the US, but there is ongoing vaccine testing.  While the risks of facility-associated 
poliovirus infections in the community in the US are low, they are not zero.  The risks are much 
higher in developing country settings.  The US has a responsibility to take a leading role and set 
a good example.  The US National Poliovirus Containment Coordinator (NPCC) reports to the 
US National Certification Committee (NCC), the NCC reports to a Regional Certification 
Commission (RCC), and the RCC reports to the Global Certification Commission (GCC).  The 
GCC ultimately will declare the eradication of polio worldwide, as was done previously with 
smallpox. 
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The NCC Task Force for Global Health in Decatur, Georgia is the Secretariat for the NCC, 
which is constituted by the eminent experts in their fields: 
 
 
 
 
 
 
 
 
Chair: Kenneth I. Berns, MD, PhD, Distinguished Professor Emeritus, Molecular 
Genetics and Microbiology, University of Florida  
Charles Brokopp, DrPH, Laboratory Director, Wisconsin State Laboratory of Hygiene 
Megan Davies, MD, Acting State Health Director, State Epidemiologist and Chief, North 
Carolina Division of Public Health 
Joseph Kanabrocki, PhD, CBSP, Associate Vice President for Research Safety, 
University of Chicago 
Ruth Lynfield, MD, State Epidemiologist and Medical Director, Minnesota Department of 
Health 
José Romero, MD, FAAP, Chief, Pediatric Infectious Diseases; Director, Clinical Trials 
Research, Arkansas Children's Hospital Research Institute 
Dominica (Dee) Zimmerman, University of Texas Medical Branch, Environmental Health 
and Safety 
 
The 2002–2003 survey was implemented among 105,356 individual laboratories in 32,429 
institutions.  Only 180 laboratories reported storage of WPV infectious or potentially infectious 
materials.  The survey did not ask about serotype.  This included 12 CDC laboratories.  The 
2002–2003 polio survey came in wake of the Select Agent Act and had a very high response 
rate, which may not have been coincidental.  The survey queried only about WPV materials, not 
OPV/Sabin strains.  There was no differentiation by serotype.  The findings from the 2002–2003 
survey were the starting point for a 2015–2016 survey conducted by the Office of the NPCC 
based at CDC, which reports to CDC, NCIRD, NCC, and the Office of Assistant Secretary of 
Health (OASH) through National Vaccine Program Office (NVPO), directed by Dr. Bruce Gellin.  
CDC developed a web-based survey instrument that was modified from the original 
WHO/PAHO (Pan American Health Organization) template.  The initial contact is by email.  Two 
surveys were distributed, one of which was an internal CDC survey that was launched 14 
December 2015 in an effort to comply with the 12 November request from the Director General 
of WHO to have this job completed by the end of 2015.  The second was an external survey that 
was launched serially with the first launch 22 December 2015 among federal facilities, academic 
institutions, state and local health departments, industrial facilities, commercial diagnostic 
laboratories, and hospitals.  The initial response rate was not very high, but has now risen to 
82%. 
 
NPCC’s approach to containment was distribution of the survey by prioritization of the estimated 
risk.  Phase IIa was containment of WPV2 and VDPV2 infectious materials.  The top priority was 
academic laboratories that had been working with WPV2 and VDPV2 recently.  The second 
priority was containment of potentially infectious materials.  Phase IIb included the third priority 
of containment of OPV2/Sabin 2 infectious materials, and the fourth priority is OPV/Sabin 
potentially infectious materials.  The priority categories frequently overlap, which was clear from 
the responses received.  This was an opportunity to contain all PV and be removed from the list 
for the facility.  Potentially infectious materials have been prioritized by risk, assigning the 
highest risk to stool specimens. 
 
Surveys have been launched in successive waves, prioritizing by estimated risks.  The highest 
priority has been assigned to WPV2 strains and enteric specimens, while the lowest priority has 
been assigned to domestic respiratory specimens and nucleic acids.  Containment is an 
ongoing process.  The immediate goal is PV2 containment in 2016.  The overall goal is full 
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poliovirus containment, potentially as early as 2019.  The survey results are used to guide the 
priorities for subsequent survey rounds.  A collaborative approach to laboratories has been 
taken.  The NPCC office has been assisted greatly by Biosafety Officers for coordination and 
further follow-up.  NVPO assistance will be sought for chronic non-responders. 
 
In terms of the internal CDC survey, CDC is the largest facility storing poliovirus infectious and 
potentially infectious materials.  Containment receives strong institutional support.  The CDC 
Polio Laboratory is the major WHO Global Polio Reference Laboratory, and contains the largest 
poliovirus collection in the world.  It is the only CDC laboratory with WPV2/VDPV2 infectious 
materials.  All WPV2/VDPV2 were moved to a containment laboratory and 189,763 vials of 
poliovirus infectious or potentially infectious materials in the CDC Polio Laboratory were 
autoclaved by 24 May 2016.  Other CDC laboratories store poliovirus potentially infectious 
materials comprised of historical US and international specimens.  All 149 CDC laboratories 
were contacted and completed the survey by 15 March 2016. 
 
The external survey was launched in successive waves, with the first launch in December 2015.  
The survey was distributed to 113 laboratories identified in a 2002–2003 survey as storing WPV 
materials (other facilities identified in 2002–2003 were no longer operating).  Special attention 
was given to laboratories known to be performing current research / testing with WPV2.  There 
was a re-launch to first-round non-responders as well as subsequent launches to newly 
identified laboratories, state and large municipal health laboratories, other non-polio enteric 
virology laboratories (rotavirus, norovirus, astrovirus, Hepatitis A virus, Hepatitis E virus, et 
cetera) and enteric bacteriology laboratories.  There is less concern about enteric bacteriology 
and parasitology laboratories, given that they do not normally store original stool specimens 
after isolation of infectious agents.  However, enteric microbiome/metagenomics laboratories do 
retain specimens for reinvestigation as methods improve.  There has been a significant amount 
of assistance from Biosafety Officers of large institutions to help fill any remaining gaps.  There 
were 178 responses to the internal survey as of September 6, 2016.  The major academic 
laboratories responded early.  Most of the laboratories that responded later have worked with 
reference strains or have stored reference strains primarily for serology.  More laboratories work 
with Type 1.  Type 2 is not the favorite one for most research laboratories.  The same is true 
with the Sabin strains. 
 
There are a number of challenges.  Some interpretations at WHO headquarters of GAPIII 
requirements are very prescriptive, and they are becoming an impediment to compliance.  High-
risk infectious materials and low-risk potentially infectious materials such as respiratory 
specimens and nucleic acids are grouped together for containment in GAPIII, without any real 
appreciation of the great differences in potential risk.  WHO is aware of these challenges and 
has empaneled a Containment Advisory Group to help guide the way forward.  Absence of 
statutory authority could limit compliance outside of federal government facilities.  While this has 
the potential to limit compliance, that has not been the experience.  The process for issuing 
certificates to Poliovirus Essential Facilities is incompletely defined.  Potentially infectious 
materials, especially of OPV/Sabin variety, present challenges for outreach. Respiratory virology 
/ microbiology laboratories have particular concerns about how poliovirus containment might 
adversely impact their vital work.  Academic laboratories, with frequent student turnover, 
present special challenges to specimen management and containment.  Non-poliovirus and 
non-virus laboratories are not generally aware of poliovirus containment.  Some may store 
potentially infectious materials.  Absolute poliovirus containment is not feasible. Undetected 
vaccine-derived excretion is likely to continue.  For example, a patient in the UK has been 
excreting for nearly 30 years, and one chronically-infected patient went undetected for 13 years 
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in the US.  That is likely to continue. Poliovirus can be easily prepared by synthetic biology, 
fortunately and unfortunately.  GenBank® sequence data exists in perpetuity.  The goal must be 
major reduction of risk, which is feasible provided that colleagues are constructively engaged. 
 
In terms of an example of the impact of Type 2 containment on US vaccination policy, the 
general recommendations for children with low or questionable documentation of vaccination 
are to take an alternative approach rather than just giving IPV, which would be the preferred 
approach.  That would be serologic testing for neutralizing antibody to all three serotypes.  This 
can be obtained commercially and at certain state health department laboratories, although 
there is limited availability.  Persons with protective titers against all three types do not need to 
repeat doses, but should complete the schedule as age-appropriate.  The alternative approach 
may no longer be feasible because commercial facilities are no longer working with Type 2, so 
they suspended Type 2 antibody in response to the request for them to contain their Type 2 
strains [This information courtesy Mona Marin and Manisha Patel DVD/NCIRD/CDC]. 
 
Discussion Points 
 
Dr. Ezeanolue asked whether consideration had been given to anticipated uptake in terms of 
moving from OPV to IPV, especially in countries like Nigeria. 
 
Dr. Kew responded that this has been part of the plan for some time.  There has been difficulty 
in Nigeria even administering OPV.  While he did not know the acceptance rate precisely, 
enormous effort has been invested in each country to raise coverage rates to as high as 
possible.  The weaknesses in the overall strategy is that routine immunization is low in some 
countries, especially in Nigeria where coverage is strong in the South and much weaker in the 
North.  Successful IPV door-to-door campaigns have been conducted in Kenya.  It remains 
unclear how high coverage rates will be with the shift away from trivalent OPV.  However, the 
bivalent OPV will continue to be used.  The bivalent will not be suspended until all three 
serotypes are eradicated.  The problem with Type 2 in recent years has been the Type 2 
vaccine-derived polioviruses from the trivalent vaccine.  Once that is removed, it is not 
anticipated that this will be as serious a problem.  Routine immunization rates must be raised as 
much as possible worldwide. 
 
Dr. Romero emphasized that this has been a Herculean effort that has been shepherded and 
led by Dr. Kew, who deserves a lot of credit for assembling these data. 
 
Given that it is stored in laboratories throughout the US, Dr. Smith wondered how the infectious 
material is destroyed, where this is done, and whether it has to be shipped. 
 
Dr. Kew responded that the virologists and microbiologists are well-trained in how to destroy 
poliovirus.  They simply put it in the autoclave and it is destroyed.  All of the laboratories have 
autoclaves, which allows them to destroy the virus readily.  There are a number of other ways 
as well.  The greater challenge has been to destroy the trivalent OPV stocks so that they are 
never used again in the field. 
 
Dr. Cohn requested that someone discuss the plan to address the serology alternative 
approach. 
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Mona Marin indicated that an effort is being made to assess the scope of this problem.  There 
has been informal contact with companies that have been providing this service.  There are 
certain state laboratories that also have been providing it.  The second part is understanding the 
degree to which that particular element in Table 14 in the General Recommendations has been 
incorporated into either local regulations or even in the case of some federal facilities.  
Currently, they are at the data gathering stage trying to understand the scope of this problem in 
terms of providing that service and the impact to state, local, and federal institutions due to 
using this particular element of the General Recommendations.  At that point, it is anticipated 
that the change would be proposed to remove it. 
 
Dr. Koger indicated that post-ACIP vote on CDC clearance in September 2015, the language 
was taken out to offer serology as an alternative approach.  Revaccination is now the primary 
approach per the CDC-level cleared draft of the General Recommendations for people 
vaccinated outside of the US who enter the US with questionable records.  This is going through 
clearance currently, so at least from an implementation perspective, that language should be 
published soon. 
 
Dr. Sun (FDA) asked whether the long-range plan was to continue with polio vaccination until 
eradication, or if there is an anticipation that vaccination of laboratory workers would be 
continued just in case they are exposed. 
 
Dr. Kew replied that the long-term plan would be to use IPV for an indeterminate period of time, 
and assess the risks moving forward.  There is no date set for the cessation of IPV use.  It may 
simply become part of a multi-antigen vaccine that is used for many years.  Some countries 
have stated that they will be using IPV indefinitely, depending upon its availability and a number 
of other factors.  Continued use will depend upon the epidemiology moving forward. 
 
 
 
Introduction 
 
Allison Kempe, MD, MPH 
Chair, ACIP HPV Vaccines WG  
 
Dr. Kempe reminded everyone that the WG has been reviewing evidence on HPV vaccine 2-
dose schedules.  During the February 2016 ACIP meeting, the HPV session focused on data 
from the 2-dose immunobridging trial.  The June 2016 session provided further evidence 
needed for consideration of a 2-dose HPV vaccination schedule that the WG hoped would result 
in a vote during the October ACIP meeting. 
 
During the February 2016 meeting, background information was provided on 2-dose schedules; 
data were presented from the 9-valent HPV vaccine 2- versus 3-dose immunogenicity trial, 
which showed non-inferior immunogenicity with 2 doses using either a 0, 6 month or 0, 12 
month schedule in 9 through 14 year olds compared with 3 doses using a 0,2,6 month schedule 
in 15 through 26 year olds.  Subsequently, a sBLA was submitted to the FDA in early 2016.  
Bivalent and quadrivalent HPV vaccine 2- versus 3-dose immunogenicity data and HPV WG 
plans also were presented at the ACIP meeting in February 2016. 
 
Human Papillomavirus (HPV) Vaccines 
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Since February 2016, the WG has reviewed data on duration of protection after HPV 
vaccination and on post-licensure effectiveness studies, drafted policy questions, conducted a 
systematic literature review and completed initial GRADE evaluation of evidence for 2-dose 
schedules, and discussed considerations for recommendations. 
 
During this session, presentations were given on the following topics: 
 
 
 
 
 
 
Duration of protection after HPV vaccination 
Modeling and cost-effectiveness of 2-dose schedules 
Review of vaccine effectiveness studies 
GRADE for 2-dose schedules 
Initial considerations for recommendations 
 
HPV Vaccine Availability in the US / HPV Vaccine Duration of Protection 
 
Lauri Markowitz, MD 
National Center for Immunization and Respiratory Diseases  
Centers for Disease Control and Prevention 
 
Dr. Markowitz began by mentioning the status of HPV vaccine availability in the US since this 
would impact some of ACIP’s discussions and approaches.  There are 3 HPV vaccines licensed 
in the US:  Quadrivalent (4vHPV), bivalent (2vHPV), and 9-valent (9vHPV).  Through 2014, 
almost all HPV vaccine used in the US was 4vHPV.  9vHPV was licensed in 2014 and was 
recommended in 2015.  Currently, almost all vaccine being ordered in the US is 9vhpv.  As 
expected with the transition from 4vHPV to 9vHPV, Merck has decided to withdraw 4vHPV from 
the US market by the end of 2016.  4vHPV has not been on CDC vaccine contracts since April 
2016.  Regarding 2vHPV, GSK has made a strategic business decision to stop supplying 
2vHPV in the US due to very low market demand.  Vaccine supplies in the US are expected to 
be used up by November 2016.  2vHPV has not been on CDC vaccine contracts since April 
2016.  GSK will maintain the 2vHPV license in the US.  4vHPV and 2vHPV will continue to be 
available outside of the US.  While by the end of the year all vaccine being used in the US will 
be 9vHPV, during this session the WG presented data on 4vHPV and 2vHPV for two reasons:  
1) data from these studies provide information that can inform the discussion about 2-dose 
schedules; and 2) millions of persons have been vaccinated with 4vHPV in the US. 
 
Dr. Markowitz reviewed data on duration of protection.  HPV vaccination is targeted to young 
adolescents to achieve protection of the largest percentage of vaccinees before exposure to the 
virus, but protection is needed through many years of sexual activity.  Therefore, long duration 
of protection from HPV vaccination is important and duration could impact the effectiveness of 
vaccination programs.  It is important to review available data on duration of protection for a 3-
dose vaccination schedule as ACIP considers reducing the number of recommended doses.  
Another reason the WG presented these data at this time was because the modeling of 2 
versus 3 doses examines different assumptions of duration of protection; understanding 
available t data on duration is needed to put the modeling into context. 
 
In this talk, Dr. Markowitz provided an update on what is known about duration of protection 
from 3-dose HPV vaccines trials as well as immunogenicity data, including persistence of 
antibody and challenge studies to evaluate immune memory by anamnestic response to an 
additional vaccine dose.  She also reviewed some data on persistence of antibody from 2-dose 
trials that were presented in February 2016. 
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Briefly as background, all available HPV vaccines are virus-like particle vaccines made from the 
L1 major capsid protein of the virus.  Vaccines differ in their production system and adjuvants. 
For the bivalent vaccine, the adjuvant is AS04, which includes MPL (3-O-desacyl-4'-
monophosphoryl lipid A) which stimulates Toll-like receptor 4 and enhances the vaccine induced 
immune response.  The adjuvant for quadrivalent and 9-valent vaccines is amorphous 
aluminum hydroxyphosphate sulfate. 
  
Data available on duration of protection that Dr. Markowitz reviewed during this session were 
from follow-up of randomized clinical trials.  Most efficacy and immunogenicity trials had about 3 
to 4 years of follow-up.  At the end of most of these trials, the control group was vaccinated.  
Extended follow-up for persistence of antibody and infection / disease outcomes was conducted 
for some trials after the original or base trial period was completed. 
 
The following table lists trials that have data on long-term duration of protection after a 3-dose 
schedule.  Included on this table are trials of monovalent HPV 16 vaccine, 2vHPV, and 4HPV: 
 
Base Trial 
Long term  
follow-up  
available (planned)  
Trial Participants age  (yrs) 
Trial 
duration 
(yrs) 
Reference  
HPV16 phase II efficacy Females 16–23  4 Koutsky, NEJM 2002 
Mao, OBGYN 2007 
   
8.5 
 
2vHPV Phase II efficacy Females 15–25   2.3  Harper, Lancet 2004     
8.9 
 
4vHPV immunogenicity Females/males 9–15 3 Reisinger, PIDJ 2007 10   
 
4vHPV phase III efficacy  Females 15–26  4 Future II, NEJM 2007 10 (14) 
4vHPV phase III efficacy Males 16–26  3 Giuliano, NEJM 2011 
Palefsky, NEJM 2011 
  8.5 (10) 
4vHPV phase III efficacy Females 24–45  4 Castellsague,  
Br J CA 2011 
  7.2 (10)  
 
For the base or original trial shown on the left is the type of trial, population, age group at time of 
vaccination, and the duration of the study in years.  The last column, on far right, shows the 
long-term follow-up period with the years of follow-up available and for those not completed, 
with the longest planned follow-up time in parentheses. 
 
The monovalent HPV 16 vaccine trial was a proof-of-concept Phase II trial in women aged 16 
through 23 years conducted by Merck.  At final follow-up, the mean time since first dose was 8.5 
years.  Enrollment for the original or base RCT was conducted in 1998-1999 and included over 
2000 women.  Vaccine efficacy against HPV 16 persistent infection was 94%, and was 100% for 
cervical intraepithelial neoplasia (CIN).  The final follow-up included 290 participants from 
Seattle.  During the follow-up period, vaccine efficacy for HPV16 infection was 100%.  There 
were no cases of HPV 16-related infection in the vaccine group and 6 in the control group.  
There were no cases of HPV 16-related CIN in the vaccine group and 3 in the control group. 
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The 2vHPV Phase II trial among women aged 16 through 23 years had long-term follow-up with 
a mean of 8.9 years.  The base trial was initiated in 2001 and included over 1000 participants.  
Vaccine efficacy for HPV 16/18 persistent infection was 100%.  Several follow-up evaluations 
were conducted.  The final follow-up included participants from Brazil.  This study found vaccine 
efficacy for HPV 16/18 infection was 100% during the follow-up period.  There were no 
HPV16/18 infections in the vaccine group and 9 in the control group.  There were no cases of 
HPV 16/18-related CIN in the vaccine group and 1 case in the control group.  Several different 
follow-up periods were investigated for this study.  VE was 95.6% [Naud, Human Vaccin 
Immunol 2014]. 
 
The four 4vHPV trials had no unvaccinated control group during follow-up; therefore, there will 
be no efficacy determination in the follow-up studies.  The results are disease detection and 
incidence. The 4vHPV immunogenicity trial in adolescents 9 through 14 years of age has 
completed the planned 10 year follow-up.  The base RCT included sexually naïve boy and girls.  
Follow-up for effectiveness began after age 16 and there was twice yearly evaluation.  The 
population and the median follow-up time for the early and the catch-up vaccination groups 9.9 
years and 7.4 years, respectively.  The final 10 year follow-up data from this study were 
presented in June at an international meeting.  There were no cases of HPV 6,11,16,18 disease 
in the per protocol population during the follow-up period.  Ten persistent infections of >6 
months duration, including 2 of >12 months duration, were detected.  All participants with 
persistent infection had antibody to the respective type, and there was no correlation between 
the persistent infection and waning titers for that HPV type.  Incidence of persistent vaccine type 
infection per 100 person years ranged from 0.3 to 0.6.   For comparison, the incidence of 
persistent 6/11/16/18 infection in the placebo group of trials in 16 through 26 year olds was 
more than 10-fold higher, with males 6/100 person-years and females 4/100 person-years. 
 
For the large 4vHPV efficacy trial in women 16 through 23 years of age, interim 10-year follow-
up data are available.  This study will be completed after 14 years of follow-up.  The base RCT 
included 12,000 women from 13 international sites.  Follow-up is being conducted through the 
Nordic Cancer Registries, which includes women enrolled from Demark, Iceland, Norway, and 
Sweden.  Registry searches are done every 2 years.  Disease detection was very low.  There 
was one case of CIN1 at 6 to 8 years after vaccination.  HPV types 16, 45, and 52 were 
detected in the lesion concurrently. 
 
The 4vHPV efficacy trial in males age 16 through 26 years now has 8 years of follow-up.  The 
base RCT included over 4000 men from 18 countries.  Annual visits are being conducted 
among men enrolled in long-term follow-up, including anal cytology for men in the MSM sub-
study.  There have been no cases of HPV 6,11,16,18 genital warts or external genital lesions in 
the per protocol population in the early vaccine group.  There was one case of anal 
intraepithelial neoplasia (AIN)1, with HPV 6 and 58 detected in the lesion concurrently.  Again, 
there is no unvaccinated control group, but the risk of AIN was 0.3/100 person years at risk.  As 
an historical comparison, the risk of AIN was 5.8/100 person-years in the placebo group of the 
base study. 
 
In a follow-up of the 4vHPV efficacy trial in women 24 through 45 years of age, interim data 
through 7.2 years of follow-up are available.  This was an RCT that included women from 7 
countries.  Follow-up is being conducted among women enrolled from Columbia with evaluation 
every 2 years.  There were no cases of HPV 6,11,16,18 external genital lesions or CIN2+ in the 
per protocol population during the follow-up to date. 
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In addition to the studies just reviewed, there are other trials with long-term follow-up planned or 
ongoing but that do not yet have data.  These include two 2vHPV Phase III efficacy trials 
(PATRICIA and the Costa Rica Vaccine trial), with planned follow-up of 14 and 10 years,  
respectively, the 9vHPV Phase III efficacy study with planned follow-up of 14 years, and the 
9vHPV immunogenicity study in adolescents with planned follow-up of 10 years. 
 
Dr. Markowitz briefly reviewed what is known about the immunogenicity of HPV vaccines. There 
is high seroconversion after vaccination: >97% in the clinical trials at one month after the third 
dose.  Vaccination induces higher antibody titers than natural infection.  Titers peak at 1 month 
after the last dose, decline, and then plateau by 18 to 24 months.  The main basis of protection 
is neutralizing antibody.  However, the minimum protective antibody threshold is not known.  
The predominant response to vaccination is neutralizing immunoglobulin G (IgG) antibody.  It 
also is important to know that the clinical trials of the 2vHPV and 4vHPV vaccines used different 
serologic assays and results are difficult to compare across studies or HPV types.  The 2vHPV 
trials used an enzyme-linked immunosorbent assay (ELISA), which measured both neutralizing 
and non-neutralizing antibody but detects antibody to one immunoglobulin class.  The trials for 
the 4vHPV and 9vHPV vaccine used a competitive Luminex® immunoassay (cLIA), which 
measures antibody restricted to one neutralizing epitope.  In clinical trials, some 4vHPV 
vaccinees lost detectable HPV 18 antibody by the cLIA, but there was no loss of protection.  In a 
direct head-to-head comparison of the two vaccines using the same assay, antibody titers were 
higher after 2vHPV than 4vHPV vaccination. 
 
Many of the trials have or are following participants for persistence of antibody in addition to 
infection or disease outcomes.  Shown here are the monovalent and 4vHPVtrials with long-term 
available or planned follow-up for persistence of antibody:  
 
Base Trial Follow-up 
Trial Participants  (yrs) 
Yrs available 
(planned) Seropositive for 6,11,16,18 Reference  
HPV 16 phase II 
efficacy  
Females 16–23  8.5   86% seropositive for 
HPV 16 in vaccine 
group; 9% in placebo  
Rowhani-Rahbar, Vaccine 2009 
4vHPV 
immunogenicity  
Females/Males 9–15 
  
10  89%, 89%, 96%, 61% Das and Saah 
EUROGIN 2016 
4vHPV phase III 
efficacy 
   
Females 16–23  9 (14) 94%, 96%, 99%, 60% Nygard, Clin Vaccin Immunol 
2015 
4vHPV phase III 
efficacy 
  
Males 16–26  6 (10) 84%, 87%, 97%, 48% Das and Saah 
EUROGIN 2016 
4vHPV phase III 
efficacy  
Females 24-45 8 (10) 89%, 89%, 96%, 61% Das 
EUROGIN 2015  
 
On the left is the base trial with the participant age group, and on the right is the follow-up  
available with the planned number of years in parentheses.  These trials have planned follow-up 
up to 10 or 14 years.  Also included is a summary of the results at the latest follow-up time point.  
The monovalent vaccine trial followed women for 8.5 years.  At that time, 86% were positive to 
HPV 16 in the vaccine group compared to 9% in the placebo group.  For the 4vHPV 
immunogenicity trial in adolescents, the 10 year follow-up is complete as mentioned before.  At 
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10 years, seropositivity was 89%, 89%, and 96% for HPV 6, 11, and 16, respectively, and 61% 
for HPV 18.  Similar patterns were observed in the follow-up of other 4vHPV trials with high 
seropositivity to 3 vaccine types, and lower for HPV 18.  Although some persons lost detectable 
HPV 18 antibody by cLIA in the 4vHPV clinical trials, there was no breakthrough disease.  Since 
efficacy remained high, this suggests that protective levels are lower than the minimum 
detectable level by the assay or that antibodies against additional epitopes can be protective.  
When sera in these trials were retested using a total IgG assay, seropositivity to all types 
increased and seropositivity to HPV 18 reached 78% to 90%. 
 
The following table shows 2vHPV trials with long-term follow-up for persistence of antibody: 
  
Base Trial Follow-up 
Trial Participants 
(yrs) 
Yrs available 
(Planned)  
Seropositive for 
16,18 
Reference 
2vHPV 
Immunogenicity1  
Females 10–14 10  100%, 100%  Schwarz, 
WSPID 2015 
2vHPV Phase II 
efficacy2 
Females 15–25  9 100%, 100%  Naud, Hum Vaccin Imm 2014 
2HPV 
Immunogenicity3 
Females 15–55   6 (10) 100%, 97%  Schwarz, 
BJOG 2014 
 
The assay used for these studies was an ELISA.  The longest follow-up available is 10 years 
from the adolescent immunogenicity study shown on first line.  All participants in the follow-up 
remained seropositive for HPV 16 and 18.  HPV 16 and 18 GMTs were 53- and 26-fold higher 
than those associated with natural infection.  Similarly, in the other studies with 9 and 6 years of 
follow-up, all vaccinees remained seropositive to HPV 16 and >97% to HPV 18. 
 
Three studies have assessed immune memory by evaluating immune response after 
administration of an additional vaccine dose after completion of the 3-dose series.  In the 
monovalent HPV 16 vaccine study, this was at 8.5 years after enrollment into the base study in 
the 4vHPV trial, 5 years after, and in a 2vHPV vaccine trial 7, years after.  In all studies, an 
anamnestic response was observed to the types in the original vaccination [1Rowhani-Rahbbar, 
J Clin Virol 2009; 2Olsson, Vaccine 2007; and 3Moscicki, Vaccine 2002]. 
 
Data are or will be available from trials of 2-dose schedules.  The following table has results 
from 9vHPV 2-dose trial presented to ACIP in February 2016:  
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As shown in the lighter bars, the GMTs in girls who received 2 doses at 0,6 months were non-
inferior and in fact higher than the titers in women (shown in red) who received the standard 3 
dose schedule for all 9 types. 
  
The 9vHPV 2- versus 3-dose immunogenicity data, which was presented to ACIP in February 
2016 included data 1 month after the last dose.  This trial will continue for 2 more years for 
assessment of antibody persistence.  One additional dose will be given at month 36 to access 
immune memory.  A separate long-term effectiveness study is being planned. 
 
While there are data only through 1 month after the last dose from the 9vHPV trial , there are 
longer follow-up data from studies of 2vHPV and 4vHPV trials that show that the kinetics of the 
antibody response of a 2-dose schedule when given at an interval of at least 6 months is similar 
to that of a 3-dose schedule.  This graphic was shown to ACIP in February 2016 and displays 
GMTs after 2vHPV vaccination in a 2-dose schedule (0, 6 months) at 9 through 14 years of age 
and a 3-dose schedule at 15 through 25 years of age: 
  
 
 
Follow-up in this study is through 60 months.  All subjects remained seropositive for HPV 16 
and 18.  The lines on the graph in orange and blue are superimposed as the GMTs and kinetics 
of antibody was similar in the 2- and 3-dose groups. 
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Similarly, for 4vHPV, this graphic was shown to ACIP in February 2016 and displays antibody 
after 4vHPV vaccination after 2-doses at 9 through 13 years of age and a 3-doses at the same 
age and at 16 through 26 years of age: 
  
 
 
Follow-up in this study was though 36 months.  For HPV 16, the general kinetics of the antibody 
response and persistence are similar for 2 doses in girls (in black), 3 doses in girls (in red), and 
3 doses women (in green). 
 
In summary, there is no evidence of waning protection after a 3-dose schedule.  Data are 
available through approximately 10 years for 2vHPV and 4vHPV.  Longer follow-up through 14 
years is ongoing in some studies.  Antibody responses are maintained over time after a 3-dose 
schedule.  Data are available through approximately 10 years for 2vHPV and 4vHPV.  Longer 
follow-up through 14 years is ongoing in some studies.  Waning of detectable antibody to HPV 
18 by cLIA in 4vHPV vaccinees is not associated with loss of protection.  Long-term protection 
data are not available yet from 2-dose trials.  Antibody kinetics are similar with 2vHPV and 
4vHPV 2-dose schedules, with an interval of > 6 months between doses, in adolescents 
compared with standard 3-dose schedule in women. 
 
Modeling and Cost-Effectiveness of 2-Dose Vaccination Schedules 
 
Marc Brisson, PhD 
Canadian Research Chair Modeling Infectious Diseases 
Professor, Université Laval 
 
Dr. Brisson reported that a 2-dose 9-valent vaccine Phase III immunogenicity trial has been 
completed.  In this trial, 2 doses of 9-valent in girls and boys 9 through 14 years old was shown 
to be as immunogenic as 3 doses in women 16 through 26 years old.  The cost-effectiveness 
study question the investigators were given was: 
 
From the societal perspective, what is the health and economic impact of switching from 
a 3- to a 2-dose schedule, in the context of an established 9-valent HPV vaccination 
program in the US? (i.e., what is the additional impact of the 3rd dose of 9-valent 
vaccine vs. 2 doses?) 
 
The objective of the study was to evaluate the population-level effectiveness and cost-
effectiveness of 3- versus 2-dose 9-valent vaccination in the US.  To do this, the investigators 
used a model called HPV-ADVISE.  HPV-ADVISE was previously developed by Dr. Bisson’s 
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group to answer HPV vaccination policy decisions in Canada and the US, and also has been 
used in the UK and Australia.  The model is an individual-based transmission-dynamic model.  
What must be understood is that this model takes into account the direct effects of vaccination 
on vaccinees, but also takes into consideration herd immunity effects.  The model includes 6 
important components:  
 
 
 
 
 
 
 
Demographics, with individuals of different age groups 
Sexual behaviour and HPV transmission between individuals 
Natural history of HPV-related diseases 
Vaccination  
Screening and treatment of cervical lesions and cervical cancer 
Economic  
 
The population is open, stable, and includes individuals 10 to 100 years of age.  Eighteen 
genotypes are modeled individually, including the 9 types in 9vHPV 
(6/11/16/18/31/33/45/52/58).  Also included are different HPV-related diseases:  Anogenital 
warts, cervical cancer (SCC and adenocarcinoma), and cancers of the anus, oropharynx, penis, 
vagina, and vulva [Brisson et al. JNCI 2016 108(1) doi:10.1093/jnci/djv282]. 
 
This is a quite complex model, but it does not mean anything unless the model is fit to data and 
parameterized appropriately.  In order to do a model of predictions, the first 50 parameter sets 
were identified that fit to highly stratified data from the US.  The following graphic is an example 
of the model fit to sexual behavior data from the US: 
 
 
 
In the above example, the dots represent the data and the boxes represent the variability and 
predictions of the 50 parameter sets.  Model fits also were done for HPV prevalence in women 
stratified by type, age, and number of sexual partners; screening outcomes such as the 
incidence of high grade cervical lesions; and disease outcomes such as cervical cancer. 
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Once the parameters sets were identified and the model was programmed, the analysis was 
performed.  The economic analysis was done from the societal perspective.  The costs included 
all direct medical costs in 2013 US dollars.  The main outcome was the usual outcome in health 
economics of cost per QALY gained.  Future benefits and costs were discounted at 3%, the time 
horizon was 100 years, and the vaccine cost per dose assumption was $158 with administration 
costs. 
 
In these predictions, the investigators modeled not only the decisions of 3 versus 2 doses 
prospectively, but also the policy decisions made in terms of HPV vaccination in the US.  In 
these models, vaccination was begun in 2007 with a girls-only 4vHPV program.  In 2011, there 
was a switch to a 4vHPV program vaccinating boys and girls.  In 2015, there was a switch to a 
9vHPV program vaccinating boys and girls.  This is followed by a policy question that regards 
whether to continue with a 9vHPV 3-dose program, or to vaccinate with a 9vHPV 2-dose 
program.  The model prediction compares these two scenarios.  To do this, vaccination 
coverage is also needed.  For vaccination coverage, age-specific uptake rates were used.  For 
2007-2014, observed uptake rates were used from the US National Immunization Survey (NIS).  
For 2015 onward, uptake rates were assumed to be constant at 2014 levels. 
 
In terms of vaccine characteristics, it is known that if efficacy and duration are similar, 2 doses 
will be cost-saving compared with 3 doses.  This means that both the 2-dose and 3-dose 
schedules would be equivalent in terms the health outcomes they would prevent, but the 2-dose 
schedule would be cheaper.  Therefore, the analysis examined the potential impact if 2 doses 
provided lower or equal efficacy or shorter or equal duration of protection than 3 doses.  So, in 
the scenarios, the 3-dose scenario was fixed.  That is, 3 doses were assumed to provide lifelong 
protection, vaccine efficacy of 95% was used, and observed vaccine coverage was used.  
Numerous 2-dose scenarios were used, including lifelong protection versus durations of 30, 25, 
20, and 15 years; a scenario of 95% versus 85% efficacy; and observed vaccination coverage 
versus a 5% to 15% percentage point increase.  That is, a scenario was examined in which 
switching to a 2-dose vaccination schedule would lead to an increase in vaccination coverage. 
 
Dr. Brisson presented two outcomes from these models:  population-level effectiveness and 
cost-effectiveness.  In terms of population-level effectiveness the key question was, “What 
vaccine characteristics are most important when considering reducing doses?”  This refers to 
the characteristics that are most desired when switching from 3 doses to 2 doses.  Sensitivity 
analyses were performed.  The first assessed the impact of vaccine efficacy assumptions on the 
model predictions of effectiveness.  In this scenario, it was assumed that vaccine duration is 
lifelong.  The two outcomes assessed were anogenital warts and cervical cancer.  For both 
vaccine efficacy scenarios, 85% and 95%, important reductions are predicted in anogenital 
warts and cervical cancer over time.  The differences in population-level effectiveness between 
scenarios are quite small due to the fact that these differences in vaccine efficacy are 
counterbalanced by herd immunity effects.  With respect to a 3-dose versus a 2-dose strategy, 
this suggests that if a 3-dose schedule provides 95% efficacy and in a worst case scenario a 2-
dose schedule provided 85% vaccine efficacy, there still would be very little difference in 
population-level effectiveness of 85% versus 83% respectively. 
 
In terms of the impact of duration of vaccine protection on the model predictions, vaccine 
duration of protection has a greater impact than vaccine efficacy.  If vaccine efficacy is 
presumed to be 95% in the two outcomes of anogenital warts and cervical cancer, even with 15 
years of duration of protection, there are substantial reductions in anogenital warts (53%) and 
cervical cancer (71%).  It also is important to understand that once a duration of protection of 20 
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to 25 years is reached, any benefits of increases in duration of protection beyond 20 to 25 years 
are very small.  This can be shown by the following figure which shows predicted health 
outcomes prevented over 100 years with different assumptions of duration of protection with 
vaccine efficacy predicted of 95%, a population of 300 million that is similar to the US, and 
undiscounted results: 
 
 
 
What the above figure shows is that if the duration of protection is assumed to be 15 years, 
there would be substantial reductions in all cancers related to HPV, with over 1.2 million cancers 
averted through vaccination over 100 years of duration.  If the duration is 20 to 25 years, there 
would be increases in the predicted number of events that are averted, but once that range of 
vaccine protection is reached, the additional benefits are very small.  In terms of 3 doses versus 
2 doses and the worst case scenario in which the 3-dose duration is lifelong and the 2-dose 
duration is 20 years, there would be very little difference in the number of cases that would be 
averted between the two scenarios.  The reason this is the case is that most HPV infections are 
acquired between the ages of 17 through 30.  If a vaccine is able to protect individuals during 
these key ages of peak sexual activity, it is doing a good job. 
 
Therefore, duration of vaccine protection is quite important to population-level effectiveness.  In 
terms of cost-effectiveness, this means that the key question is, “What is the cost-effectiveness 
of 2-dose and 3-dose vaccination for different assumptions of duration of protection?”  In this 
analysis, 3-dose duration of protection was fixed at lifelong.  The population is similar in size to 
the US.  The first results regard the cost-effectiveness of 2 doses versus no vaccination.  In all 
scenarios examined for 2-dose duration of protection, 2-dose schedules are cost-savings versus 
no vaccination.  This means that it produces QALYs gained, or health benefits, and saves costs.  
The second result is from a comparison of the cost-effectiveness of receiving 3 versus 2 doses, 
in which 2-dose and 3-dose duration were presumed to be lifelong.  In this case, the cost-
effectiveness of the third dose is dominated because while saving money by going to a 2-dose 
schedule, there is no change in benefits.  The other question is, “What is the impact of the cost 
effectiveness of a third dose versus two doses depending on the duration of the protection of 
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two doses?”  The results suggest that if a duration of protection of 2 doses is at least 20 years, 
the cost-effectiveness ratios of giving the third dose are quite high. 
 
Regarding the sensitivity analysis to influential variables, scenarios were assessed in which 
giving a 2-dose schedule would facilitate an increase in coverage of 5%, a 2-dose schedule 
would lead to a 15% increase in coverage, and a scenario in which 2-dose efficacy is lower than 
a 3-dose.  In the base case, it was assumed that screening is cytology-based, but an 
assessment also was done in which a screening program is co-testing.  Then the sensitivity 
analyses are varied to economic parameters.  The first results pertaining to the cost-
effectiveness of 2-dose vaccination compared to no vaccination; in most of the scenarios, even 
if it is assumed that 2-dose protection lasts for 20 years, a 2-dose strategy is cost-saving versus 
no vaccination.  There are certain exceptions, but even in these exceptions, the cost-
effectiveness ratio is very low.  The second result pertains to the cost-effectiveness of 3 versus 
2 doses, in which both schedules provide lifelong protection.  In all of the scenarios, the 3-dose 
schedules are dominated by 2-dose schedules except one in which it was assumed that 2-dose 
vaccine efficacy was lower than 3-dose vaccine efficacy.  Even in this scenario, the cost-
effectiveness ratio for 3-dose vaccination is quite high.  Finally, a worst case scenario was 
assessed in which 2-dose duration of protection was 20 years and 3-dose protection was 
lifelong.  For most scenarios, the results vary at around $100,000 / QALY gained.  In terms of 
switching to a 2-dose strategy with higher coverage, in this scenario the model predicts that if 
vaccination coverage can be increased by moving to a 2-dose strategy, this would provide equal 
or additional gains than a 3-dose strategy.  Therefore, the 3-dose strategy would be dominated. 
 
In terms of limitations, two are related to uncertainty.  The first is that a duration of 2-dose and 
3-dose 9-valent vaccine efficacy and future vaccination coverage remain unknown.  This is why 
duration of protection and vaccination coverage were varied in these analyses.  Duration of 
protection and coverage assumptions have an important impact on conclusions.  The second 
uncertainty is that screening may change in the coming years, which may modify the incidence 
of lesions and cervical cancer.  While both cytology-based screening and HPV co-testing were 
modeled, the screening method did not impact the conclusions. 
 
This is the first effectiveness and cost-effectiveness analysis of 2- versus 3-dose vaccination 
with 9vHPV in the US or elsewhere.  Thus, it is very difficult to compare the results with other 
studies.  Nevertheless, the conclusions are consistent with a 4vHPV effectiveness and cost-
effectiveness analyses in Canada and the UK[1,2] and recently an Australian study.  In these 
studies, the conclusion is that 2 doses must protect for more than 20 years for the third dose to 
be cost-ineffective [1Laprise Vaccine, 2014; 2Jit BMJ, 2015]. 
 
In summary, the incremental health benefits and cost-effectiveness of a third dose of HPV 
vaccine depends upon relative duration of efficacy provided by 2 versus 3 doses.  A 2-dose 
vaccination schedule is predicted to reduce HPV-burden of disease substantially and is cost 
saving if 2 doses provide protection for greater than 20 years.  A 3-dose vaccination is predicted 
to have a high cost per QALY gained of greater than $118,000 compared to 2-dose vaccination, 
except when 2-dose protection is less than 20 years.  A 2-dose vaccination will provide similar 
population-level health benefits to 3-dose vaccination, unless 2 doses provide shorter duration 
of vaccine protection and 2-dose schedules do not enable higher vaccination coverage. 
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Discussion Points 
 
Dr. Messonnier asked whether cost-effectiveness was assessed if the cost per dose in a 2-dose 
regimen is higher than the cost per dose in a 3-dose schedule. 
 
Dr. Brisson responded that this was not assessed, and he felt uncomfortable defining a cost 
where it would be better to stick with a 2- versus 3-dose strategy.  However, this can easily be 
done.  There is a price at which a 2-dose strategy would not be cost-effective. 
 
To build upon that, Dr. Bennett asked how much of the costs are actually the cost of the vaccine 
and how much are other costs (administration) such that even if the cost of the vaccine 
increased, it might still be cost-effective for 2 doses. 
 
Dr. Brisson replied that if both schedules are equally effective, the cost per dose would have to 
increase substantially not to be cost-effective or dominate the 3-dose scenario.  It is up to the 
companies, but they may vary their vaccine costs.  That is a key question. 
 
Regarding the antibody kinetics of 9vHPV versus 4vHPV, Dr. Stephens asked whether it was 
anticipated that there would be equivalent 9vHPV data at least for the types that are in both 
vaccines. 
 
Dr. Markowitz replied that this is the assumption since the monovalent, 2vHPV, and 4vHPV 
trials have all shown the same pattern of an antibody peak one month after the last dose 
followed by a plateau.  The data available are only for one month past the last-dose, but more 
data should be available soon that would include a later time point to assess whether that is 
true.  She called upon a representative from Merck to address this. 
 
Dr. Luxembourg (Merck) responded that additional data would be available for Months 25 and 
36 by the end of 2017.  Regarding whether the 9-valent has similar immunogenicity, so far for all 
studies measured, no substantial differences have been found in immunogenicity between the 
vaccines.  Therefore, it is a reasonable to assume that it will be the same. 
 
Dr. Kempe acknowledged that duration of protection is the most important aspect of modeling, 
but the other thing that they tried to vary was the percentage of potential increase in 
immunization.  She wondered whether data are available from the countries that have made the 
switch from 3 to 2 doses and if changes in uptake greater than 15% have been observed. 
 
Dr. Markowitz responded that many of the countries that have switched have school-based 
vaccines so the impact of changing from a 3-dose to a 2-dose schedule on coverage might not 
be relevant to the US situation.  An effort is being made to acquire data to find out what is 
occurring.  Some countries in Europe have clinic/primary care-based vaccination programs and 
there may be some data available from those programs. 
 
Regarding vaccination coverage and trends over the 100 year time period, Dr. Thompson 
(NVAC) wondered whether it would be cost-effective to give 9vHPV vaccine to those who 
already received 2vHPV or 4vHPV. 
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Dr. Brisson replied that in terms of the assumptions regarding coverage based on observed 
rates, from 2000 through 2014, they used the percent of coverage with 3 doses only.  That was 
predicted into the future, so for 2015 onward those would be the assumptions if the uptake rates 
remain the same.  When the 2-dose schedule was modeled without any increase in coverage, 
the same assumptions about coverage were used.  When a predicted increase in vaccination 
coverage was modeled with a 2-dose program, it was cost-saving.  Regarding revaccination of 
those previously vaccinated with 2vHPVt and 4vHPV, Dr. Chesson has published a paper on 
that in which this question was assessed with 3 doses with the HPV-ADVISE model and with a 
CDC model.  The cost-effectiveness ratios were quite high.  In terms of the results with 2 doses, 
a sensitivity analysis was performed. 
 
Dr. Chesson added that the result for 2 doses was approximately $100,000 per QALY to 
revaccinate. 
 
Dr. Reingold suggested that if by the October 2016 ACIP meeting they were able to use this 
information to shift from a 3- to a 2-dose strategy, perhaps it would be possible to model 
pneumococcal conjugate vaccine doses shifting from 4 to 3. 
 
HPV Vaccine Effectiveness Studies  
 
Sara Oliver, MD, MSPH 
EIS Officer, Division of Viral Diseases 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
 
Dr. Oliver reminded everyone that to inform policy decisions, current evidence is being reviewed 
for 2 doses of HPV vaccine, including evidence regarding immunogenicity, efficacy, and post-
licensure effectiveness.  A previous presentation to ACIP in February 2016 reviewed data from 
HPV vaccine 2-dose immunogenicity studies and presented data from the major efficacy 
studies.  During this session, Dr. Oliver presented a systematic review of vaccine efficacy and 
effectiveness for 2 doses.  She began by searching for studies on HPV vaccine effectiveness, 
identifying 930 papers on vaccine impact or effectiveness.  Studies were selected if they 
evaluated effectiveness by number of doses.  Thirteen papers were reviewed that discussed 
vaccine effectiveness with 2 doses.  The WG reviewed these studies in detail previously.  
During this session, Dr. Oliver presented studies by vaccine and outcomes evaluated.  She 
described all 13 studies, and showed detailed data for studies evaluating outcomes by timing of 
interval between Dose 1 and Dose 2. 
 
To better understand the background of the studies presented, it is worth nothing that there are 
many methodological challenges to using post-licensure effectiveness studies within the context 
of a 3-dose program to evaluate 2-dose effectiveness.  Most vaccinees received 2 doses at a 
0,1 or 0,2 month interval.  In addition, many studies were conducted during a catch-up 
vaccination period, meaning that many females were vaccinated at ages older than current 
recommendations.  Also, the partially vaccinated population is different from those fully 
vaccinated, potentially having implications for exposure to HPV prior to vaccination and different 
sexual risk status.  However, in spite of these challenges, Dr. Oliver presented an overview of 2-
dose effectiveness studies for a complete review of the evidence and in order to highlight their 
limitations with interpretation.  No studies on 2-dose effectiveness of 9vHPV have been 
published to date, since 9-valent was licensed only recently. 
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For 4vHPV, 8 studies have been published on effectiveness by number of doses:  1 study 
evaluating effectiveness with regards to HPV infection (Sankaranarayanan Lancet Oncol 2016), 
3 studies evaluating genital warts (Herweijer JAMA 2014, Dominiak-Felden PLOS ONE 2015, 
and Blomberg Clin Infect Dis 2015), and 4 studies evaluating cervical pre-cancers (Hofstetter 
JAMA Peds 2016, Crowe BMJ 2014, Gertig BMC Medicine 2013, and Brotherton Papillomavirus 
Res 2015). 
 
The Sankaranarayanan study was a 2- versus 3-dose trial conducted in India.  Immunogenicity 
data was discussed at the previous ACIP meeting in February.  Infection outcomes also were 
reported, evaluating incident and persistent cervical HPV infections.  The study was designed 
as a cluster-randomized trial, but was stopped prior to completion, so it was analyzed as an 
observational cohort study.  Subjects were randomized to receive 3 doses or 2 doses at a 0,6 
month interval.  In addition, since the trial was stopped early, some participants received 2 
doses at a 0,2 month interval or 1 dose.  There were no persistent infections in any group.  
Overall, 2 doses at a 0,6 month interval was similar to 3 doses.  The primary limitation with 
interpretation remains that the study was designed as a randomized trial that was analyzed as a 
cohort study.  Because randomization was disrupted, there could be differences between 
groups as well. 
 
Three studies evaluated 4vHPVeffectiveness for genital warts by number of doses (Herweijer, 
Dominiak-Felden, and Blomberg).  Each study had a slightly different study population, but all 
were designed as population-based retrospective cohorts.  The conclusion of all 3 studies was 
that maximum vaccine effectiveness was noted with 3 doses.  However, all studies evaluated 
effectiveness from those partially vaccinated in the setting of a 3-dose recommendation.  The 
partially vaccinated cohort was different than the fully vaccinated cohort in that they were 
generally older at the time of vaccination and most received 2 doses at a (0,2 month) interval.  
The Blomberg study evaluated 2-dose effectiveness for genital warts by interval.  As the time 
between Dose 1 and Dose 2 increases from 2 to 6 months, the incidence rate ratio for 2 versus 
3 doses approaches 1, meaning the effect of 2 doses when given at a longer interval, 
approaches 3 doses.  This is the only effectiveness study to clearly demonstrate this effect by 
interval.  However, while the findings are of interest, the authors point out that a limited number 
of vaccinees received 2 doses at the longer interval, compared with those who received the 
shorter interval. 
 
Four studies assessed 4vHPV effectiveness for cervical pre-cancer by number of doses 
(Hofstetter, Crowe, Gertig, and Brotherton).  One was a case-control study and the other 3 were 
retrospective cohort studies.  All 4 studies concluded that maximum vaccine effectiveness was 
found with 3 doses.  However, as before, all evaluated a partially vaccinated population in the 
setting of 3 recommended doses.  Again, the partially vaccinated cohort was different than the 
fully vaccinated cohort in that they were generally older at time of vaccination and had potential 
indicators of earlier sexual exposure, including younger cervical screening, vaccinated at a 
family planning clinic, or sexually transmitted infection (STI) screening.  Most received 2 doses 
at a (0,2 month) interval. 
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The Brotherton study from Australia assessed risk reduction for cervical pre-cancer by number 
of doses and interval.  This table shows hazard ratios by number of doses and timing of the 2-
dose interval: 
 
Vaccination Time between doses Hazard Ratio 
3 doses - 0.71 (0.64–0.80) 
2 doses <6 months 1.25 (1.03–1.51) 
2 doses ≥6 months 1.05 (0.72–1.55) 
 
For 2 doses, an interval greater than or equal to 6 months had a slightly lower hazard ratio 
compared to an interval less than 6 months, but neither ratio was significantly lower than the 
unvaccinated population.  However, in this particular study, the partially vaccinated females 
were older at vaccination, younger at first cervical screening, and had a lower socioeconomic 
status (SES). The numbers were small in the 2-dose cohort, with less than 20% of vaccinees 
receiving 2 doses, and less than 5% receiving 2 doses at least 6 months apart. 
 
Moving now to 2vHPV, there have been 5 studies evaluating vaccine effectiveness or efficacy, 4 
evaluating HPV infection (Kavanagh BJC 2014, Cuschieri BJC 2016, Kreimer JNCI 201, and 
Kreimer Lancet Oncol 2015), and 1 evaluating cervical pre-cancers (Pollock BJC 2014). 
 
Two studies evaluated 2vHPVeffectiveness for HPV infection by number of doses, both 
conducting a cross-sectional study using residual cervical screening samples and registry data 
(Kavanagh and Cuschieri).  In the first study, no statistically significant risk reduction was found 
with 2 doses compared to the unvaccinated population.  However, the study noted that they 
were not powered to detect a difference for two doses.  The second study was conducted, over-
selecting for those who were partially vaccinated.  An impact was then found for 2 doses, but 
still less than the impact observed for those fully vaccinated.  However, Scotland had a 3-dose 
recommendation at the time both studies were conducted, and the partially vaccinated females 
were older at the time of vaccination than those fully vaccinated, and primarily received a 0,1 
month interval. 
 
Two published studies evaluated 2vHPV efficacy by number of doses, both as a post-hoc 
analyses of clinical trials (Kreimer 2011 and Kreimer 2015).  The first study was a post-hoc 
analysis of the Costa Rica Vaccine Trial, evaluating those who did not receive all 3 doses.  The 
second analysiscombined the data from both the Costa Rica Vaccine Trial and the PATRICIA 
trial, again evaluating those partially vaccinated.  In both studies, a high efficacy was found with 
1, 2, and 3 doses.  However, all subjects were initially randomized to receive 3 doses of HPV 
vaccine, and a small proportion were unable to complete the series, most commonly due to 
pregnancy. 
  
Advisory Committee on Immunization Practices (ACIP)                                               Summary Report                                             June 22-23, 2016 
 
 
141 
 
 
A sub-analysis from the 2015 Kreimer paper, only including data from the Costa Rica Vaccine 
Trial, evaluated efficacy by timing of a second dose.  This table shows vaccine efficacy by 
number of doses and timing of the 2-dose interval: 
 
Vaccination Interval Vaccine efficacy  (95% CI) 
3 doses* — 77.0% (74.7–79.1%) 
2 doses 1 month 75.3% (54.2–87.5%) 
2 doses 6 months 82.6% (42.3–96.1%) 
 
For comparison, the efficacy for 3 doses is shown. Of note, the 3-dose cohort includes 
participants from both the Costa Rica Vaccine Trial and the PATRICIA trial.  High efficacy was 
seen for both a 1-month and 6-month interval, with an estimate slightly higher for a longer 
interval.  However, a small percentage of study participants received the second dose after 6 
months, providing wide confidence intervals for the estimate. 
 
A final study evaluated 2vHPVeffectiveness for cervical pre-cancers by number of doses 
(Pollock).  Only females who had received a colposcopy were included in this analysis. No risk 
reduction was found with 2 doses compared to those unvaccinated.  However, the partially 
vaccinated females were older and more likely to have received their vaccination after 
graduation from school.  Most were vaccinated a 0,1 month interval and, in the setting of a 3-
dose recommendation, only a small proportion of the population received 2 doses. 
 
In summary, 13 studies evaluated 2-dose effectiveness.  Of these, 3 were post-hoc analyses of 
clinical trials and 10 were post-licensure effectiveness studies evaluating partially vaccinated 
individuals in settings of a recommended 3-dose schedule.  Additionally, 4 studies included 
evaluations of at least a 0,6 month interval. 
  
In conclusion, 3 studies found similar outcomes for 2 doses compared to 3 doses, and all 3 of 
those studies were post-hoc analyses of clinical trials.  Ten studies found 2 doses were not as 
effective as 3 doses.  However, it is important to note that all 10 were post-licensure 
effectiveness studies performed within settings of a recommended 3-dose schedule, where 
most received a 0,1 or 0,2 month interval.  Persons who only received 2 doses were different 
from those completing the series.  Several studies found the partially vaccinated females to be 
older, of lower SES, or to have earlier cervical screening—a potential indicator for earlier onset 
of sexual activity.  All of those factors have implications for exposure to HPV prior to 
vaccination.  There were 4 studies evaluated a 0,6 month interval compared to a shorter 
interval.  Of those four studies, 1 showed a longer interval was more effective.  The other 3 
studies suggest that a longer interval could impact vaccine effectiveness, but statistical 
significance was not always tested or achieved.  As mentioned previously, there are many 
methodological challenges to using post-licensure effectiveness studies within the context of a 
3-dose program to evaluate 2-dose effectiveness.  Data from these post-licensure effectiveness 
studies may not be directly applicable to the currently policy question of a 2-dose 
recommendation due to differences in age at vaccination, the interval between the 2 doses, and 
the population in the studies receiving 2 doses compared to those who received 3 doses.  
These important factors have impacted the studies included in GRADE, which are addressed in 
the next presentation. 
 
Advisory Committee on Immunization Practices (ACIP)                                               Summary Report                                             June 22-23, 2016 
 
 
142 
 
 
GRADE for 2-Dose Schedules 
 
Elissa Meites, MD, MPH 
Medical Epidemiologist 
National Center for Immunization and Respiratory Diseases  
Centers for Disease Control and Prevention 
 
Dr. Meites discussed the GRADE process for 2-dose schedules of HPV vaccine.  During this 
and the February 2016 ACIP meeting, there were discussions of various components of the 
GRADE process.  Before making an ACIP recommendation and assigning a GRADE category, 
the steps of this evidence-based method are to:  
 
 
 
 
 
 
 
 
 
 
Develop policy questions  
Consider critical outcomes  
Review and summarize evidence of benefits and harms  
Evaluate the quality of evidence  
Assess population benefit  
Evaluate values and preferences  
Review health economic data  
Offer considerations for formulating recommendations  
The WG’s main policy question was, “Should 2 doses of any HPV vaccine be recommended for 
9-14 year-olds?”  Given anticipated changes in availability, each HPV vaccine was considered 
separately.  The population of interest was girls and boys aged 9 through 14 years.  The 
intervention was 2 doses of HPV vaccine, separated by 6 to 12 months.  The comparison was 3 
doses of HPV vaccine on a standard schedule, among women in the age group in which 
vaccine efficacy has been demonstrated against infections and histopathological lesions 
associated with HPV vaccine types.  This was done in immunobridging studies.  Note that 
exploratory analyses comparing groups in the same age range of 9 through 14 years were 
considered supplemental data in this presentation.  The main outcome of interest was 
immunogenicity or antibody response to vaccine-type HPV. 
 
Most of the studies in this presentation were immunobridging studies, because the minimum 
threshold level of HPV antibodies required for clinical protection has not been established and 
might vary depending on the assay.  Data from clinical trials suggest that this minimum level of 
antibody needed for protection could be below that which is detected by current assays. 
Immunobridging studies are used to compare immunogenicity in a group of interest (for 
example, those aged 9 through 14) with a comparison group in which efficacy has been 
demonstrated in clinical trials (for example, those aged 16 through 26).  Non-inferiority criteria 
are met when the lower bound of the 95% confidence interval for the ratio comparing the two 
groups is not less than a pre-set value such as 0.5.  Immunobridging studies are the basis upon 
which HPV vaccines were originally licensed in the US for use in 9 through 15-year-olds. 
 
In terms of outcomes relevant to HPV vaccination as determined by the WG, immunogenicity is 
an early measurable effect of HPV vaccination, and a surrogate marker for prevention of other 
important outcomes such as HPV infections, genital warts, or condylomas; and critical outcomes 
including HPV-associated pre-cancers and cervical, oropharyngeal, anal, and other cancers.  
Immunogenicity outcomes are included in the evidence profile for GRADE.  These include the 
following: 
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 
 
 
Rates of seroconversion, which means having any detectable vaccine-type antibody after 
vaccination 
GMTs, which quantify antibody levels 
Antibody avidity, which measures how strongly antibody binds to its antigenic target  
 
Data on other important outcomes, including the efficacy studies reviewed in the previous 
presentation by Dr. Oliver, were considered by the WG, but were not included in GRADE 
because they did not include data on the relevant dosing interval or age range specified in the 
policy question.  To date, no data are available on the later outcomes listed as critical. 
 
For evidence retrieval, the WG conducted a systematic review of studies from PubMed and 
Clinicaltrials.gov published between 2006, when HPV vaccine was first licensed in the US, and 
June 17, 2016.  Efforts were made to obtain unpublished or other relevant data. Initial search 
terms included both: 
 
 
 
“HPV” and “vaccine,” or “HPV vaccine,” or “papillomavirus” and “vaccine,” or “papillomavirus 
vaccine,” AND 
“2-dose” or “2 doses” or “two-dose” or “two doses” 
 
Relevant studies included human subjects, primary data, and data relevant to the outcomes 
shown above for 9-valent, quadrivalent, or bivalent HPV vaccines. 
 
The search identified 117 publications listed in PubMed.  Nine relevant publications were 
reviewed in detail, and six immunogenicity studies that were non-redundant were included in the 
evidence tables.  The other 108 were excluded as 31 were not primary data (reviews, 
editorials); 57 had other outcomes (coverage, knowledge/preferences, cost-effectiveness); and 
19 assessed relevant outcomes, but did not report results by timing of doses administered or 
number of doses in the age group of interest.  In addition, 14 studies were identified that were 
registered on clinicaltrials.gov, including 1 additional relevant study with unpublished data.  This 
was the 9-valent vaccine 2-dose trial that was presented by the manufacturer during the 
February 2016 ACIP meeting.  All of the relevant immunogenicity studies and additional data 
included in GRADE were previously presented to ACIP during the February meeting. 
 
Initial evidence types in GRADE are either a type 1 for RCTs or Type 3 for observational 
studies.  For immunobridging studies, the main analyses are considered observational since it is 
not possible to randomize participants to an age group even if these studies are considered 
strong evidence.  Therefore, an evidence type of 3 is the highest possible for this type of study. 
  
For the GRADE evaluation of 9-valent HPV vaccine, the policy question was, “Should 2 doses 
of 9-valent vaccine be recommended routinely for 9 through 14 year-olds?”  Regarding the 
characteristics of included studies, one immunobridging study funded by the manufacturer that 
was submitted to FDA and was presented to ACIP in February 2016.  This study compared 2 or 
3 doses of 9-valent vaccine in girls and boys 9 through 14 years of age with 3-doses given to 
women 16 through 26 years of age.  The two doses were given at an interval 0 and 6 months 
apart, or 0 and 12 months apart, plus or minus 4 weeks.  The main immunogenicity outcomes 
from the study were seroconversion and GMTs. 
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For seroconversion, in each group of vaccinees at least 97.9% had seroconverted to all 9-valent 
vaccine types at 4 weeks post-last dose.  When comparing 2-dose girls-and-boys to 3-dose 
women, noninferiority criteria were met for all 9-valent vaccine types regardless of whether the 2 
doses were administered at a 0,6 or a 0,12 interval, and whether girls and boys were assessed 
separately.  GMTs for 9-valent vaccine types were significantly higher in the 2-dose girls and 
boys compared with the older controls.  For the finding of non-inferior immunogenicity with 2 
doses of 9-valent HPV vaccine in girls and boys compared with 3 doses in a group in which 
clinical efficacy has been demonstrated, this immunobridging study is considered observational 
and receives an initial evidence level of 3.  Evidence type was not downgraded for risk of bias, 
inconsistency, indirectness, imprecision, or any other considerations, giving a final evidence 
type of 3. 
 
For the sake of transparency, Dr. Meites mentioned additional analyses from this study that 
compared 2-doses in girls-and-boys with 3 doses in the same age group.  These analyses are 
considered exploratory or supplemental because the comparison was not with the group in 
which efficacy was demonstrated in the clinical trials and, therefore, falls outside of the 
parameters of the study question.  For seroconversion, in the first row, at least 99.2% in all the 
2-dose groups seroconverted to all 9-valent vaccine types at 4 weeks post-last dose.  GMTs 
were statistically lower in the 2-dose group for some HPV types at 4/9 for the 0,6 month group 
and 1/9 in the 0,12 month group, although formal non-inferiority comparisons were not 
performed. 
 
For quadrivalent HPV vaccine, the policy question was, “Should 2 doses of quadrivalent vaccine 
be considered adequate vaccination for 9 through 14 year-olds?”  In terms of the characteristics 
of the included studies, two published studies were identified.  Both were publically-funded 
immunobridging studies, one from Canada (Dobson) and one from Mexico (Hernandez-Avila). 
These studies compared girls in the 9 through 13 year-old age range with women in the age 
group in which efficacy was demonstrated in the clinical trials.  In both studies, the 2-doses were 
given at an interval of 0, 6.  The main immunogenicity outcomes from these studies were 
seroconversion and GMTs.  In both studies, among all vaccinees at least 97.1% were 
seropositive to all quadrivalent vaccine types at 7 months in all groups.  For GMTs, both studies 
found that when comparing 2-dose girls to 3-dose women, noninferiority criteria were met for all 
four quadrivalent vaccine types through 36 months, and GMTs for 9-valent vaccine types 
usually were significantly higher in the 2-dose groups.  For the finding of non-inferior 
immunogenicity with 2 doses of quadrivalent HPV vaccine in girls compared with 3 doses in a 
group in which clinical efficacy has been demonstrated, these two immunobridging studies are 
considered observational, and received an initial evidence level of 3.  Evidence type was not 
downgraded, giving a final evidence type of 3. 
 
Supplemental analyses of same-age comparisons from these studies were presented for 
completeness, although they were not included in the GRADE analysis.  For seroconversion, at 
least 97.2% in all the 2-dose groups were seropositive to all quadrivalent vaccine types at 
month 7.  For GMTs, the two studies had similar findings in that GMTs to quadrivalent vaccine 
types were high in all vaccinees, but relatively lower in the 2-dose girls compared with the 3-
dose girls, even though noninferiority criteria usually were met.  One study showed that 
noninferiority was lost for HPV 18 by month 18, and also HPV 6 by month 36.  However, the 
other study showed that noninferiority was not lost by the end of the study at month 21 for any 
of the quadrivalent vaccine types. 
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For bivalent HPV vaccine the policy question was, “Should 2 doses of bivalent vaccine be 
considered adequate vaccination for 9 through 14 year-olds?”  Regarding the characteristics of 
the included studies, there were 4 published studies.  There were 3 immunobridging studies 
from various countries (Romanowski, Puthanakit, Lazcano-Ponce), and 1 observational 
laboratory study (Boxus).  These studies compared girls in the 9 through 14 age range with 
women in the age group in which efficacy was demonstrated in the clinical trials.  Interventions 
included either 2 doses at an interval of 0,6 months or 0,12 months versus 3 doses on a 
standard schedule.  Main outcomes for the three immunobridging studies were seroconversion 
and GMTs, and the laboratory study assessed antibody avidity. 
 
In all three immunogenicity studies, 100% of vaccinees seroconverted to both bivalent vaccine 
types and were seropositive through Month 60.  For GMTs, all three studies found that when 
comparing 2-dose girls to 3-dose women, noninferiority criteria were met for both bivalent 
vaccine types through 60 months, and GMTs for 9-valent vaccine types were higher in the 2-
dose groups.  For antibody avidity (bivalent vaccine), there were no differences in avidity index, 
suggesting similar quality of antibody response in 2-dose versus 3-dose recipients.  For the 
finding of non-inferior immunogenicity with 2 doses of bivalent HPV vaccine in girls compared 
with 3 doses in a group in which clinical efficacy has been demonstrated, these four studies are 
considered observational and received an initial evidence level of 3.  Evidence type was not 
downgraded, giving a final evidence type of 3. 
 
Again for completeness, same-age comparisons from the graded studies in this section were 
presented.  Two studies had both a 2-dose and a 3-dose arm for girls in the same age group. 
For seroconversion in two studies, 100% of vaccinated girls seroconverted to both bivalent 
vaccine types and were seropositive through month 60 (Romanowski, Lazcano-Ponce).  For 
GMTs, one paper provided GMT results for both 2-dose girls and 3-dose girls (Lazcano-Ponce).  
At month 21, GMT ratios were lower in the 2-dose group, but noninferiority criteria were met for 
both bivalent types. 
 
In addition to benefits, the workgroup also discussed potential harms.  For AEs, the safety 
profile has been well-established for HPV vaccines, and SAEs are extremely rare.  Dr. Meites 
reiterated that in the 9-valent vaccine trial presented to ACIP and included in GRADE earlier, 
there were no serious vaccine-related adverse events.  In 2-dose cohorts, the incidence was 
zero among 883 participants, and in 3-dose controls it was zero among 616 participants.  Any 
potential AEs following a dose of vaccine, for example injection site reactions, can be expected 
to be reduced when fewer doses are given.  No data suggest that AEs would increase with 
fewer doses. 
 
In summary, for 2 doses of HPV vaccine in girls or boys age 9 through 14 years, compared with 
3 doses of HPV vaccine in a group in which clinical efficacy has been demonstrated, data were 
available on immunogenicity outcomes for 9-valent, quadrivalent, and bivalent HPV vaccines.  
All found evidence of non-inferior immunogenicity with 2 doses, and the overall evidence type is 
3.  Considerations for formulating recommendations for 2-doses of HPV vaccine include 
balances between benefits and harms, evidence type for benefits, values, and cost-
effectiveness.  In terms of benefits and harms, benefits are non-inferior and harms are reduced 
compared to 3 doses.  If benefits are expected to be similar and the potential AEs are lower, 
then the balance of benefits over harms is greater.  The evidence type for benefits was 
evidence type 3.  Regarding values, the WG placed a high value on programmatic 
considerations, as well as prevention of outcomes due to HPV vaccine types.  As discussed by 
Dr. Brisson, 2-doses are likely cost-effective compared to 3 doses.  
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Discussion Points 
 
As a matter of principle, Dr. Sun (FDA) asked whether when considering potential harm, the 
potential for infection during the period after the first dose before the second dose was 
considered.  All of the immunogenicity studies compared post-six month dose.  Theoretically, if 
one acquired infection during that interval, that could represent potential harm.  In this particular 
case, the immunogenicity of the vaccine is probably so high that this is not an issue.  
Nonetheless, that would be important to consider as a potential harm in any reduced dose 
strategies.  One can look at the boost response when the second vaccine is given at 1 month 
versus at 6 months and could compare it with the quality of the anamnestic response. 
 
Dr. Meites responded that in terms of how the WG assessed harms, several studies have 
evaluated any reported AEs after each dose—so by timing and dosing of the different vaccines.  
Comparing after dose 1, dose 2, dose 3, there was not an appreciable difference.  Dr. 
Markowitz added that the recommended age for vaccination in the US is at 11 or 12 years.  
Ideally, people would be vaccinated before risk of exposure.  The 2-dose recommendation 
would be exclusively in the younger age group based on the data being submitted to the FDA.  
This is a strong argument for vaccinating at the younger age. 
 
Recommendation Options 
 
Lauri Markowitz, MD 
National Center for Immunization and Respiratory Diseases  
Centers for Disease Control and Prevention 
 
Dr. Markowitz presented the draft proposed recommendations for a 2-dose schedule.  She 
emphasized that these were general recommendations rather than specific wording, and that 
they do not include specifics on minimum intervals, special conditions, or precautions.  This is 
simply a general outline of what the WG has been considering.  The WG’s proposed 
recommendation for routine vaccination is that:  
 
 
 
ACIP recommends routine HPV vaccination at age 11 or 12 years* 
A 2-dose schedule is recommended+.  The second dose should be administered 6 to 12 
months after the first dose.  
 
*Vaccination series can be started at age 9 years  
+A 3-dose series can be given (0, 1-2, 6 months)  
 
The text in blue indicates issues for further discussion.  For example, the interval between 
doses could be a range as stated here, specific intervals, or just a lower minimum interval. 
Furthermore, the specific range might change depending what is in label. The other text for 
discussion is the statement about an optional 3-dose series, so that although the 
recommendation is for a 2-dose schedule, a 3-dose series could be given at the discretion of 
the provider. 
 
Consistent with ACIP’s current recommendations, the draft includes a recommendation for 
vaccination through 26 years of age for females and 21 years of age for males if not previously 
vaccinated.  For this recommendation, there would be different recommendations for those who 
initiate vaccination before or after their 15th birthday as follows: 
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 
 
 
 
 
Vaccination is also recommended for females through 26 years and for males through 
21 years not previously vaccinated 
For persons initiating vaccination before their 15th birthday, ACIP recommends 2 doses 
of HPV vaccine.* The second dose should be administered 6 to 12 months after the first 
dose. 
For persons initiating the vaccination series after their 15th birthday, ACIP recommends 3 
doses of HPV vaccine.  The second dose should be administered 1 to 2 months after the 
first dose and the third dose 6 months after the first dose (0, 1-2, and 6 month schedule). 
 
 *A 3-dose series can be given (0, 1-2, 6 months) 
 
Again, the text in blue indicates wording for further discussion related to how to state the interval 
between doses and whether a 3-dose series should be an option for those initiating vaccination 
before the 15th birthday. 
 
The following wording pertains to what would be considered adequate vaccination for those who 
started vaccination in the past. 
  
If vaccination was initiated before the 15th birthday: 
 
 
– 
– 
– 
 
– 
– 
– 
 
Persons who started the HPV vaccination series with 9vHPV, 4vHPV or 2vHPV and 
received 2 doses > 6 months apart: are considered adequately vaccinated 
received 2 doses < 6 months apart: should receive a third dose > 6 months after 
dose 1 
received 1 dose: should receive a second dose > 6 months after dose 1 
 
If vaccination was initiated on or after the 15th birthday: 
 
Persons who started the HPV vaccination series with 9vHPV, 4vHPV or 2vHPV and  
received 3 doses with the third dose > 6 months after dose 1: are considered 
adequately vaccinated 
received 2 doses: should receive a third dose > 6 months after dose 1  
received 1 dose: should complete a 3-dose series (0, 1-2, 6 months) 
 
The draft recommendation for special populations is: 
 
For immunocompromised patients of any age, including those with HIV infection, ACIP 
recommends 3 doses of HPV vaccine (0, 1-2, 6 months) 
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 
 
 
 
– 
– 
Dr. Markowitz posed the following issues for discussion: 
 
General support for a 2-dose recommendation  
Whether ACIP recommends “HPV vaccine” or “9vHPV” since that will be the only 
vaccine available going forward in the US 
Recommendations for those starting series before 15th birthday 
Whether ACIP feels that it will be helpful to specify intervals between doses (0, 6 
months or 0, 12 months), to have a range of the interval (6 to 12 months), or a 
minimal interval (at least 6 months) 
If a 2-dose schedule is recommended, should there be an option for a 3-dose 
schedule? 
 
Discussion Points 
 
Dr. Reingold said he assumed that if there were an option for a 3-dose schedule formally, that 
would have implications in terms of who would pay for it or whether it would be covered by a 
program or insurance company.  He asked for further insight into what the rationale would be for 
continuing to include a 3-dose schedule option. 
 
Dr. Markowitz replied that while discussion regarding this issue is ongoing, it is partially a legacy 
issue, since a 3-dose scheduled has been recommended.  Also, some practices may be 
vaccinating a wide age range and may give a 3-dose schedule to some individuals 
inadvertently, and would want that to be covered.  Some individuals may want a 3-dose 
schedule.  While it was not a unanimous consideration among the WG members, some 
members felt strongly about including this option. 
 
Dr. Riley said she was confused with the 3-dose option as well.  She asked for clarity regarding 
whether this meant an option for a 3-dose schedule in those less than 15 years of age.  She 
wondered whether this made sense for some medical reason.  Using HIV as an example, she 
asked whether that would be a patient for whom there would be concern about the immune 
response. 
 
Dr. Markowitz confirmed that this was what was for those less than 15 years of age at the time 
of vaccine initiation.  Some WG members wanted a 3-dose option for this group. However, the 
recommendation for 3-doses would remain for immunocompromised persons, including those 
with HIV infection for all age groups. 
  
As a Program Manager, Dr. Moore weighed in on the interval suggestions.  She would not 
include the “at least 6 months” with the open end, because it makes it very hard for any registry 
to calculate whether a patient is overdue for something.  With just “at least 6 months” they would 
never be overdue theoretically.  Understanding the antibody data, she liked the range of 6 to 12 
months rather than being prescriptive with 0 to 6 or 0 to 12 because from a practice standpoint, 
a 6-month interval will work easily into the schedule for others having their first vaccine at their 
11-year old visit and their next vaccine at their 12-year old visit.  Depending upon the setting, 
both are reasonable and the 6 to 12 month range offers that flexibility. 
 
Dr. Kempe agreed that the 6 to 12 month range offers clinicians the option with individual 
patients.  Some patients are 11 years old who are clearly far away from sexual activity for whom 
it might make much more sense to wait a year.  That might be much easier for programmatic 
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reasons, so she really liked that.  With regard to Immunization Information Systems (ISS), she 
requested further information on whether having a range is problematic for that. 
 
Dr. Moore replied that there are other vaccines that have ranges for when doses are due, so 
that is programmable. 
 
Dr. Finley (AIM) added that the range of 6 to 12 months would be very helpful, and it is in all of 
the forecasters so it would work well for them. 
 
Dr. Walter noted that many children in his practice present on yearly intervals and are currently 
receiving their vaccine that way. 
 
Dr. Schaffner (NFID) asked whether they may infer that because of what had been said about 
people who have completed their immunization series, ACIP would not be considering at this 
time the question of whether the series was completed with a 2vHPV or 4vHPVand if patients 
who had completed either of those series should receive 9vHPV.  He also made a plea for 
simplification of the adult immunization schedule, perhaps considering the upper age limit of 
women and men and making them the same. 
 
Dr. Markowitz responded that the WG has been dealing exclusively with reviewing the evidence 
for 2 doses since February and has not revisited some of the issues that have arisen previously.  
They are aware of the upper age range differing for males and females, and can further 
consider this issue.  They have not addressed again the issue of the additional vaccination with 
9vHPV. 
 
Dr. Kempe requested people’s perspective on “HPV vaccine” or “9vHPV”.  ACIP has been 
careful not to specify specific vaccines in the past.  In this case, two of the vaccines are 
essentially being phased out.  She personally could foresee a problem with having the 
specificity.  If people come in from other countries, there may be confusion about whether they 
received the correct vaccine.  Some members of the WG felt that it should be specified.  She 
said she would like to hear from anyone who felt that it should be specified and why. 
 
Dr. Lett (CSTE) agreed with not specifying.  The concern is that it will raise questions about 
revaccination, which it seemed the WG did not wish to address at this point. 
 
Dr. Belongia agreed, given that as of the end of the year, only 9vHPV would be available in the 
US. 
 
Dr. Moore agreed with Drs. Lett and Belongia.  Many individuals come in from other countries, 
and they do not want to cause confusion in the schedule.  No evidence has been presented to 
raise concern about the other vaccines. 
 
Dr. Reingold asked whether this was relevant because of requirements to have had the vaccine 
to attend school.  He was not clear why others entering the country were relevant in terms of 
whether they received a different HPV vaccine with regard to what ACIP specifies. 
 
Dr. Moore clarified that they were saying it is not relevant.  The preference is to say “HPV 
vaccine” rather than specifying 9vHPV. 
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Dr. Bennett thought the concern was that if a practitioner was assessing someone’s vaccination 
status, if the recommendation is 9vHPV, if the person might be perceived as being un-
immunized if they received 2vHPV or 4vHPV.  That was not what was intended. 
 
Regarding the 6- to 12-month span in terms of the second dose, Dr. Middleman (SAHM) 
reminded everyone that the Youth Risk Behavior Survey (YRBS) indicates that approximately 
25% of adolescents have had sex by 9th Grade.  She thought they should keep that in mind 
when considering a 6 to 12 month window in terms of whether people may have intercourse 
before the series is completed.  
 
Dr. Wexler (Immunization Action Coalition) said that if ACIP decided to use “9vHPV,” she 
recommended use of HPV9, HPV4, HPV2 as 9vHPV has posed difficulties in terms of the use of 
abbreviations in tools and informational pieces.   They have emailed CDC about this issue. 
HPV9, HPV4, HPV2 would be consistent with PPSV23 and PCV13.  Putting the number 
afterward is less awkward in terms of writing / space. 
 
Dr. Markowitz noted that the feedback received suggested that only “HPV” should be used in 
the recommendation. 
 
 
 
My Name is Deborah Sullivan. I live in Little Silver New Jersey. I have been an oncology nurse 
in New York City for 25 years.  My family sits on the board of many NY hospitals and have 
floors named after them. I would like my voice to be heard at the June 22nd meeting. I have 
four children, all of whom have been fully vaccinated. Although one of my daughters was 
diagnosed with type 1 diabetes at the age of 5, and it was speculated at the time it could have 
been triggered by the R part of the MMR. Anyway, I still continued to vaccinate my children with 
the understanding there is always a risk of reaction. However, in the summer of 2015, my 
daughter received the HPV vaccine Gardasil and in less than 24 hours she was on the floor 
having what looked to be a panic attack. This occurred for three days and then tonic clonic 
seizure like activity began. I won't get into the whole story, but my daughter now has POTS, a 
cardiac arrhythmia ventricular tachycardia as well as joint pain, brain fog,  
repeated throat infections, and severe new allergies. My other daughter as well was affected 
and had all of the same symptoms with added vomiting and diarrhea. This is my type 1 diabetic 
daughter who received two shots all symptoms became worse after second shot, including 
debilitating headaches. 
 
This is what I want to be heard!! I understand the benefit of vaccines. I also understand there is  
potential risk. What I don't understand is WHY when someone is affected that no doctors will 
help and the government does all it can not to payout to the victims. 
 
The anti-vaccine people get a bad wrap because they have had to go out and fend for 
themselves with no help from doctors, so now they go out and promote "don't give vaccines". 
They know their child was affected, but because the link can't be proven, it is just dismissed. IF 
the government would take measures to set up protocols to treat victims and then try to change 
HPV Public Comments Submitted Via Email 
From: sullivan75@comcast.net.  
Sent: Sunday, June 12, 2016.8:09 PM  
To: Advisory Committee on Immunization Practices (CDC)  
 Subject: June 22 meeting  
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formulas of vaccine, or at least look into and honestly evaluate, perhaps there would not be 
such a distrust. What happened to our system? What happened to doctors’ oath of "Do No 
Harm"? 
 
I can say this, my daughters were straight A honor students, AP and IB classes, recruited 
athletes, and then became chronically ill after the first Gardasil injection. Because I did not 
know symptoms were because of vaccine my oldest daughter got the second shot at same time 
my second daughter got first shot. My daughter became increasingly ill. I have been in over 20 
ambulance rides in the last 10 months. I deal with their lines on a daily basis. My kids have 
been dismissed by many as having a psychological cause for the symptoms. However, 
because of my connections at hospitals in NY, we got to the bottom of their issues: Autonomic 
dysfunction, histamine intolerance, and high levels of circulating levels of epinephrine, 
norepinephrine, renin, and vasopressin. My once brilliant loving daughter cannot even have 
empathy for others as her affect completely changed within five days of vaccine.  
 
Please hear the cry of these parents. I personally talk on a daily basis with 800 other moms 
whose children have been affected in the exact same way. I am out over 20,000 in doctor bills. 
It is unfair that I had to seek and seek and seek just for someone to listen. And I am the lucky 
one. Please look into the study done by Dr. Sin Hang Lee. I know you are aware of his letter to 
the WHO, but his science is good and it is what happened to our children. 
 
God is watching and weather you believe or not, on Judgement day all who knew something 
was ignored and did it anyway will pay. My children have lost so much and not sure they will 
ever get it back. There are ways to help these kids. Take responsibility get this vaccine off the 
market and demand doctors find ways to help. I am begging.  
 
Sincerely a grieving Mother  
Deborah Sullivan 
 
 
 
No public comments were offered during this session. 
  
Day 2:  Public Comment 
Advisory Committee on Immunization Practices (ACIP)                                               Summary Report                                             June 22-23, 2016 
 
 
152 
 
 
 
  
 
Upon reviewing the foregoing version of the June 22-23, 2016 ACIP meeting minutes, Dr. 
Nancy Bennett, ACIP Chair, certified that to the best of her knowledge, they are accurate and 
complete.  Her original, signed certification is on file with the Management Analysis and 
Services Office (MASO) of CDC. 
  
Certification 
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